This annual meeting is the third for this premier research conference sponsored by the American Heart Association Council on Basic Cardiovascular Sciences, the world's leading organization of cardiovascular scientists. The conference placed emphasis on bridging the gap between basic research and clinical practice, focusing on new concepts and mechanistic insights that have the potential to be translated into clinically-applicable therapies. The meeting featured both invited presentations and poster abstract presentations, with participants from more than 20 different countries.
BCVS Symposium Abstracts

P1 Functional Regeneration of the Canine Ventricle Using Adult Human Mesenchymal Stem Cells Committed In Vitro to a Cardiac Lineage
We have developed a novel approach to rapidly (7 days) commit adult human mesenchymal stem cells (hMSCs) to a cardiac lineage. These cardiogenic cells express the following cardiac proteins: 1) alpha sarcomeric actinin, 2) atrial natriuretic polypeptide, 3) cardiotin, 4) alpha myosin heavy chain, 5) Troponin T and 6) Cav1.2 (the alpha subunit of the L-type calcium channel). In some cells anti-alpha sarcomeric actinin and anti-troponin T immunostaining showed myofibrillar structure. L-type calcium currents of size roughly equivalent to those found in cardiac myocytes have been recorded in some of these cells. More than 50% of these cardiogenic cells stain positive for cyclin D1 in the nucleus indicating retention of the capacity to divide and multiply. We used our right ventricular defect model to test whether these cardiogenic cells can promote regeneration of mechanical function (Circulation 2005; 112: I-144 ). In this model a full thickness portion of the right ventricle is removed and replaced with an acellular patch made of extracellular matrix from porcine urinary bladder (ECM). Recovery of mechanical function in the implant region is studied 8 weeks later by an optical technique with submillimeter spatial resolution called high density mapping (HDM, Journal of Biomechanics 2006; 39: 717) . We compared cardiogenic cell seeded ECM (nϭ8) to ECM seeded with hMSCs that were not committed to the cardiac lineage (nϭ5). Systolic contraction was significantly improved in cardiogenic cell seeded patches (mean Ϯ sem: 8.2 Ϯ 1.0 vs. 3.7 Ϯ 1.2; cardiogenic seeded vs. hMSC seeded scaffolds; p Ͻ 0.05). Regional stroke work was also significantly improved (mean Ϯ sem: 6.7 Ϯ 0.8 vs. 4.1 Ϯ 0.5; cardiogenic seeded vs. hMSC seeded scaffolds; p Ͻ 0.05). In conclusion, we have developed a method for rapid commitment of hMSCs to a cardiac lineage that when delivered to the canine heart results in a doubling of systolic contraction and a more than 50% increase in regional stroke work compared to normal hMSCs. These cardiogenic cells thus represent a potent new cellular source for mammalian myocardial regeneration.
The aim of this project is to develop a gene delivery approach to treat Pompe Disease, a form of muscular dystrophy caused by mutations in the acid alpha glucosidase gaa gene. Deficiency in GAA leads to glycogen accumulation resulting in cardio-respiratory failure in early onset patients within the first year of life. Here we present a characterization study of the cardiac phenotype in our mouse model of Pompe Disease (gaa-/-) using ECG, MRI and tissue assessment. By 2 weeks abnormal amounts of glycogen are observed in lysosomes of cardiac cells. At 3 months, ECG analysis detects a shortened PR interval (gaa-/-33.41ϩ1.35 ms, control 44.95ϩ1.58 ms) mimicking the conduction phenotype observed in human patients. MRI analysis at 3 months shows a decrease in stroke volume SV (gaa-/-36.13ϩ1.19 ul, control 51.84ϩ3.59 ul) , decrease in cardiac output CO (gaa-/-7.95ϩ0.26 ml/min, control 11.40ϩ0.79 ml/min) and a significant increase in myocardial mass (gaa-/-181.99ϩ10.7 mg, control 140.79ϩ5.12 mg) by 12 months of age. We are currently performing PV loop procedures to determine EDPVR in these mice. Using this model of cardiac dysfunction, we are developing a cardiac gene delivery technique which can be applied to many inherited heart disorders. Previously, we have demonstrated that IV delivery of the rAAV2/1-CMV-hGAA construct to gaa-/-neonates restores GAA activity. We have also shown that LacZ transgene delivery using the systemic administration route and rAAV2/9 pseudotype results in approximately 200 fold higher levels of expression in hearts than rAAV2/1, suggesting a natural preference for cardiac tissue. Here we have combined the most optimal AAV serotype for cardiac transduction with a systemic administration route in order to treat gaa-/-mice. NMR and tissue staining analysis has demonstrated a decrease in glycogen accumulation in mice injected with 4x10 10 vg of rAAV2/9-CMV-hGAA. The shortened PR interval phenotype and MRI detected decrease in SV and CO phenotypes are abrogated in these mice as well. Studies are underway in order to determine longevity of these therapeutic effects. In conclusion, we have demonstrated the ability of rAAV2/9 to transcend the vasculature and transduce cardiac tissue in order to treat the cardiac phenotypes of Pompe Disease.
P3 Genetic and Genomic Approaches to Study Zebrafish Heart Regeneration
Ellen Lien, Children's Hosp, Boston, MA; Michael Schebesta, Shinji Makino, Geoffrey G Whitehead, Gerhard J Weber, Mark T Keating; Children's Hosp, Boston, MA Mammalian hearts cannot regenerate in response to tissue damage. In contrast, zebrafish hearts regenerate even when up to 20% of the ventricle is amputated. The mechanism of zebrafish heart regeneration is not understood. We analyzed two zebrafish fin-regeneration defective mutants, no blastema (nbl) and devoid of blastema (dob), to determine whether they have heart regeneration defects. nbl encodes heat shock protein 60 (HSP60) and fails to regenerate hearts. DNA synthesis in cardiomyocytes is decreased in nbl mutants. dob encodes a new family member of fibroblast growth factor, FGF20. No obvious heart regeneration defects were detected in dob mutants. These results suggest that heart and fin regeneration are controlled by two partially overlapping set of genes. We decided to systematically characterize and compare heart and fin regeneration by transcriptional profiling with DNA microarrays. Distinct gene clusters were identified based on temporal expression patterns throughout a time course of heart and fin regeneration. Comparisons of gene expression profiles between heart and fin regeneration revealed a set of regeneration core genes as well as tissue specific factors. Further characterization focused on heart regeneration. Most proliferating cardiomyocytes are localized to the lateral sides of the wound. Thus, it is likely that initiation signals for post injury cardiomyocyte proliferation are secreted molecules from the wound. Several secreted molecules identified by microarray analysis are expressed around the wound site, suggesting that they play an important role in heart regeneration. With a set of candidate genes identified from our microarray analysis, we now can use reverse genetic and pharmacological approaches to study the functions of these genes.
P11 Cardiac Differentiation in Xenopus Requires the Cyclin-Dependent Kinase Inhibitor p27Xic1
Mehregan Movassagh, Anna Philpott; Hutchison/MRC Rsch Ctr, Univ of Cambridge, Cambridge, United Kingdom Cyclin-Dependent Kinase Inhibitors (CDKIs) play a critical role in negatively regulating the proliferation of cardiomyocytes, although their role in cardiac differentiation remains largely undetermined. We have shown that the most prominent CDKI, p27Xic1, is expressed in the developing Xenopus heart and have gone on to investigate its role in cardiac differentiation. Microinjection of a translation blocking p27Xic1 morpholino into Xenopus embryos dosedependently decreased the expression of markers of cardiac differentiation, cardiac Troponin I (TIc) and Nkx2.10, as determined by in situ hybridization. Following injection of 20ng of p27Xic1 morpholino, 44% of embryos (72/163) demonstrated no expression or very significant decrease in the area expressing xNkx2.10 and xTIc, compared to only 8% (13/154) of embryos injected with a specific control morpholino. Furthermore, this phenotype could be rescued in 80% (72/90) of embryos by co-injection of 30pg of p27Xic1 RNA construct, but not with 50pg of human p21Cip1 RNA (55%: 22/40). Hence, our data demonstrates that p27Xic1 is specifically required for cardiac differentiation and we have further investigated whether this was dependent on its ability to arrest the cell cycle. Upon incubation of Xenopus embryos with Hydroxyurea and Aphidicolin, cell cycle arrest was induced as confirmed by a significant decrease in number of phosphohistone-H3 (phH3) positive cells (2Â Ϯ2, nϭ3 vs untreated control: 110Â Ϯ10, nϭ3); however, both Nkx2.10 and TIc were expressed normally suggesting that cardiac differentiation can occur even when cell cycle is arrested. Furthermore, we have shown that full-length p27Xic1 (1-210), deletion mutant N-terminal (1-96), C-terminal (97-210) and (35-96)-p27Xic1 constructs can all arrest the cell cycle (significant decrease in the number of phH3 positive cells); however, only the full length (78%: 25/32) and the N-terminal (82%: 32/39) construct but NOT the C-terminal (51%: 18/35) or (35-96)-p27Xic1 (40%: 16/40) constructs could rescue the p27Xic1 morpholino phenotype (55%: 35/64). Hence, our data strongly suggests that the N-terminus, but not the C-terminus of p27Xic1 is important in Xenopus cardiac differentiation and this is distinct from its ability to arrest the cell cycle.
P12 In Vitro Cardiogenic Potential of Human Myocardial and Marrow Stromal Cells
Federico Quaini, Caterina Frati, Gallia Graiani, Costanza Lagrasta, Davide Sorianini, Stefano Cavalli, Mirca Lazzaretti, Univ of Parma, Parma, Italy; Piero Anversa, New York Med College, Valhalla, NY; Eugenio Quaini, Poliambulanza, Brescia, Italy; Francesco Fagnoni; Maugeri Foundation, Pavia, Italy Effort has been made to identify the most appropriate cell for cardiac repair. So far, the bone marrow is the predominant source for the collection of immature progenitors capable of regenerating the damaged myocardium. Importantly, the heart possesses a resident population of stem/progenitor cells that may be employed for the reconstitution of lost myocardium. The present study was designed to compare the growth properties of human cardiac and bone marrow primitive cells in vitro. For this purpose, myocardial fragments (H) and bone marrow specimens (BM) were obtained from 10 patients affected by severe aortic stenosis and a parallel analysis of the in vitro growth characteristics of cells from these organs performed. A similar exponential growth was observed in both cell cultures at multiple passages. The surface phenotype was studied by FACS analysis and immunocytochemistry. The mesenchymal antigens, CD44, CD73, CD90 and CD105, were detected in cultured H and BM cells. When receptors for SCF, HGF, VEGF and EGF were evaluated, cells positive for c-kit, c-met, Flk1 and c-erb-B2 were found in both cultures. Only 1% of H and BM cells expressed c-kit but 80% of H cells had already acquired the cardiac phenotype. Interestingly, the expression of c-erb-B2 on a subset of cells of both sources was observed. We are currently testing the biological outcome of agonistic and antagonistic binding of c-erb-B2 in terms of growth, survival and differentiation. Although the expression of GATA-4 and MEF2D was 4-fold higher in H cells, 4% of BM cells were positive for these cardiac transcription factors. Differentiation into myocytes, smooth muscle cells (SMCs) and endothelial cells (ECs) was observed in both cultures in the absence of serum or following the addition of dexamethasone. H cells generated a larger proportion of cardiomyocytes than vascular cells whereas BM cells acquired predominantly the SMC and EC lineages. Importantly, co-culture of female H cells with male BM cells enhanced the differentiating ability of both cell types. Cardiomyocytes, ECs and SMCs carrying XX or XY chromosomes were detected by FISH. In summary, resident cardiac progenitors and BM cells possess cardiogenic potential and may be implemented clinically for the treatment of the diseased failing heart.
P13 In Vivo Labeling of Stem Cell Populations
Hesham A Sadek, Sean C Goetsch, Mary G Garry, Daniel J Garry; UT Southwestern Med Ctr, Dallas, TX Introduction: Cell labeling strategies are important in defining the viability and fate of stem cells. While numerous cell labeling strategies are available for animal research, safety concerns limit their use in clinical studies. Feridex is an iron oxide based, FDA approved, MRI contrast agent. Protamine sulfate, an FDA approved heparin antidote, can be used with feridex (Fe-pro complex) to increase its labeling efficiency. We investigated the use of Fe-pro complex in labeling human stem cells. Methods: Mouse skeletal myoblasts C2C12 cells were utilized for in vitro studies evaluating the effect of cellular proliferation on loss of labeling. We observed that Fe-Pro efficiently labeled C2C12 myoblasts and had no adverse effects on cellular viability, proliferation or differentiation capacity. To further examine the efficiency of labeling human stem cell populations we collected G-CSF mobilized mononuclear cells and labeled them overnight with Fe-Pro complex. In vivo studies were conducted to determine the Fe-pro labeling efficiency of human stem cells in a rat myocardial cryo-injury model. Athymic nude rats lacking T-cell mediated immunity were utilized to minimize rejection. Fe-pro labeled human mononuclear cells were delivered to the border zone directly following anterior wall injury. Each rat received 3-4 x 10 5 Fe-pro labeled human mononuclear cells. Following myocardial injury, the hearts were evaluated using Prussian blue staining. Results: Compared to the intravenous FDA approved dose of feridex (390 g/ml for a 70 Kg patient), we effectively labeled both human mononuclear cells and C2C12 cells at 50 g/ml with no effect on cellular viability at any of the protamine sulfate concentrations tested. Studies in C2C12 studies indicate that iron staining can be detected in 30% of cells after 9 doublings. Human Fe-pro labeled mononuclear cells were detected in the myocardial injury border zone after two weeks of myocardial injury by prussian blue staining. Conclusion: Feridex-Protamine sulfate (Fe-pro) complex can be detected by Prussian blue staining of C2C12 cells for up to 9 cellular doublings and can be used to identify human mononuclear cells in vivo following delivery in the myocardial injury border region.
P14 Cardiac Differentiation Capacity of Human Bone Marrow-Derived Stem Cells
Hesham A Sadek, Sean C Goetsch, Cindy M Martin, Mary G Garry, Daniel J Garry; UT Southwestern Med Ctr, Dallas, TX Introduction: Human bone marrow derived stem cells are believed to be a source of stem cells that are capable of regenerating an injured myocardium. Several clinical studies have demonstrated gross improvement of cardiac function following autologous bone marrow derived stem cell transplantation. There is however little evidence of acquisition of cardiac fate by these stem cells. In this study, we investigated the cardiac differentiation potential of human mononuclear cells and side population (SP) cells following Granulocyte-colony stimulation factor (G-CSF) mobilization. Methods: Athymic nude rats lacking T-cell mediated immunity were utilized to minimize rejection of the human cells. The rats underwent anterior wall cryoinjury by using a liquid nitrogen treated probe. G-CSF mobilized human cells were collected by apheresis and mononuclear cells were isolated by Ficoll gradient centrifugation. SP cells where isolated by flow cytometry based on their ability to efflux the hoescht33342 nuclear stain. Both human mononuclear and SP cells underwent DAPI staining to facilitate subsequent detection. The DAPI labeled human cells were delivered in the myocardial injury border zone directly following anterior wall injury (3-4 x 10 5 mononuclear cells or 1-1.4 x 10 5 SP cells). At different time periods, the animals were sacrificed and the DAPI labeled cells were isolated by flow cytometry following enzymatic digestion of the hearts. The SP cells underwent RNA isolation followed by RT-PCR analysis for markers of early cardiac differentiation. The mononuclear cells were fixed on glass slides and underwent immunohistochemical analysis by utilizing a cardiac specific antibody against ␣-actinin. Results: RT-PCR analysis of the SP cells retrieved from the myocardium indicates that adult human SP cells activate the early cardiac specific genes GATA-4 and NKX 2.5. Moreover, immunohistochemical analysis of the labeled mononuclear cells after recovery from the injured myocardium demonstrated positive expression of the cardiac specific protein ␣-actinin. Conclusion: Adult human bone marrow derived stem cells activate cardiac genetic programs and express cardiac specific genes following the delivery into the injured myocardium.
Smooth muscle cells (SMCs) display remarkable phenotypic diversity and plasticity and can readily switch between proliferative and differentiated states in response to extracellular cues. In an effort to identify novel transcriptional regulators of smooth muscle phenotypes, we compared the gene expression profiles of arterial and venous SMCs by microarray-based transcriptional profiling. Among numerous genes displaying distinct expression patterns in these two SMC types, we discovered an expressed sequence tag encoding a previously uncharacterized zinc finger protein belonging to the PRDM (PRDI-BF1 and RIZ homology domain) family of chromatin-remodeling proteins and named it PRISM (PR domain in smooth muscle). PRISM is expressed in a variety of smooth muscle-containing tissues and displays especially robust expression in the cardiac outflow tract and descending aorta during embryogenesis. PRISM is localized to the nucleus and contains an amino-terminal PR domain and four Krü ppel-like zinc fingers at the carboxy terminus. We show that PRISM contains two domains capable of mediating transcriptional repression in a histone deacetylase-independent manner. We also show that PRISM interacts with a variety of chromatin remodeling enzymes including the class I histone deacetylases, CBX1, EHMT2, and p300, thereby identifying PRISM as a novel SMC-restricted epigenetic regulator. Overexpression of PRISM in cultured primary SMCs induces genes associated with the proliferative smooth muscle phenotype while repressing regulators of differentiation, including myocardin and GATA-6. Conversely, small interfering RNA-mediated knockdown of PRISM slows cell growth and induces myocardin, GATA-6, and markers of SMC differentiation. High percentage chimeras from targeted ES cells are currently being bred and will allow for an in vivo analysis of PRISM function. Taken together, our data suggests that PRISM acts as a novel epigenetic regulator of SMC phenotypic plasticity by suppressing differentiation and maintaining the proliferative potential of vascular SMCs.
P16
An Essential Role of Angiotensin II Type 1 Receptor in the Recipient Arterial Wall, Not in Bone Marrow, in the Pathogenesis of Angiotensin II-Induced Atherosclerosis Junichiro Koga, Kensuke Egashira, Yoshiko Ihara, Kenji Sunagawa; Graduate Sch of Med Sciences, Kyushu Univ, Fukuoka, Japan
[Background] Angiotensin II type 1 receptor (AT1R) is expressed on multiple cell types in atherosclerotic lesions such as bone marrow (BM)-derived cells (leukocytes, progenitor cells) and non-BM intrinsic arterial wall cells (endothelial cells, smooth muscle cells and fibroblasts), which are concerned with cardiovascular diseases. Although pivotal roles of AT1R in atherogenesis have been shown in animals and humans treated with AT1R blocker as well as in ApoE/AT1R-KO mice, relative roles of AT1R in BM versus AT1R in non-BM-derived intrinsic host cells in the pathogenesis of atherosclerosis have not been addressed. Here, we investigated the role of AT1R in BM versus non-BM intrinsic arterial cells in atherogenesis.
[Methods and Results] A bone marrow transplantation technique (BMT) was used to create ApoE-KO mice with selective AT1R deficiency in BM cells (BM-AT1R -/group) and those with selective AT1R deficiency in non-BM host cells (host AT1R -/group). As control, BMT-ApoE -/and BMT-ApoE -/-AT1R -/groups, in which BM were transplanted from ApoE -/and ApoE -/-AT1R -/mice into ApoE -/and ApoE -/-AT1R -/mice, respectively, were generated. Angiotensin II (Ang II) was chronically infused from 10 to 14 weeks of age. En face oil red O staining and histopathological analysis of the aorta revealed that Ang II-induced increases in atherosclerotic plaque size were evident in control BMT-ApoE -/-(1Ϯ0 % to 5Ϯ2 %) and BM-AT1R -/mice (1Ϯ1 % to 8Ϯ3 %). In contrast, Ang II-induced atherosclerosis was blunted in host AT1R -/mice (2Ϯ2 %, PϽ0.01 vs control) as well as in BMT-ApoE -/-AT1R -/mice (2Ϯ2 %, pϽ0.01 vs control). Ang II infusion raised arterial pressure in BM-AT1R -/and BMT-ApoE -/mice, whereas no Ang II-induced increase in arterial pressure was noted in host AT1R -/and BMT-ApoE -/-AT1R -/mice. There was no difference in serum lipid levels among groups with or without Ang II infusion.
[Conclusion] These results demonstrate an essential role of AT1R in host arterial wall in the pathogenesis of Ang II-induced atherosclerosis. The present study provides novel insights into Ang II-induced vascular pathobiology and suggests that AT1R-mediated signals in intrinsic endothelial and smooth muscle cells may play a principal role in Ang II-induced atherogenesis.
P17 VEGF Secretion by Skeletal Muscle-Derived Stem Cells Induces Angiogenesis, Prevents Remodeling, and Improves Function in Ischemic Hearts
Thomas R Payne, Hideki Oshima, Masaho Okada, Nobuo Momoi, Kimimasa Tobita, Bradley B Keller, Hairong Peng, Johnny Huard; Univ of Pittsburgh/Children's Hosp Pittsburgh, Pittsburgh, PA Cardiac cell therapy can improve the performance of ischemia-damaged hearts after myocardial infarction (MI); however, the mechanisms underlying this beneficial effect are not fully understood. We have previously shown that skeletal muscle-derived stem cells (MDSCs) injected into hearts after MI prevent adverse left ventricle (LV) remodeling and improve LV function more effectively than do committed skeletal myoblasts. We largely attributed this difference to the greater ability of MDSCs to induce infarct neovascularization, because very few donor-derived cells differentiated or fused to form new cardiomyocytes and blood vessels. In addition, we observed the donor myocytes in the MDSC-injected hearts to express vascular endothelial growth factor (VEGF) for up to 12 weeks. These results led us to hypothesize that the milieu within ischemic myocardium stimulates transplanted MDSCs to secrete angiogenic factors that induce neovascularization and ultimately improve cardiac function. To test this hypothesis, we subjected MDSCs to hypoxia and cyclic stretch, conditions likely found in ischemic myocardium. We observed a 9-fold and a 2-fold increase in VEGF secretion from MDSCs after 24 hours of hypoxia and cyclic stretch, respectively, when compared to normal culture conditions. To determine the therapeutic impact of cell-secreted VEGF, we used a gainor loss-of-function approach based on MDSCs engineered to overexpress VEGF or soluble Flt1, a VEGF-specific antagonist. Intramyocardial transplantation of MDSCs overexpressing VEGF or control MDSCs significantly induced angiogenesis, prevented adverse cardiac remodeling, and improved function after MI compared to the saline-injected hearts (PϽ0.05). In contrast, no such beneficial effects occurred in hearts transplanted with MDSCs expressing soluble Flt1, which displayed no significant improvement in infarct vascularization and LV contractility when compared to control saline-injected hearts. These findings indicate that VEGF secretion by transplanted MDSCs is an important mechanism by which the cells induce neoangiogenesis and functional recovery after MI. It is also tempting to speculate that such a mechanism could explain how other cell types can provide therapeutic benefit.
Introduction
We previously reported the inhibitory effects of Granulocyte colony-stimulating factor (G-CSF) on left ventricular remodeling after myocardial infarction (MI) . But the effect of G-CSF on atherosclerosis is unclear. Methods We used two kinds of rabbit atherosclerotic models. Myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHL-MI) rabbits were randomly treated with G-CSF (group G) or saline (group C), beginning at 14 months old and continuing daily for 7 days. The vascular injury model was created by inflating angioplasty balloon in the iliac artery of rabbits and treated with G-CSF (G) or saline (C) for 7 days. Each rabbits were analysed at 1 and 4 weeks after treatment. Results The treatment with G-CSF significantly reduced the stenosis score of coronary artery in WHHL-MI rabbits (G, 9.3 Ϯ 2.3 vs. C, 22.6 Ϯ 2.3, pϽ0.05) . The lipid plaque area of thoracic aorta was decreased by the treatment with G-CSF group. In the balloon injury model, the neointima/media ratio was significantly smaller in G-CSF group than control group (G, 0.91Ϯ0.22 vs C, 1.24Ϯ0.21, PϽ0.05). The ratio of reendothelialization was significantly accelerated by the treatment with G-CSF at both 1 week and 4 weeks (1 week; G, 62.8Ϯ2.2% vs C, 46.7Ϯ2.9%, PϽ0.05, 4 weeks; G, 79.6Ϯ3.7% vs C, 58.9Ϯ8.5%, PϽ0.05). The pretreatment with L-NAME, which suppress the EPC mobilization, significantly inhibited G-CSF-induced reendothelialization. Conclusions In the present study, we demonstrated using two kinds of rabbit models of atherosclerosis that the treatment with G-CSF ameliorates the progression of atherosclerosis. The treatment with G-CSF inhibited the progression of atherosclerosis and neointimal formation. These results suggest that G-CSF has a therapeutic potential for the progression of atherosclerosis. Randomized clinical trials to evaluate the feasibility and safety of G-CSF on coronary artery diseases are warranted.
P19 Withdrawn
P20 Nitric Oxide Mediates Migration of Endothelial Cells and Circulating Progenitor Cells Through Both Nitric Oxide Synthase-Dependent and NOS-Independent Processes
Christian Heiss, Andrea Schanz, Wendy May Real, William Grossman, Yerem Yeghiazarians, Matthew L Springer; UCSF, San Francisco, CA S-Nitrosothiols represent a bioactive NO storage pool and are decreased in plasma of humans with cardiovascular risk factors. Impaired vascular maintenance was associated with dysfunction of endothelial cells and endothelial progenitor cells (EPCs). We thus hypothesized that the migration of endothelial cells and EPCs is NOS-dependent and is enhanced by S-nitrosothiols. Using timelapse microscopy of cultured human uterine microvascular endothelial cells and human umbilical vein endothelial cells (HUVECs), we observed that the formation of capillary tubes by each was abolished by inhibition of NOS using L-NNA, while random movement was not abolished. EPCs were isolated from peripheral blood of human volunteers (nϭ4), and migratory capacity of both EPCs and HUVECs was measured in culture. This was accomplished by plating 2-4x104 cells in one of two chambers divided by a membrane with 8 m pores, and adding VEGF to the other chamber as a chemoattractant. After 6 h, we counted the migrated cells on the opposite side of the membrane. HUVECs and EPCs ( Fig.) exhibited similar chemotaxis toward VEGF that was abolished by L-NNA. Addition of the S-nitrosothiol NO-donor SNAP (S-nitroso-N-acetyl-penicillamine) to both chambers enhanced random cell movement (white bars), while chemotaxis toward VEGF in the presence of SNAP increased cell migration synergistically (striped bars). In the latter case, L-NNA inhibited the chemotaxis to VEGF but did not affect the enhanced random movement of cells exerted by SNAP. We conclude that random cell movement of endothelial cells and EPCs is modulated by S-nitrosothiols but NOSindependent, while chemotaxis and tube formation are NOS-dependent. respectively (pϭ.05 vs GSH-untreated cells). Conclusions. PDE5a modulation of ␤-adrenergic contractility is suppressed in myocytes from chronic hypertrophied or failing hearts. The effect is downstream of the ␤-receptor but involves cAMP-mediated inotropy. Oxidative stress contributes to this behavior, perhaps by diminishing cGMP synthesis via nitric oxide-soluble guanylate cyclase. Rescue by antioxidants may be a useful strategy to enhance effects of PDE5 inhibitors to blunt cardiac adrenergic stress. Thomas J Mulhearn, IV, Hazim El-Haddad, Mobusher Mahmud, Milena Gebska, Michael Bridges, Djahida Bedja, Kathy Gabrielson, Anna R Hemnes, David A Kass, Hunter C Champion; Johns Hopkins Univ Sch of Med, Baltimore, MD
P23
PDE5A Inhibition Suppresses Maldative but Not Physiological Cardiac Hypertrophy
We have recently shown that PDE5A inhibition has potent antihypertrophic activity in models of increased afterload (transverse aortic constriction; TAC). However, mice subjected to TAC and PDE5A inhibition do show modest cardiac hypertrophy but lack cardiac remodeling. In this series of experiments, we tested the hypothesis that PDE5A inhibition allows physiological cardiac hypertrophy to take place. Mice were subjected to TAC or swimming (4 weeks of 90 min of swimming twice daily). Mice were randomized to receive vehicle or sildenafil citrate (100 mg/kg/d). Mice were evaluated at 4 weeks by echocardiogram, PV Loop, and biochemical analysis. Afterload induced hypertrophy (TAC) and physiologic hypertrophy demonstrated an expected increase in cardiac mass (241 Ϯ 9.7 mg (TAC) vs 152.0 Ϯ 19.5 mg(swimming); PϽ0.05). TAC was associated with a reduction in heart systolic function and worsening diastolic cardiac function whereas physiologic hypertrophy demonstrated improved cardiac function in all parameters. Sildenafil markedly improved LV function and reduced heart size in TAC (136 Ϯ 6.0 mg, PϽ0.05 compared to TAC) mice but did not alter function or heart size in swimming mice (153.9 Ϯ 21.3 mg). Swimming mice, while exhibiting significant hypertrophy, did not show increased superoxide activity/staining (by DHE fluorescence) or hydrogen peroxide staining (by dcf fluorescence). Swimming mice showed increased NOS activity when compared to TAC mice and reduced baseline PDE5A activity when compared to TAC. In sum, physiologic hypertrophy is a beneficial adaptive hypertrophy while TAC is associated with maladaptive hypertrophy and results in the progression to heart failure. Sildenafil selectively blocks maladaptive hypertrophy without an effect on physiologic hypertrophy by swimming. Interestingly, both TAC-induced and exercise-induced hypertrophy were both associated with an increase in PI3K/AKT signaling. Sildenafil treatment reduced the expression of p-AKT in TAC-associated hypertrophy, but did not alter the expression of p-AKT in exercise-induced hypertrophy. These findings may reflect differences in special localization of AKT and or PDE5/cGMP signaling in the heart. Background: Despite the huge potential of human embryonic stem (hES) cells, cardiomyocyte availability has been limited. Identifying early cardiac markers on undifferentiated hES cells can be used for improving the efficiency of cardiomyocyte derivation protocols, culture enrichment and isolation of adequate amounts of cardiomyocytes to generate new heart muscle. Objective: We aimed to test the hypothesis that hES cells might express cardiac-specific marker(s) that could be used for cardiomyocyte isolation from hES cells. Methods and Results: We applied microarray technology to examine gene expression in undifferentiated hES cells (H9.2). Relative levels of mRNA expression were compared with human fetal heart tissue and mRNA pooled from non-cardiac human fetal tissues (15 weeks). Hybridization was performed on the Hg-U133A chip from Affymetrix. A total of 662 genes were expressed in the fetal heart but were absent in the pool. This list enabled the identification of genes specific to the fetal heart. An additional group of 206 genes were expressed both in the fetal heart and in the hES cells but were absent in the pool. Cardiac alpha actin, troponin I and troponin C-slow were the most significant genes with regard to increased expression in undifferentiated hES cells. We verified those results in transcripts and protein-level expression by real-time RT PCR method and Immunostaining studies such as Immuonofluorescence staining and Immunocytochemistry staining. We also analyzed differential expression of cell surface markers in hES cells and fetal heart. Eighteen common genes were found, among which 2 genes that are known to be exclusively expressed in the heart: plakophilin 2, solute family 16 -member 1. Conclusions: Our study presents novel evidence suggesting that there are common genes expressed both in hES cells and fetal heart. Our findings can be used to improve the methods for directing myogenic differentiation and culture enrichment to obtain sufficient numbers of cardiomyocytes for transplantation Background: Brain natriuretic peptide (BNP) has emerged as an important diagnostic and prognostic biomarker for human heart failure (HF). Both the N-terminal (NT-proBNP) and the C-terminal (BNP-32) forms of BNP are measured by the multitude of commercial radioimmunoassays (RIAs) and point-of-care tests (POCTs) now used in health care facilities worldwide. Although these tests have proven to be highly effective, recent evidence has suggested that unidentified forms of BNP may be detected with the tests. Furthermore, these heterogeneous forms of BNP may have reduced biological activity that adversely affects the pathophysiology of HF. The objective of this research is to unambiguously characterize the molecular forms of BNP in HF patients using mass spectrometry-based proteomics strategies. Methods and Results: Healthy patient plasma (Ͻ5 fmoles BNP-32/ml) was spiked with 500 fmoles/ml of exogenous human BNP-32 (SIGMA, St. Louis, MO). Fractions (1 ml) of the spiked plasma were incubated as a function of time and primary antibody (rabbit anti-BNP-32: Phoenix Pharmaceuticals, Belmont, CA) concentration ([IgG]/[BNP-32]). A secondary antibody (MagnaBindTM goat anti-rabbit IgG: PIERCE, Rockford, IL) was used to recover the antibody-BNP-32 complex. Exogenous BNP-32 recovery efficiencies were determined by spiking each assayed plasma sample with 100 fmoles of stable isotope labeled BNP-32 (SIL-BNP-32) prior to nano-liquid chromatography electrospray ionization Fourier transform mass spectrometer (nLC-ESI-FTMS) analysis. The exogenous BNP-32 recovery from healthy plasma using the optimized assay (1 hour incubation with 100 [IgG]/ ) was found to be 31 Ϯ 10% (nϭ5). We then applied the optimized assay to plasma from 4 patients with severe HF (NYHA IV) and high levels of BNP-32 (Ͼ300 fmoles/ml determined by the Triage TM POCT). One exception to assaying the NYHA IV plasma was that we spiked 500 fmoles of the SIL-BNP-32 into each 1 ml plasma sample before the assay. Despite mass spectrometric detection of SIL-BNP-32 in each of the 4 assayed samples, we were unable to detect any endogenous BNP-32. These results suggest the existence of novel molecular forms of BNP in severe human HF that are potentially interfering with conventional RIAs and POCTs for BNP.
P24
Discovery of Cardiac Marker Expression in Human Embryonic Stem Cells by Gene Expression Profiling
P25
Investigating Molecular Heterogeneity of Circulating Brain Natriuretic Peptide in Human Heart Failure Patients by Mass Spectrometry
P26 An Avian Model to Study High-Fat Diets and Cyclooxygenase 2 Gene Expression: A Biomarker for Atherosclerosis
Karri D Folks, Robert N Corley, III, Michelle M Corley; Tuskegee Univ, Tuskegee, AL Cyclooxygenase 2 (COX 2) in humans is involved in the synthesis of prostanoids, which are involved in pathological processes such as acute and chronic inflammation. Atherosclerosis is a disease condition caused by the buildup of fatty deposits or plaques on the inside walls of arteries. Inflammation in human heart tissue due to plaque buildup has been found to cause an increase in the levels of COX 2. Since COX 2 in avian species has the same function as in humans, and atherosclerosis can be induced in less than 16 weeks, they can serve as excellent animal models to simulate the human condition. Therefore, the objective of this research was to evaluate the effect of a high fat diet on the expression of the cox-2 gene in broiler chickens. Cobb X Cobb chickens were fed a high fat diet (feed with 2.5g in100g of crude fat in addition to 2g in 100g peanut oil) from day 1 of age through sexual maturity (16 wks of age). Total RNA was isolated from blood samples collected on weeks three, six, nine, and sixteen. Quantitative Reverse Transcriptase Polymerase chain reaction was then performed to determine the level of expression of the cox 2 gene compared to those that consumed a regular diet. The study was repeated twice. Birds that consumed a high fat diet induced expression of cox-2 (PϽ0.05) when compared to birds that consumed a normal fat diet. There was no linear, quadratic or cubic effect (PϾ0.05) of cox 2 expression over the 16 week period, however, there was a significant increase (PϽ0.05) in cox 2 expression after birds were fed the high fat diet for 9 weeks. These data imply that feeding a high fat diet for 16 weeks did trigger inflammation. Therefore, the cox-2 gene may be an excellent biomarker for atherosclerosis, and broiler chickens can serve as a convenient model to study the onset of the human condition.
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Apo E Genotypes Modulate the Plasma Lipid Response to Atorvastatin in Indian Patients with Coronary Artery Disease
Madhu Khullar, Taranjit S Rai, Anil Grover, Rajesh Vijayverghia; Post Graduate Inst of Med Education and Rsch, Chandigarh, India Considerable variability exists in the plasma lipid and lipoprotein response to statin treatment due, in part, to genetic factors. The gene for apolipoprotein E (ApoE) is polymorphic and the different genotypes modulate baseline lipid levels. The objective of the present study was to evaluate the effect of the apoE genotypes on the lipid response to atorvastatin treatment in patients with coronary artery disease (CAD), followed-up in cardiology clinic at Post Graduate Institute of Medical education and Research, India. Subjects and methods. 100 patients who were clinically confirmed with CAD and treated according to NCEP-ATPIII guidelines were included in the study. Plasma lipids were measured before and after 16 weeks of treatment with 10 mg /day of atorvastatin. Polymorphisms of ApoE were determined by restriction fragment length polymorphism (RFLP). RESULTS: ApoE genotype distributions were 4.28% with epsilon 2/2, 3.5% with epsilon 2/3, 17.41% with epsilon3/3 and 30.0% with epsilon 2/4 ,21.4% with epsilon 3/4 and 23.57% with epsilon 4/4 respectively. Apo E allele frequencies for epsilon 2, 3 & 4 were 0.21, 0.296 and 0.492 respectively in these patients. ApoE genotype did not have any effect on baseline lipid levels after adjustment for age, gender and body mass index (BMI) (P Ͼ 0.05). The reduction in total cholesterol level was significantly higher in patients carrying epsilon 4 allele than in those with epsilon 2 or 3 alleles following treatment (-28.4% vs. -13. 1%, P Ͻ 0. 05). Compared with patients carrying epsilon 3 or epsilon 4 allele, those with epsilon 2 allele showed a significantly higher percentage reduction of LDL-C level after treatment (P Ͻ 0.05). CONCLUSION The reduction in total cholesterol level was more prominent in patients carrying epsilon 4 allele, and those with epsilon 2 allele showed a significantly higher percentage in reduction of LDL-C level after treatment. Apo E gene polymorphism appears to influence the response to atorvastatin in Indian patients with CAD. angiogenic activity. The effect can be abolished by nAChR antagonists. In this study we examined the contribution of genes encoding different nAChR isoforms, as well as downstream genes, in nicotine-induced EC migration. Methods: Total RNA and protein from HMVECs was subjected to RT-PCR and Western blotting analysis. EC migration and cell proliferation, key events in angiogenesis, were assessed by standard wounding and MTT assays. Thioredoxin activity was measured after EC cells were treated with nicotine. HMVEC gene expression profiling was performed using cDNA microarrays (Stanford, 43,000 elements) after exposure to vehicle or angiogenic factor for 2, 6 and 24 hours. Results: We detected mRNA transcripts for multiple nAChR subunits. Subunit expression was confirmed by Western blotting. To determine the role of different isoforms as functional nACh receptors, we used siRNA technology to suppress the expression of each receptor subunit. Knockdown of nAChR ␣4, ␣7 subunits fully abolished NIC-induced migration, whereas scrambled RNAi and nAChR ␤ subunits(␤ 2, ␤3, ␤4) had no effect. Furthermore, we found that nicotine, VEGF and FGF induce HMVECs migration. This activity is accompanied by increased thioredoxin activity. In parallel, message for TXNIP, a key inhibitor of thioredoxin activity, was downregulated by all three angiogenic agents. Heat maps of transcriptional profiles of stimulated EC revealed a large array of genes downstream of nAChR activation that are shared with VEGF or FGF treated cells. A subset of these genes have not previously described to be involved in angiogenesis. Knockdown of several of these commonly regulated genes abolished EC migration. Conclusion: Nicotine promotes angiogenesis via stimulation of nAChR-dependent endothelial cell migration. Furthermore, activation of the EC nAChRs induce a transcriptional profile similar to those induced by other angiogenic cytokines. Analysis of transcriptional overlap among angiogenic cytokines reveals genes not previously considered to be involved in angiogenesis.
P29 Genetic Ablation of Bak Protects Against Myocardial Ischemia-Reperfusion Injury
John W Elrod, Weimin Fu, Mark R Duranski, Richard N Kitsis, David J Lefer; Albert Einstein College of Med, Bronx, NY Background: Bak is a multidomain, proapoptotic Bcl-2 protein, which together with Bax, controls access of upstream death signals to the mitochondria. Bak is highly expressed in cardiac myocytes. We investigated the effects of genetic ablation of bak in an in vivo murine model of myocardial ischemia-reperfusion (I-R). Methods: bak -/-(n ϭ 7) mice and wild-type (WT) littermates (n ϭ 6) were subjected to 30 min left coronary artery occlusion and 72 h reperfusion. Left ventricular (LV) dimensions and function were assessed utilizing highresolution echocardiography at baseline and post myocardial infarction. Area-at-risk (AAR) and infarct size (INF) were determined using Evans blue and TTC staining respectively. Results: bak -/mice displayed a 53% reduction (p Ͻ 0.001, vs. WT) in myocardial infarct size per area-at-risk (INF/AAR) (27.26 Ϯ 4.36%) as compared to wild-type littermates, which displayed an INF/AAR of (58.08 Ϯ 2.56%). In correlation, INF/LV was also reduced in bak -/mice by 50% (p Ͻ 0.001) compared to wild-type littermates. AAR/LV was similar in both groups. Echocardiography at baseline revealed no significant differences in LV dimensions or function between WT and bak -/mice. Following myocardial infarction bak -/mice displayed significantly decreased LV dilatation (LV end-diastolic dimension and LV end-systolic dimension) (p Ͻ 0.01 vs. WT mice). Conclusions: This is the first in vivo evidence that genetic deletion of bak decreases myocardial infarct size and lessens left ventricular dilatation following I-R injury. Thus, despite the redundancy between Bak and Bax in many systems, Bak plays a critical function in the pathogenesis of myocardial I-R injury.
P30
Bcl-2 Plays an Essential Role in Attenuating Ischemia-Reperfusion Injury in the Naive Myocardium and Modulates Mitochondrial Permeability Transition
David A Liem, David Woo, Jun Zhang, GuangWu Wang, Aldrin Gomes, Xiaohai Li, John Streicher, Thomas M Vondriska, Peipei Ping; UCLA, Los Angeles, CA A role for Bcl-2 has been implicated in myocardial preconditioning, and over-expression of this molecule protects against myocardial ischemia/reperfusion (I/R) injury. However, the participation of Bcl-2 in injury to the naïve heart, and its subcellular targets under such conditions, remain elusive. Using a mouse line with ablation of the Bcl-2 gene, we found that myocardial infarct size (IS) was exacerbated (53Ϯ5%) vs. matching wild type (WT) mice (29Ϯ4%; pϽ0.05), demonstrating that Bcl-2 limits IS in the naïve myocardium. Furthermore, protection afforded by the NO donor diethylenetriamine/nitric oxide (DETA/NO; 0.1 mg/kg x 4, i.v.), given 24 h prior to 30-min coronary artery occlusion (CAO), was attenuated in the Bcl-2 null mice (a reduction in IS of 34% vs ϳ53% in WT), indicating a role of Bcl-2 in DETA/NO cardioprotection. Interestingly, a separate model of cardioprotection (engendered by activation of PKC⑀) exhibited increased levels of Bcl-2 protein as compared to wild type controls while mice expressing dominant negative PKC⑀ were refractory to preconditioning and did not show and increase in Bcl-2 protein. Isolated cardiac mitochondria from Bcl-2 null mice exhibited increased matrix swelling in response to CaCl 2 as compared to WT, indicating an increased susceptibility to mitochondrial permeability transition (MPT). Moreover, provision of either recombinant Bcl-2 or PKC⑀ was sufficient to attenuate MPT, suggesting Bcl-2 and PKC⑀ can directly modulate the MPT pore. In addition, reactive oxygen species-induced cytochrome-c release from proteoliposomes containing the core MPT pore-forming protein, voltage dependent anion channel (VDAC), was abrogated by recombinant Bcl-2 or PKC⑀. Finally, in vivo treatment with the VDAC specific inhibitor Ro68 -3400 (0.25mg/kg i.v.) at onset of reperfusion abolished the increase in IS in Bcl-2 null mice. These data suggest that Bcl-2 is pivotal in limiting IS in the naïve myocardium by modulating VDAC-dependent MPT, and implicate signaling by the known protective kinase, PKC⑀, in this process.
P31
Hexokinase I and II Protect Against Oxidant-Induced Cell Death by Increasing Glucose Phosphorylation and Inhibition of Mitochondrial Permeability Transition
Lin Sun, Shetha Shukair, Farzad Moazed, Tejaswitha J Naik, Hossein Ardehali; Northwestern Univ, Chicago, IL Alterations in glucose metabolism have been demonstrated in heart failure and cardiac hypertrophy. The first step in glucose metabolism is carried out by the hexokinase (HK) family of enzymes. Overexpression of HKI and HKII in tissue culture protects against oxidant-induced cell death. The protective effects of these enzymes are thought to be due to either an increase in glucose phosphorylation or closure of the mitochondrial permeability transition pore (mPTP) as a result of HK binding to the voltage dependent anion channel (VDAC) on the mitochondrial outer membrane. VDAC is believed to form part of mPTP, opening of which causes cellular injury. The relative contribution of HK binding to the mitochondria and the increase in glucose phosphorylation to the overall protective effects of HKs is not clear. Furthermore, there is no clear evidence supporting the hypothesis that HK binding to mitochondria inhibits mPTP. In order to better understand the mechanism(s) behind the protective effects of HKs, we overexpressed green fluorescence protein (GFP)-tagged full length HKI and HKII (FL-HKI and FL-HKII, respectively) and their truncated proteins lacking the N-terminal hydrophobic domains (Tr-HKI and Tr-HKII, respectively) in HEK 293 cells. The truncated constructs cannot bind to the mitochondria since they lack the hydrophobic N-terminal sequence. Overexpression of FL-HKI, FL-HKII resulted in complete protection against H 2 O 2 -induced loss of mitochondrial membrane potential and cell death. Although overexpression of Tr-HKI and Tr-HKII reduced cell death, the degree of protection was less than that of the full-length proteins. Furthermore, FL-HKI and FL-HKII inhibited mitochondrial permeability transition (MPT) in the presence of H 2 O 2 , while the truncated forms only caused partial inhibition. These results suggest that both glucose phosphorylation and inhibition of mPTP contribute to the protective effects of HKI and HKII, and that binding of HKs to the mitochondria inhibit MPT. These findings bear implications of HK overexpression and binding to the mitochondria as a potential clinical treatment strategy for various forms of heart disease.
P32 Transient Exposure to Extracellular Hydrogen Peroxide Is Associated with a Persistent Increase in Intracellular Calcium and Superoxide Release from the Mitochondria in Ventricular Myocytes Without Apoptosis
Helena M Viola, Peter G Arthur, Livia C Hool; The Univ of Western Australia, Crawley Perth, Australia Hydrogen peroxide (H 2 O 2 ) can act as a signaling molecule to mediate cardiovascular pathology. In this study we sought to understand the effects of a transient H 2 O 2 exposure on myocyte function at a concentration insufficient to cause apoptosis or necrosis. Myocytes were exposed to 30 M H 2 O 2 for 5 min followed by 10U/ml catalase for 5 min to degrade the H 2 O 2 . Cellular superoxide was measured using dihydroethidium (DHE). Transient exposure to H 2 O 2 caused a 66.1 % increase in DHE signal (nϭ45; PϽ0.05) compared to controls exposed to catalase only (nϭ8) without activation of caspase 3 or evidence of necrosis. The increase in DHE signal was attenuated when cells were exposed to the mitochondrial inhibitor myxothiazol (7 nM; nϭ14) and when calcium uptake by the mitochondria was inhibited with 5 M Ruthenium Red (nϭ5). We investigated the L-type Ca 2ϩ channel (I Ca-L ) as a source of calcium influx. The increase in superoxide could be attenuated when I Ca-L function was inhibited with 2 M nisoldipine (nϭ9). Consistent with this, basal channel activity was significantly increased from 5.4 pA/pF (nϭ7) to 8.9 pA/pF (nϭ25) after H 2 O 2 . The response of the channel to ␤-adrenergic receptor stimulation was used as a functional reporter for changes in cellular production of reactive oxygen species since a decrease in cellular H 2 O 2 is associated with an increase in the sensitivity of the channel to the ␤-adrenergic receptor agonist isoproterenol (Iso). After exposure to H 2 O 2 , the K 0.5 for activation of the channel by Iso was significantly increased from 5.8 to 27.8 nM. More importantly, this effect and the increase in basal current density persisted for several hours after exposure to H 2 O 2 . In addition, intracellular calcium was persistently elevated with a two fold increase from a resting calcium of 68 nM (nϭ5, PϽ0.05). We propose that extracellular H 2 O 2 is associated with an increase in superoxide production from the mitochondria via calcium influx from the L-type Ca 2ϩ channel. The effect persists because a positive feedback exists between increased basal channel activity, elevated intracellular calcium and superoxide production by the mitochondria. This may represent a mechanism for cardiovascular pathology that involves elevated calcium and reactive oxygen species. metabolism. PPAR␣ and PPAR␦ are important transcriptional regulators of fatty acid oxidation in the heart. However, the function of PPAR␥ in the heart remains obscure. To investigate the tissue specific role of PPAR␥ in the heart, we generated a cardiomyocyte-restricted PPAR␥ knockout mouse line (CR-PPAR␥ -/-). CR-PPAR␥ -/mice revealed no gross phenotype after birth until reached two months of age. Adult CR-PPAR␥ -/mice showed cardiac hypertrophy, progressive heart failure and premature dead. Further analyses revealed that expression of Sod2, (encoding manganese superoxide dismutase; MnSOD), a mitochondrial antioxidant enzyme was decreased by about 40% both in transcript and protein levels in cardiac samples from cardiomyocyte-restricted PPAR␥ knockout hearts prior to major pathological changes compared with those of controls. We further identified that Sod2 is a PPAR␥ target gene in the heart. Depressed MnSOD in the CR-PPAR␥ -/hearts exhibited myocardial superoxide accumulation, leading to severe oxidative stress. Taken together, this study shows that PPAR␥ is critical to myocardial redox homeostasis. These findings provide a framework for new therapeutic approaches to heart disease.
P34
Impaired Mitochondrial Ultrastructure and Metabolic Function in Cardiac and Skeletal Muscle in Taurine-Deficient Mice
Takashi Ito, Yoriko Uozumi, Yasushi Fujio, Kyoko Takahashi, Junichi Azuma; Osaka Univ, Suita, Osaka, Japan Background: Taurine, a sulfur-containing ␤-amino acid, is the most abundant amino acid in cardiac and skeletal muscle. Taurine has previously been shown to play a role in ion movement, calcium handling and tissue protection in muscles, though molecular mechanisms are unclear. Recently it has been demonstrated that taurine could critically affect mitochondrial function, whereas physiological significance has not been elucidated. Methods and Results: To address the physiological role of taurine in tissues, we generated taurine transporter-(TauT-) knockout mice (TauTKO). KO mice showed a deficiency in tissue taurine content in the hearts and the skeletal muscles (heart; not detectable (TauTKO) v.s. 6.7Ϯ2.7 (wild) mol/g wet weight, pϽ0.001, skeletal muscle; 0.70Ϯ0.33 (TauTKO) v.s. 16.9Ϯ5.1 (wild) mol/g wet weight , pϽ0.001) as well as the other tissues. Histological analyses assessed by hematoxylin-eosin stain showed wall thickness and dilation of left ventricles, and skeletal muscle atrophy in TauTKO mice compared with wild-type littermates. Though cardiac fibrosis was not observed in TauTKO hearts as assessed by Masson's trichrome stain, TauTKO hearts exhibited increased expressions of cardiac failure marker BNP and ␤-MHC, but not ␣-skeletal actin, as assessed by northern blot analyses. Transmission electron microscopy analyses showed abnormal mitochondrial ultrastructure in TauTKO hearts. Enzymatic histological staining revealed that succinate dehydrogenase (SDH) activity, but not cytochrome c oxidase (COX), was remarkably decreased in the hearts of TauTKO compared with wild-type littermates (SDH; 43Ϯ16 % (pϽ0.05), COX; 79Ϯ30 % (not significant), respectively), indicating the impairment of the capacity of oxidative phospholylation in cardiac mitochondria by taurine depletion. Interestingly, mitochondrial abnormal ultrastructure and impaired SDH activity were also observed in the skeletal muscles in TauTKO. Conclusion: These results indicate that taurine depletion causes mitochondrial dysfunction in cardiac and skeletal muscle, suggesting that modulation of mitochondrial function may underlie tissue protective roles of taurine.
P35
Can "Elderly" Hearts Be Rendered Resistant to Ischemia? D-myo-Inositol Trisphosphate, but Not Ischemic Preconditioning, Limits Infarct Size in Aged Mouse Hearts
Karin Przyklenk, Michelle Maynard, Peter Whittaker; Univ of Massachusetts Med Sch, Worcester, MA Infarct size reduction with preconditioning (PC) has been extensively documented in adult cohorts. Moreover, although PC-induced cardioprotection is purportedly triggered in part by activation of PKC, recent evidence has shown that: (1) release of inositol trisphosphate (IP3: second messenger generated in parallel with diacylglycerol-PKC) and subsequent binding to IP3 receptors contributes to the infarct-sparing effect of PC; and (2) D-myo-IP3 (analog of native IP3), given in lieu of brief ischemia, mimics the benefits of PC. Limited data obtained in elderly populations (the specific subset in which clinical exploitation of PC would be most relevant) suggests that PC may fail to evoke protection, possibly due to age-associated defects in PKC signaling. However, the integrity of IP3 signaling in aged hearts -and, in particular, the ability of exogenous D-myo-IP3 to initiate protection in this cohort -has not been explored. To investigate this issue, isolated buffer-perfused mouse hearts were harvested from adult (3 month) and elderly (2 year old) animals. In Protocol 1, hearts received 2 5-min cycles of PC ischemia; an amplified PC stimulus (4 5-min cycles: old cohort only); pretreatment with D-myo-IP3 (6 M), or no intervention (controls). All hearts then underwent 30 min global ischemia ϩ 2 h reperfusion, and infarct size was delineated by tetrazolium staining and expressed as a % of the LV. In Protocol 2, additional adult and old hearts were used to assess myocardial expression of IP3 receptor protein. Infarct size reduction with PC was seen in adult, but not old, hearts (*pϽ0.05 vs age-matched Controls). In contrast: (1) the infarct-sparing effect of D-myo-IP3 was maintained in aged hearts; while (2) Protocol 2 revealed a marked, Ͼ5-fold increase in IP3 receptor protein in old vs adult myocardium. Thus, although hearts from 2 year old mice are refractory to PC-induced protection, reduction of infarct size can be triggered by exogenous D-myo-IP3 in this aged cohort.
INFARCT SIZE (% OF LV)
Control PC: 2 x 5 min PC: 4 x 5 min D-myo-IP3
Adult: 53Ϯ5% 30Ϯ6%* -34Ϯ 7% * 'Elderly': 44Ϯ4% 48Ϯ5% 43Ϯ4% 32Ϯ 4% *
P36 Mitochondrial Localization and Cellular Function of Cytoglobin: A Novel Calcineurin-Dependent Hypoxia-Responsive Globin in the Cardiovascular System
Qiu Ye, Shilpa M Manda, Rani Chirumamilla, Teresa Gallardo, Sean Goetsch, Daniel J Garry, Pradeep P A Mammen; UT Southwestern Med Ctr, Dallas, TX Cytoglobin (Cygb) is a novel tissue hemoglobin that has a 30% amino acid homology to myoglobin. Since cytoglobin shares several structural features with myoglobin, we hypothesized that Cygb may play a cytoprotective role by scavenging free radicals or modulating oxygen/nitric oxide metabolism within the cardiovascular system. We have demonstrated that Cygb is regulated by the calcineurin-NFAT pathway, is predominantly expressed in the heart and brain and its expression is upregulated with stress at both the transcriptional and translational levels (hypoxic heart/brain and ischemic cardiomyopathic heart). In-vitro studieswere undertaken to investigate the subcellular localization and mechanistic role(s) of cytoglobin within the cell. Western blot analysis indicated that Cygb is found in both the cytoplasm and the nucleus of normoxic C2C12 myoblasts; however, upon exposure to hypoxia (1% O 2 for 16 hours) Cygb translocates out of the nucleus. This was conferred by immunocytochemistry (ICC). In addition, the translocation of Cygb out of the nucleus with hypoxia is blocked when C2C12 cells were incubated with leptomycin B, a potent inhibitor of nuclear export. ICC data also revealed that Cygb co-localizes to the mitochondria upon hypoxic exposure. Transfection assays involving C2C12 cells demonstrated that over-expression of cytoglobin promotes cellular viability upon exposure to menadione, an agent known to induce free radical production (67Ϯ1.6% cell survival in overexpressed cells vs. 48Ϯ1.6% cell survival in control cells; pϽ0.05; nϭ3) and under anoxic conditions (72Ϯ8.0% cell survival in overexpressed cells vs. 49Ϯ0.7% cell survival in control cells; pϽ0.05; nϭ3). Conversely, the silencing of Cygb expression by siRNA resulted in a significant reduction in cell survival under anoxic conditions (32.7Ϯ0.2% cell survival in Cygb-knockdown cells vs. 63Ϯ1.5% cell survival in control cells; pϽ0.05; nϭ3). Finally, microarray analysis of Cygb knockdown cells indicated an upregulation of genes involved in apoptosis and cell cycle regulation. These new data collectively establish that cytoglobin is a novel stress-responsive globin that may play a key signaling role as well as a cytoprotective role in the hypoxic/ischemic heart.
P37 An ␣1A-Adrenergic-ERK Signaling Pathway Mediates Survival Signaling in Cardiac Myocytes
Yuan Huang, Casey D Wright, Chastity Merkwan, Nichole L Baye, Qiangrong Liang, South Dakota Health Rsch Foundation, Sioux Falls, SD; Paul C Simpson, San Francisco VA Med Ctr, San Francisco, CA; Timothy D O'Connell; South Dakota Health Rsch Foundation, Sioux Falls, SD In ␣1ABKO mice, which lack cardiac myocyte ␣1-adrenergic receptors (␣1-ARs), aortic constriction induces apoptosis, dilated cardiomyopathy and death, demonstrating that ␣1-ARs are required for myocardial adaptation to stress. Here we investigated ␣1A and ␣1B subtype-specific survival signaling in cultured cardiac myocytes to demonstrate a direct protective effect of ␣1-ARs in cardiac myocytes. We cultured myocytes from ␣1ABKO hearts and reconstituted ␣1-signaling with adenoviruses expressing ␣1Aor ␣1B-GFP fusion proteins. Myocyte death was induced by norepinephrine (NE), and measured by annexin V/propidium iodide staining. In WT myocytes, NE (1 M) did not induce cell death (Con Apoptosis (Apop) 3Ϯ0%, Necrosis (Nec) 12Ϯ2%, nϭ5; NE Apop 4Ϯ1%, Nec 11Ϯ1%, nϭ5, PϭNS). However, in ␣1ABKO myocytes, NE significantly increased both apoptosis and necrosis (Con Apop 3Ϯ0%, Nec 11Ϯ1%, nϭ5; NE Apop 9Ϯ1%, Nec 19Ϯ1%, nϭ5, PϽ0.05). Reconstitution of the ␣1A rescued ␣1ABKO myocytes from NE-induced death (NE; Apop 4Ϯ1%, Nec 11Ϯ1%, nϭ3, PϽ0.05 vs. ␣1ABKO NE), but reconstitution of the ␣1B did not (NE; Apop 9Ϯ2%, Nec 21Ϯ3%, nϭ3 PϭNS vs. ␣1ABKO NE). To determine the mechanism of ␣1A survival signaling, we examined ␣1-AR activation of ERK, a kinase involved in survival signaling. In ␣1ABKO mice, aortic constriction failed to activate ERK, which is correlated with our previous finding of apoptosis and dilated cardiomyopathy. In ␣1ABKO myocytes, expression of a constitutively active MEK1, the upstream activator of ERK, rescued ␣1ABKO myocytes from NE-induced death, suggesting that ERK activation is sufficient to protect ␣1ABKO myocytes from death. Interestingly, only the ␣1A activated ERK in ␣1ABKO myocytes (both subtypes activated ERK in HeLa cells). In addition, expression of a dominant-negative MEK1 blocked ␣1A survival signaling in ␣1ABKO myocytes expressing the ␣1A-GFP, suggesting that ERK activation is required for ␣1A survival signaling. In summary, these results demonstrate a direct protective effect of the ␣1A subtype in cardiac myocytes. Further, the lack of ␣1A-ERK survival signaling could explain the failure to activate ERK following aortic constriction in ␣1ABKO mice, and possibly explain the development of apoptosis, dilated cardiomyopathy and death.
P38
Role of Testosterone in Heat Shock Protein 70 Activation and Delayed Cardioprotection of Preconditioning in Male Rats
Jing Liu, Sharon Tsang, Tak M Wong; The Univ of Hong Kong, Hong Kong, China
The cardioprotection of ischemic preconditioning appears to be reduced with age in the male, suggesting that testosterone may be responsible. There is evidence of a link between testosterone and heat shock protein 70 (HSP70), which mediates the delayed cardioprotection of preconditioning. We therefore hypothesize that testosterone is needed for full activation of HSP70, which mediates the cardioprotection of IP. Male Sprague-Dawley rats (7-8 weeks) underwent sham operation or gonadectomy without (G) or with testosterone replacement (200 g/100g BW) daily for 8 weeks (GT). The preconditioned groups received intravenously 10 mg/kg U50,488H (UP), a kappa opioid receptor agonist, known to confer delayed cardioprotection. 24 hours later, hearts were removed and then subjected to regional ischemia and reperfusion. For ventricular myocytes preparation, myocytes isolated from sham and G rats were also preconditioned with U50,488H and then subjected to metabolic inhibition and anoxia after 24h incubation with or without testosterone. Infarct size, viability and LDH release were determined. Cardiac functions were monitored continuously by a PowerLab/4SD analog-todigital converter. HSP70 and HSF1 expression were analyzed by Western Blotting. UP reduced the infarct size and LDH release upon ischemia / reperfusion in sham rats. This was accompanied by improved contractile functions, activation of HSF1 and increased HSP70 expression. In contrast, all effects of UP disappeared in G rats, which was restored by testosterone replacement. Similar observations in cardioprotection of UP were found in ventricular myocytes. Moreover, the effects of testosterone replacement were abolished by androgen receptor blockade. In conclusion, testosterone is required for the activation of HSP70 upon preconditioning, which mediates the delayed cardioprotection. The effects of testosterone are androgen receptor mediated.
P39
Mechanisms of Myocardial Protection by Atorvastatin: 5'-Nucleotidase Is Upstream to eNOS Activation
Yochai Birnbaum, Yumei Ye, Yu Lin, Barry F Uretsky, Univ of Texas Med Branch, Galveston, TX; Masafumi Kitakaze, National Cardiovascular Ctr, Osaka, Japan; Juan D Martinez, Jose R Perez-Polo; Univ of Texas Med Branch, Galveston, TX Background: Previous studies have shown that statins protect against ischemia-reperfusion injury by activating phosphatidylinositol 3-Kinase (PI3K), leading to phosphorylation of Akt that activates endothelial nitric oxide synthase (eNOS) by phosphorylation. PI3K also activates ecto-5'-nucleotidase (E5N). Blocking E5N abrogates the infarct size (IS)-limiting effects of statins in the dog. It was suggested that E5N and eNOS are activated in parallel. We have shown in the rat that inducible NOS (iNOS) and cycloxygenase-2 (COX2) activation are mandatory steps for mediating the IS-limiting effect of atorvastatin (ATV) and are downstream to eNOS. Purpose: To assess whether E5N activation is downstream or upstream to eNOS. Methods: Wild-type (WT), eNOS -/and iNOS -/mice were pretreated with oral ATV (ATVϩ; 10 mg/kg/d) or water alone (ATV-) for 3 days. Mice were subjected to 30 min coronary artery occlusion and 4h reperfusion (IS protocol), or hearts were harvested, without being subjected to ischemia, for measurement of myocardial E5N (ng/mg protein/min), calcium-dependent (cNOS) and independent (ciNOS) NOS activity (X1000 cpm); and adenosine (g/g) and 6-keto-PGF 1␣ (the stable metabolite of PGI 2 ; pg/ml) levels. Results: Body weight, LV size and area at risk size (AR) were comparable among groups. ATV decreased IS only in the WT mice. cNOS activity was increased in the ATVϩ WT and iNOS -/mice. ATV increased ciNOS activity and myocardial 6-keto-PGF 1␣ levels only in the WT mice. ATV increased E5N activity and tissue adenosine levels in all groups. E5N activity was significantly higher in the eNOS -/than in the WT mice (pϭ0.017) or iNOS -/group (pϭ0.025). Conclusions: ATV activates E5N in the mouse. E5N upregulation by ATV does not limit IS in eNOS -/and iNOS -/mice, suggesting that E5N activation is upstream to eNOS, iNOS and PGI 2 production. 
P40 Pioglitazone Reduces Myocardial Infarct Size and Increases Myocardial PGI 2 Levels by Upregulating cPLA 2
Yochai Birnbaum, Yumei Ye, Yu Lin, Shaul Atar, Ming-He Huang, Jose R Perez-Polo, Barry F Uretsky; Univ of Texas Med Branch, Galveston, TX Background: Several studies have shown that thiazolidinediones (TZD) reduce myocardial infarct size (IS). However, the underlying mechanism is still unclear. It has been demonstrated that the IS-limiting effect of statins involves increased expression and activity of phosphorylated endothelial nitric oxide synthase (P-eNOS), inducible NOS (iNOS), phospholipase A 2 (cPLA 2 ), and cycloxygenase-2 (COX2). Blocking COX2 abrogated the protective effect of atorvastatin. We investigated whether pioglitazone (PIO) shares the same mechanisms, protecting the heart by increasing myocardial PGI 2 production. Methods: Sprague-Dawley rats received 3-day oral treatment with: 1) PIO 10 mg/kg/d or 2) water (control). Rats underwent 30 min ischemia and 4h reperfusion (IS protocol)(nϭ12 per group), or hearts were explanted (nϭ4 in each group) without being subjected to ischemia [immunoblotting and ELISA for 6-keto-PGF 1␣ (the stable metabolite of PGI 2 )]. Additional rats (nϭ4 in each group) received PIO (10mg/kg/d) for 3 days and intravenous SC58125 (a COX2 inhibitor) or SC560 (a COX1 inhibitor) 15min before ischemia. Results: Body weight, left ventricular weight and the area at risk (AR) were similar between groups. PIO reduced IS (Table) . PIO did not affect myocardial expression of P-eNOS, iNOS, and COX2. However, PIO increased expression of cPLA 2 and the myocardial contents of 6-keto-PGF 1␣ . The protective effect of PIO was abrogated by SC58125 (22.7Ϯ1.7%), but not by SC560 (9.5Ϯ0.4%; pϭ0.004). Conclusions: IS limitation with PIO is associated with increased expression of myocardial cPLA 2 , leading to increased PGI 2 content. However, it is independent of upregulation of P-eNOS, iNOS and COX2. The muscle-related RING-finger protein 3 (MuRF3), a member of the TRIM family, is restricted to heart and skeletal muscle and is implicated as an E3 ubiquitin ligase within the ubiquitin proteasome pathway. MuRF3 is localized to the sarcomere and its expression in muscle cells is induced during muscle differentiation. Yeast-two-hybrid analysis and biochemical characterization revealed gamma-filamin and FHL-2 as MuRF3 interaction partners and targets for proteasome dependent degradation through the MuRF3 coiled-coil domain. To determine the role of the coiled-coil domain for MuRF3 function in vivo, we generated a germline deletion of the coiled-coil domain of MuRF3 (referred to as MuRF3⌬cc) in mice. Mice homozygous for this mutation are viable and display an increase in gamma-filamin and FHL-2 protein compared to wild type (WT) mice, indicating that both proteins are degraded in vivo by MuRF3. At baseline, echocardiographic analysis of MuRF3⌬cc hearts showed a mild reduction of systolic left ventricular (LV) function compared to controls. When subjected to acute myocardial infarction (MI) by ligation of the left anterior descending artery, MuRF3⌬cc mice developed a severe phenotype five days after induction of MI. Strikingly, these mice exhibit a doubling of mortality compared to control mice due to ventricular rupture in the border zone of the MI. This rupture is preceded by LV dilation with a severe decrease in cardiac function and diastolic and systolic posterior wall thicknesses. Histological analysis showed myocyte necrosis and deficient scar formation in the peri-infarct zone and excessive TUNEL positive cells in MuRF3⌬cc mice compared to WT mice following MI. Cardiac stress markers (ANF, BNP, CTGF) were also upregulated to a greater extent in MuRF3⌬cc MI mice. Upon oxidative stress, MuRF3 was co-localized with mitochondria and stress fibers in myocytes. Cells overexpressing MuRF3 showed a reduction of cell death in response to oxidative stress and MuRF3 expression was increased in response to oxidative stress. We conclude that MuRF3 plays a protective role in the heart by maintaining integrity and function of the myocardium. This cardioprotective role is partially mediated through MuRF3 mediated turnover of gamma-filamin and FHL-2.
Control
P42 G-CSF Directly Inhibits Myocardial Ischemia-Reperfusion Injury Through Akt-eNOS Pathway
Kazutaka Ueda, Hiroyuki Takano, Hiroshi Hasegawa, Yingjie Qin, Masashi Ohtsuka, Issei Komuro; Chiba Univerity Graduate Sch of Medicine, Chiba, Japan Background-Granulocyte-colony stimulating factor (G-CSF) has been recently reported to prevent cardiac remodeling and dysfunction after acute myocardial infarction. In this study, we examined acute protective effects of G-CSF on myocardial ischemia-reperfusion (IR) injury. Methods and Results-Rat hearts were subjected to global 35 minutes ischemia and 120 minutes reperfusion in Langendorff system with or without G-CSF (300 ng/ml). G-CSF administration was started at the onset of reperfusion. Infarct size was assessed by triphenyltetrazolium chloride (TTC) staining. G-CSF markedly reduced the infarct size (control, 58.6Ϯ3.6% vs G-CSF, 34.7Ϯ4.5%, PϽ0.001). To examine G-CSF-induced signaling pathways, perfused rat hearts were subjected to 35 minutes ischemia and 7 minutes reperfusion (nϭ5, per group). G-CSF strongly activated Jak2, STAT3, extracellular signal-regulated kinase (ERK), Akt and endothelial NO synthase (eNOS). To identify the role of signaling pathways that are activated by G-CSF, hearts were preperfused with inhibitors of phosphatidylinositol 3-kinase (PI3K) (LY294002, 5 microM), Janus kinase 2 (Jak2) (AG490, 5 microM), MEK (PD98059, 10 microM), or nitric oxide synthase (NOS) (N -nitro-L-arginine methyl ester (L-NAME), 30 microM). The G-CSF-induced reduction in infarct size was abolished by LY294002, AG490, L-NAME, but not PD98059. Conclusions-These results suggest that G-CSF acts directly on the myocardium during IR injury and has acute non-genomic cardioprotective effects through the Akt-eNOS pathway.
P43 Myocardial Susceptibility to Ischemic-Reperfusion Injury in a Viscerally Obese, Pre-Diabetic Rodent Model
Eugene F Du Toit, Wayne Smith, Christo Muller, Hans Strijdom, Univ of Stellenbosch, Cape Town, South Africa; Angela J Woodiwiss, Gavin R Norton, Univ of Witwatersrand, Johannesburg, South Africa; Amanda Lochner; Univ of Stellenbosch, Cape Town, South Africa
Background. The impact of obesity and insulin resistance on clinical outcomes post-myocardial infarction is presently controversial. We set out to determine whether obesity and insulin resistance in the absence of clinically detectable diabetes mellitus, have deleterious effects post myocardial infarction. Methods and results. After feeding rats a high calorie diet for 16 weeks, body weight (512Ϯ11g vs. 603Ϯ10g, pϽ0.05), visceral fat content (29.8Ϯ1.6g vs. 49.5Ϯ2.2g, pϽ0.05), plasma insulin (31.4Ϯ49.5IU/ml vs. 49.5Ϯ6.2IU/ml, pϽ 0.002) and triglycerides concentrations (0.72Ϯ0.07mmol/L vs. 1.91Ϯ0.18mmol/L, pϽ0.05) ventricular weight (1.23Ϯ0.02g vs. 1.56Ϯ0.03g, pϽ 0.05), and left ventricular posterior wall thickness (0.12Ϯ0.01cm vs. 0.16Ϯ0.01cm, pϽ 0.05) were increased. Fasting blood glucose concen-trations of control and obese rats were similar, while glycosylated hemoglobin concentrations were only mildly elevated in obese rats (3.52Ϯ0.06% vs. 3.97Ϯ0.10%, pϽ 0.05). Hearts from obese rats were perfused on the isolated working rat heart perfusion system and subjected to left anterior descending coronary artery occlusion (CAO) and reperfusion. Reperfusion function, arrhythmias and infarct size was assessed using TTC staining. CAO resulted in an increased infarct size (22.9Ϯ2.3% vs. 41.8Ϯ1.85%, pϽ0.05), an increased incidence of reperfusion ventricular fibrillation (0% vs. 86%, pϽ0.05) and a decreased reperfusion aortic output recovery (27.7Ϯ3.4% vs. 4.2Ϯ4.2%, pϽ0.05) in obese compared to control rat hearts. Coronary effluent nor-epinephrine release before, and subsequent to CAO was similar in both groups. Myocardial glucose uptake was however reduced in obese rat hearts when compared to controls (0.56Ϯ0.07nmol/g/min vs. 0.30Ϯ0.01nmol/g/min, pϽ0.05). Conclusions. These data indicate that obesity without clinically detectable diabetes mellitus increases myocardial infarct size and incidence of reperfusion arrhythmias and decreases reperfusion function after CAO. This reduced ischemic tolerance was not associated with increased myocardial catecholamine release but with alterations in myocardial glucose metabolism. The effects of the addition of insulin to the perfusion solution is currently under investigation.
P44 Surgical Ischemia Induces Phosphorylation and Translocation of Heat Shock Protein 27 and ␣B-Crystallin in Human Myocardium
Richard T Clements, Jun Feng, Neel Sodha, Basel Ramlawi, Shigetoshi Mieno, Munir Boodhwani, Shu Xu, Cesario Bianchi, Frank W Sellke; Beth Israel Deaconess Med Ctr, Boston, MA The small heat shock proteins HSP27 and ␣B-crystallin (cryAB) are highly expressed in cardiac and skeletal muscle. Evidence from cell culture and animal models indicates that HSP27 and cryAB are dramatically regulated via phosphorylation in response to ischemic insults. The phosphorylation of these proteins is implicated in the regulation of diverse cellular processes including myocyte redox regulation, protein chaperone function, signal transduction scaffolding, and recently, myocyte contractile function. It is unknown if HSP27 and cryAB play a role in the response to ischemia in human myocardium in vivo. Patients undergoing open heart sugery (CABG, valve replacement) are subjected to ischemic insults via cardioplegia and cardiopulmonary bypass (CP/CPB). Cardioplegia solutions used to arrest the heart during surgery are associated with ischemic insults including hypoxia and myocardial contractile deficits. We performed the following experiments to determine any changes in the phosphorylation and localization of HSP27 and CRYAB in human myocardium following CP/CPB. Right atrial appendage and chest wall skeletal muscle samples were collected from patients immediately before and after CP/CPB. In whole tissue lysates, CP/CPB induced a robust increase in the atrial phosphorylation of HSP27 at ser82 and cryAB at ser59. There were no changes in the expression level of either protein. Furthermore, phosphorylation of HSP27 and cryAB following CP/CPB associated with translocation from a Triton X-100 soluble to an insoluble pool. There was no detectable increase in phosphorylation of either protein in skeletal muscle, suggesting an ischemia specific response. In addition, confocal microscopy of atrial tissue revealed movement of HSP27 and cryAB from a diffuse/membrane localization pre-CP/CPB to a striated sarcomeric pattern after CP/CPB. Double labeling with an atrial specific myosin light chain -2a antibody revealed prominent staining of total and ser82, ser78, and ser15 phosphorylated HSP27 along I-bands of cardiomyocytes after CP/CPB. These results demonstrate that two members of the sHSP family, HSP-27 and cryAB, are phosphorylated and translocate to cardiac myofilaments following surgical ischemia associated with CP/CPB.
P45
Activation of PKN Causes Cardiac Hypertrophy and Resistance to Ischemia-Reperfusion
Hiromitsu Takagi, Katsuya Kajimoto, Peiyong Zhai, Junichi Sadoshima; UMDNJ New Jersey Med Sch, Newark, NJ PKN is a serine/threonine kinase, whose catalytic domain is highly homologous to that of protein kinase C. PKN causes ANF gene expression in cardiac myocytes. However, in vivo function of PKN in the heart is poorly understood. In yeast, Pkc1, whose amino-terminal regulatory region is highly homologus to that of PKN, is activated by cell wall stress including hypotonic stress (HS). It has been shown that ischemia reperfusion (I/R) induces hypotonic cell swelling in the myocardium. Hyposomotic buffer perfusion has a protective effect on the heart subjected to I/R. In the present study, therefore, we examined whether PKN is activated by hypotonic stress in cardiac myocytes in vitro, and by I/R in the heart in vivo. We constructed transgenic mice with cardiac specific overexpression of constitutive active (CA) PKN (Tg-CAPKN) and examined whether activation of PKN has a protective effect in the heart. In neonatal rat ventricular myocytes, PKN was activated by HS (67% osmolarity) within 15 min. Activation of PKN by HS reached a peak within 60 min, which was accompanied by Thr774 phosphorylation. Phosphorylation of PKN was also observed in the heart subjected to I/R in vivo. In Tg-CAPKN mice, left ventricular (LV) weight to body weight ratio was heavier and LV wall thickness was thicker than in non-transgenic (NTg) mice, indicating that PKN stimulates cardiac hypertrophy. Cardiac function assessed by echocardiography was comparable in both Tg-CAPKN and NTg mice. In NTg hearts, 45min ischemia followed by 24 hr reperfusion caused myocardial infarction (MI), whereas the size of MI was dramatically smaller in Tg-CAPKN heart (NTg vs. Tg-CAPKN, 37.5Ϯ6.0 vs. 11.4Ϯ6.0%, pϽ0.01). The number of TUNEL positive nuclei in the I/R hearts was also significantly smaller in Tg-CAPKN mice than in NTg mice (0.98Ϯ0.23% vs. 0.30Ϯ0.15%, pϽ0.05). These results suggest that PKN is activated by HS in cardiac myocytes and I/R in the mouse heart. Furthermore, activation of PKN causes well compensated LV hypertrophy and also has protective effects in the ischemia-reperfused heart in vivo.
P46
Reduced Incidence of Vagally Induced Atrial Fibrillation and Expression Levels of Connexins by n-3 Polyunsaturated Fatty Acids in Dogs
Pascal Daleau, Jean-Franç ois Sarrazin, John Kingma, Geneviè ve Comeau, Dominique Fournier, Franck Molin; Quebec Heart Inst, Quebec, Canada Atrial fibrillation (AF) is a common arrhythmia with limited successful treatment. Dietary fish oils are a major source of omega-3 polyunsaturated fatty acids (n-3 PUFAs) and may lower mortality by reducing sudden cardiac death and in all likelihood ventricular tachyarrhythmias; the exact antiarrhythmic mechanisms involved remain unclear. Changes in spatial organization of gap junctions or cellular levels of cardiac connexins (Cx) have been linked to arrhythmogenesis. The aims of this open-label, uncontrolled study in dogs were to assess whether n-3 PUFAs prevent AF and to evaluate their impact on atrial tissue expression levels of Cx40 and Cx43. Twenty-five dogs were studied using the vagally-induced AF model. Eight dogs were treated with 1.2g PO of n-3 PUFAs daily for 14 days. Of 17 control dogs we were able to induce AF in 8; the latter were re-evaluated for AF inducibility following IV treatment with a fish oil emulsion (1.4g in saline). Episodes of AF induced by extra stimuli or burst induction were compared. Atrial tissue biopsies were obtained to assess n-3 PUFAs levels and for western blot analysis of Cx40 and Cx43 protein levels. Total n-3 PUFAs atrial tissue levels were increased significantly in the oral treatment group (5.78 Ϯ 0.71% vs 2.48 Ϯ 0.42% in controls, pϽ0.001). No difference was observed for hemodynamic or electrocardiographic parameters between groups. The number of episodes of sustained AF in the oral treatment group was reduced by 79% with the extra stimulus technique (10.5 vs. 48.9%, pϭ0.001) and by 42% with burst induction (22.5 vs. 38.8%, pϭ0.034). Cx40 and Cx43 protein levels were lower in oral treatment dogs (average decrease of 60% (pϭ0.019) and 42% (pϭ0.038), respectively); protection against AF appeared to be specifically related to reduced Cx40 expression levels (pϽ0.001). In dogs that were given IV n-3 PUFAs, AF inducibility by the extra stimulus technique was reduced by 61.9% (pϭ0.0001). In conclusion, oral treatment with fish oils increased plasma and atrial n-3 PUFAs levels and reduced vulnerability to induction of AF in this dog model. Modulation of cardiac Cx by n-3 PUFAs probably contributes to the antiarrhythmic effects of fish oils.
P47
Interleukin-1 Receptor Antagonist Reduced Infarct Size and Improved Heart Function After Ischemia/Reperfusion in Rats
Steffen Rabald, Heinz G Zimmer, Alexander Deten; Carl-Ludwig-Inst for Physiology, Leipzig, Germany
The expression of the ,,pro-inflammatory" cytokines interleukin (IL) -1 and -6 is induced after myocardial ischemia. The pathophysiological role of these cytokines, however, is largely unknown. In this study the effect of IL-1 receptor antagonist was analyzed after ischemia/ reperfusion (IR) in rats. Methods: Myocardial ischemia was induced in 12 weeks old female Sprague-Dawley rats by ligation of the left coronary artery. After 60 min reperfusion was established and treatment with IL-1 receptor antagonist (rhIL-1ra, Kineret®, 3 x 33 mg s.c., IR-K)) or NaCl (IR) started. Heart function was measured with Millar-tip catheters after 5, 10, 24 and 72 h of reperfusion (nϭ5-8 in each group). Thereafter, the hearts were analyzed for mRNA expression (RPA), MMP activity (zymography) and protein expression/-phosphorylation (Western-Blot). Results: Myocardial function after IR improved by IL-1ra treatment (after 72 h: LVEDP 13Ϯ1 vs. 9Ϯ1 mmHg, LVdP/dt max 7658Ϯ360 vs. 9138Ϯ599 mmHg/s, LVtau 13.8Ϯ0.5 vs. 11.7Ϯ0.3 ms, HMV 72Ϯ6 vs. 92Ϯ9 ml/min in IR vs. IR-K, respectively, for all pϽ0.05). This was associated with reduced MI size (TTC/Evans Blue staining after 24 h: 64Ϯ7 vs. 37Ϯ5 % MI/AAR in IR vs. IRϩK, each nϭ4, pϽ0.05). Furthermore, there was increased Akt phosphorylation but reduced mRNA expression of FAS Ag, bax and Caspase 3 as well as of bcl-x and IL-6. In contrast, MMP-8/-9 expression as well as MMP-9 activity was unchanged indicating comparable cell infiltration. Conclusion: The application of IL-1ra reduced infarct size and improved heart function after ischemia/reperfusion in rats.
P48
Effects of Ng-nitro-arginine Methylester (L-NAME) on Coronary Blood Flow, Myocardial Infarct Size, and the Extent of the No-Reflow Phenomenon in an Experimental Model of Ischemia-Reperfusion
Elias J Tsolakis, Efstratios I Charitos, Panagiotis Papazoglou, George Maroulidis, Nikolaos Lazaris, Stavros G Drakos, Stilianos Efentakis, Paraskevi Savvari, John N Nanas; Univ of Athens, Athens, Greece Background: L-NAME has been used in clinical practice in the treatment of patients with refractory cardiogenic shock. The purpose of our study was to examine the effect of L-NAME on coronary blood flow (CBF), myocardial infarct size (MIS), and the extent of the no-reflow phenomenon (NRP) in an experimental model of ischemia-reperfusion. Methods: A randomized study was conducted in an experimental model of ischemia-reperfusion. In fifteen piglets, 25-35 kg, after mid-thoracotomy, ischemia was provoked by ligation of the mid portion of the left anterior descending (LAD) coronary artery for 60 minutes, followed by 120 minutes of reperfusion. The animals were randomized 10 minutes before reperfusion into 2 groups: Group A, where no medical intervention was made, and Group B, where L-NAME was administered (loading dose 1 mg/kg, followed by continuous infusion 1 mg/kg/h) until the end of reperfusion. CBF was measured by a transit time probe at the site of LAD ligation, and expressed as a percentage of baseline CBF. The extent of NRP was measured with thioflavine stain, and expressed as a percentage of the myocardial area at risk (AAR). Myocardial infarct size (MIS) was measured with triphenyltetrazolium chloride stain (TTC) and expressed as a percentage of the AAR. Results: Eight animals were included in Group A, and 7 in Group B. A statistically significant reduction of CBF was observed in Group B during reperfusion. A trend towards reduction of the extent of NRP was observed in Group B (Group A: 60.9Ϯ11.4%, Group B: 51.8Ϯ19.7%, pϭ0.350). The MIS did not differ between the 2 groups (Group A: 77.1Ϯ8.8%, Group B: 77.9Ϯ13.9%, pϭ0.921). Conclusions: In this porcine experimental model of ischemia-reperfusion, although L-NAME reduced CBF, it did not cause further damage to microcirculation, and did not affect MIS. According to the results of this study, L-NAME may be safely used in patients with acute myocardial infarction complicated by refractory cardiogenic shock.
P49 Detrimental Role of Complement Factor C3 After Myocardial Infarction
Stefan Frantz, Helga Wagner, Georg Ertl, Johann Bauersachs; Med Universitaetsklinik, Wuerzburg, Germany Background: Complement contributes to tissue injury in ischemic organs, with or without reperfusion. Activation of complement is an early event in ischemia/reperfusion injury and complement factors like C3 are produced in the myocardium after cardiac injury. However, the expression and function of complement in heart failure has not been defined yet. Methods and results: The complement factor C3 is activated in the failing mouse heart up to 8 weeks after large myocardial infarction as determined by immunohistochemistry. After coronary artery ligation mortality was not different between wild-type (WT) and C3 knockout (KO) mice. However, C3 KOs exhibited significantly reduced ventricular dilatation over 3 weeks after myocardial infarction compared to WT controls (endsystolic areas by transthoracic echocardiography, WT vs. KO, 19.6Ϯ1.2 mm 2 vs. 13.9Ϯ1.2 mm 2 , pϭ0.01). C3 levels were absent in KO animals. Collagen content was significantly lower in the KO mice after myocardial infarction and may account for improved left ventricular remodeling. Conclusion: The complement factor C3 is activated after myocardial infarction. Absence of C3 reduces left ventricular dilatation after myocardial infarction. C3 might therefore be an attractive target to treat heart failure.
P50 Apoptosis Inhibition Improves Left Ventricular Function After Prolonged Cold Cardioplegic Arrest
Uwe M Fischer, Werner O Monzon-Posadas, Jü rgen H Fischer, Univ of Cologne, Cologne, Germany; Wilhelm Bloch, German Sports Univ, Cologne, Germany; Uwe Mehlhorn, Thorsten Wahlers; Univ of Cologne, Cologne, Germany
Objectives: Cardioplegic arrest (CA) is associated with myocardial apoptosis induction. Data suggest that apoptosis inhibition during regional myocardial ischemia reduces infarct size and improves regional contractility. We sought to investigate whether inhibition of the apoptosissignal-pathway would also improve left ventricular (LV) function following prolonged cold CA. Methods: Ten adult rats were anesthetised and mechanically ventilated. Hearts were arrested by administration of ice-cold crystalloid cardioplegia (Bretschneider solution, Custodiol ® , 10 ml/kg) with and without supplementation of a cell permeable non-selective caspase-inhibitor (z-VAD-fmk, 10 M, nϭ5 each). Hearts were stored for 4h in cardioplegia (4°C). Subsequently, hearts were reperfused with Krebs-Henseleit-Solution (37°C) on a Langendorff-System. A balloon connected to a pressure transducer was inserted in the LV and inflated to a diastolic pressure of 10 mmHg. LV pressure and heart rate were recorded continuously for 60 min. Five additional rats without ischemic storage served as controls. Results: After 4h cold CA, hearts with apoptosis-inhibition had higher left ventricular pressure throughout the 60min reperfusion as compared to those without apoptosis-inhibition. Apoptosis-inhibition even resulted in significantly higher LV pressures as compared to controls at 30, 40 and 50 min reperfusion (58.6Ϯ10, 59.2Ϯ8.1 and 58.6Ϯ8.6 mmHg vs. 42Ϯ8.7, 42.8Ϯ10.6 and 42.2Ϯ8.6 mmHg, respectively; pϽ0.013). Recovery time on reperfusion defined as duration until heart rate and LV pressure reached steady state was significantly shorter with apoptosis inhibition as compared to non-inhibition (13.4Ϯ11.6 vs 29.6Ϯ8.2 min, pϭ0.017). Conclusions: Apoptosisinhibition improves LV-function after prolonged cold CA and represents a new promising strategy in myocardial protection for cardiac allografts.
P52 The Stabilization of ␤-Catetin Inhibits Physiological Hypertrophy in Adult Mice Hearts
Anthony Baurand, Laura Zelarayan, Sandra Dunger, Russel Betney, Bä rbel Pohl, Rainer Dietz, Martin Bergmann; Max-Delbrü ck-Ctr fü r Molekulare Med, Berlin, Germany Constitutive activation of cardiac glycogen synthase kinase-3␤ (GSK-3␤) is known to suppress cardiac hypertrophy in vivo. Among other substrates GSK-3␤ phosphorylates ␤-catenin, leading to its degradation. In order to study the role of ␤-catenin in cardiac hypertrophy, we studied the effect of its stabilization in adult mice at baseline and after angiotensin II (Ang II) stimulation. We employed a cardiac-specific mifepristone-inducible Cre transgene to induce ␤-catenin stabilization in cardiomyocytes. The exon 3 of ␤-catenin gene regulates its stability trought proteolysis. Recombination of loxP sites flanking exon 3 was confirmed by PCR of genomic heart extracts and the truncated ␤-catenin product was confirmed by Western blot as well as in the nucleus. Mice with cardiac specific ␤-catenin stabilization were viable and the echocardiography and histology analysis of the hearts at baseline conditions showed apparently no significant structural modifications. Infusion of Ang II by osmotic minipumps induced as expected cardiac hypertrophy in wild type mice demonstrated by echocardiography analysis (intraventricular septum (IVS) 0,84Ϯ0,05 [meanϮSEM], and left ventricular posterior wall (LVPW) 0,8Ϯ0,03). Surprisingly, a clearly reduced cardiac hypertrophy was seen in the mutants (IVS 0,69Ϯ0,04, and LVPW 0,7Ϯ0,05). The expression of hypertrophic markers such as atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) was decreased in comparison with the cardiac hypertrophic hearts in the wt mice as measured by real-time RT-PCR. Additionally, measurement of the cell surface using a wheat germ agglutinin (WGA-FITC) staining showed a decrease augment of the cell size, which is a common feature in hypertrophied hearts. Moreover, the fractional shortening (FS), which is normally increased in physiological hypertrophied hearts, was found reduced in the mutants (FSϭ 22,4Ϯ4,5) when compared with the controls (36,2Ϯ1,6), indicating a bad left ventricular performance after Ang-II stimulation. Taken together these findings, we could suggest that ␤-catenin may block the process of physiological heart hypertrophy to increased stress, which lead to an inappropriate adaptation of the heart to enhance its pumping capacity.
P53 Withdrawn
P54 TRPC6 Forms a Positive Regulatory Loop of Calcineurin-NFAT Pathway During Cardiac Remodeling
Koichiro Kuwahara, Eric N Olson; UT Southwestern Med Ctr, Dallas, TX
The heart responds to injury and chronic pressure-overload by pathological growth and remodeling, which frequently results in heart failure and sudden death. Calcium-dependent signaling pathways promote cardiac growth and changes in gene expression in response to cardiac stress. The calcium/calmodulin-dependent phosphatase calcineurin, which signals to nuclear factor of activated T cells (NFAT) transcription factors, serves as a transducer of calcium signals and is sufficient and necessary for pathological cardiac hypertrophy and remodeling. Transient receptor potential (TRP) proteins regulate calcium entry into cells in response to a variety of signals and, in skeletal muscle, TRPC3 is increased in response to neurostimulation and activated calcineurin. Here we show that TRPC6 is up-regulated in mouse hearts in response to activated calcineurin and pressure-overload, as well as in failing human hearts. Two conserved NFAT consensus sites in the promoter of the TRPC6 gene confer responsiveness to cardiac stress. Cardiac-specific over-expression of TRPC6 in transgenic mice results in cardiomyopathy and heart failure, and an increase in NFAT-dependent expression of ␤-myosin heavy chain (MHC), a sensitive marker for pathological hypertrophy. These findings implicate TRPC6 as a positive regulator of calcineurin-NFAT signaling and a key component of a calcium-dependent regulatory loop that drives pathological cardiac remodeling.
P55 The Transcription Factor CHF1/Hey2 Prevents the Development of Pathological Hypertrophy and Heart Failure
Fan Xiang, Nobutaka Koibuchi, Darragh Cullen, Ronglih Liao, Michael T Chin; Brigham and Women's Hosp, Boston, MA
We have previously reported that overexpression of CHF1/Hey2 in the myocardium is protective against phenylephrine-induced hypertrophy, both in vitro and in vivo. To examine whether this protective effect can be demonstrated in other models of hypertrophy, we performed transaortic constriction on 8 -12 week old wild type and transgenic mice. We measured left ventricular contractile function before and one week after ascending aortic constriction. Control groups were subjected to sham operation. Hearts were analyzed by gravimetry and histology at the end of the study. After aortic banding, wild type mice demonstrated hypertrophy as evidenced by increased ventricular weight to body weight ratio when compared to sham operated controls (6.34 mg/g vs. 4.02 mg/g, p ϭ 0.012), and decreased left ventricular fractional shortening, as measured by echocardiography (0.33 vs. 0.62, p ϭ 0.02). Histological analysis showed increased fibrosis in the hearts from WT banded animals, as expected. Transgenic mice, in contrast, developed a milder degree of hypertrophy when compared to sham operated controls (5.37 mg/g vs. 4.07 mg/g, p ϭ 0.003) and had normal ventricular fractional shortening (0.60 vs 0.61, p ϭ 0.90), with no evidence of fibrosis. Sham operated animals showed no evidence of hypertrophy, fibrosis or change in ventricular function. Our findings demonstrate that overexpression of CHF1/Hey2 attenuates the hypertrophic response to aortic banding and prevents the progression to heart failure, most likely by limiting myocyte death and subsequent fibrosis. The molecular mechanisms by which CHF1/Hey2 controls the development of pathological hypertrophy and progression to heart failure are currently being explored.
P56 The Functional Role of COX-2 and p38/MK2-Mediated Regulation in Heart Failure
John M Streicher, Ken-ichiro Kamei, Harvey Herschman, Yibin Wang; UCLA, Los Angeles, CA One of the mechanisms implicated in heart failure is the induction of inflammation in heart. COX-2 is a critical regulator of inflammation and its induction was observed in stressed myocardium. However, the regulatory mechanism of COX-2 expression and whether COX-2 has a protective or detrimental role in heart are unclear. Here we investigated the role of the stress-activated protein kinase p38 and its downstream kinase MK2 in COX-2 expression in cardiomyocytes. We demonstrated that MK2 was necessary and sufficient for COX-2 protein upregulation in cultured myocytes, and necessary for COX-2 mRNA upregulation. MK2 also regulated the protein expression and cellular distribution patterns of the p38 kinase. In order to investigate the functional impact of COX-2 induction in adult heart, a ubiquitous promoter was used to drive a GFP expression cassette flanked by two loxP sites, and followed by a COX-2 cDNA-IRES-Luciferase expression unit (CAG-GFP-COX2). The transgenic mouse carrying the CAG-GFP-COX2 construct has ubiquitous GFP expression in multiple tissues, including heart, but no detectable level of COX-2. This transgenic line was bred with ␣MHC-MCM mice carrying a cardiac specific ␣MHC promoter driving the tamoxifen inducible cre (Mer-Cre-Mer) to create double transgenic animals carrying both COX2 and MCM constructs. Upon tamoxifen treatment, the COX2 expression was markedly induced at protein level detected from heart tissues. The cardiac specific COX2 induction was also monitored in living animals by luciferase imaging using a highly sensitive CCD camera. Therefore, our study shows a critical role for the p38/MK2 mediated pathway in COX-2 regulation in cardiomyocytes, and we have established a novel animal model where COX-2 can be specifically induced and monitored in adult mouse heart to allow detailed functional and molecular analysis for COX-2 mediated signaling and function in heart.
P57 Withdrawn
P58
Characterization of Fibroblast Growth Factor 16 Promoter Activity in Postnatal Cardiac Cells In Vitro and In Vivo
Alina G Sofronescu, Scott Gregoire, Peter A Cattini; Univ of Manitoba, Winnipeg, Canada
The heparin-binding fibroblast growth factor (FGF) family plays important roles in the embryonic growth and development of the heart. FGF-16 expression is reported to be cardiac-specific, with significant induction at birth. This suggests a role for FGF-16 in the postnatal heart and thus its regulation and the mechanisms underlying spatial and temporal control of FGF-16 gene expression are of interest. We hypothesize that spatial control of FGF-16 occurs at the transcriptional level through cardiac-specific promoter activity. Genomic sequences (ϳ6 kb) upstream of the ATG start codon of the murine FGF-16 gene were cloned. A combination of RNA blotting and RT-PCR was used to localize a putative promoter region including CCAAT and TATAA sequences. The transcription initiation site was identified 1073 bp upstream of the ATG codon in this region by primer extension, and was designated nucleotide ϩ1. To test FGF-16 promoter function, a series of hybrid luciferase reporter genes was generated with varying lengths of upstream flanking FGF-16 sequences. These genes (-4.7, -2.7, -1.2 and -0.2FGF-16p.GFP/Luc) were used to transiently transfect neonatal rat cardiomyocytes and rat glial (C6) cells. A Renilla luciferase gene was co-transfected as a control for DNA uptake. Hybrid -4.7, -2.7 and -1.2FGF-16p.GFP/Luc genes were expressed significantly above 'background' promoterless gene (-pGFP/Luc) levels in transfected cardiomyocytes; no activity of -0.2FGF-16p.GFP/Luc was observed. No significant expression above 'background' levels was seen for any hybrid FGF-16/luciferase gene in transfected C6 cells. These data suggest that the FGF-16 promoter is located 1073 bp upstream of coding sequences and contained within 1.2 kb of upstream flanking sequences. Furthermore, sequences located between -1.2 and -0.2 kb are required for cardiac-specific expression. To test the FGF-16 promoter region for activity in vivo, transgenic mice containing a hybrid ␤-galactosidase reporter gene directed by 4.7 kb of upstream FGF-16 sequences (equivalent to -4.7FGF-16p.GFP/Luc) were generated by pronuclear injection. Preliminary data from one line (FB-06; 6wks) suggest the FGF-16 sequence contains promoter activity and works preferentially in the postnatal heart in vivo.
P59
Blockade of Vascular Endothelial Growth Factor by Catheter-Based Adenoviral sFlt-1 Gene Transfer Attenuates Stent-Associated Neointima Formation in Nonhuman Primates
Kouta Funakoshi, Kensuke Egashira, Kaku Nakano, Kenji Sunagawa; Kyushu Univ Graduate Sch of Med Science, Fukuoka-shi, Fukuoka-ken, Japan Background: We have previously reported that blockade of VEGF by sFlt-1 gene transfer limits neointimal lesion formation induced by balloon injury or high cholesterol diet. Inversely, overexpression of VEGF or PlGF is reported to exacerbate neointima formation. However, the role of VEGF in the pathogenesis of stent-associated neointima formation has not been addressed. This point is important, because (1) the pathogenesis of neointima formation differs considerably between injury models and (2) stent procedure now becomes the major clinical revascularization technique. Therefore, we here investigated the role of VEGF in stentassociated neointima formation in non-human primates. Methods and Results: Male cynomolcgus monkeis fed high-choleterol diet underwent stent implantation procedure in iliac arteries. Immediately after stenting, adenovirus solution containing sFlt-1 or LacZ (1-3 x 109 pfu, 4mL) was introduced into the stent site through a REMEDY channel balloon catheter. As control, untreated animals undergone stent procedure were studied. The stented iliac artery segments were excised and processed for immunohistochemical and histopathologic analyses 28 days after stenting. The sFlt-1 gene transfer reduced neointima formation (%stenosis: 53.6 Ã 'Â Ϯ 5.6, 51.5 Ã 'Â Ϯ 4.5, 30.7 Ã 'Â Ϯ 5.1% for no TX, LacZ, and sFlt-1, respectively, pϽ0.05, nϭ10 -12) with no obvious toxic effect. In addition, there were no significant differences in the degrees of stent-associated injury and inflammation as well as in endothelial regeneration among the three groups. To gain mechanistic insight, the effects of sFlt-1 on migration of human coronary artery smooth muslce cells were examined in vitro, which showed suppression of VEGF-induced migration by sFlt-1. Conclusions: Blockade of VEGF by catheter-based adenovirus-mediated local gene transfer of sFlt-1 was effective in reducing stent-associated neointima formation in monkeys. Inhibitory effects of sFlt-1 on migration of vascular smooth muscle cells might contribute to the beneficial effects of sFlt-1. The benefits in nonhuman primates suggest that this strategy might be a clinically feasible and promising therapeutic strategy for prevention of in-stent restenosis in humans.
P60
Ablation of Myotrophin Gene by RNA Interference Attenuates Cardiac Hypertrophy
Sudhiranjan Gupta, Cleveland Clinic Foundation, Cleveland, OH; Ratan K Maitra, Cleveland BioLabs, Cleveland, OH; Anasuya Gupta, Dave Young, Subha Sen; Cleveland Clinic Foundation, Cleveland, OH Ablation of myotrophin gene by RNA interference attenuates cardiac hypertrophy Sudhiranjan Gupta, Ratan Maitra 1 , Anasuya Gupta, Dave Young and Subha Sen Department of Molecular Cardiology, Cleveland Clinic, Cleveland, OH 44195; 1 Cleveland BioLabs, Cleveland, OH 44106 Myotrophin (myo), a 12-kDa protein, has been shown to be a candidate gene for myocardial hypertrophy (JBC, 1990) . We have shown that NF-B activation is required for myo-induced cardiac hypertrophy in rat neonatal myocytes (J Cell Biol, 2002) and transgenic mice that overexpress myotrophin (Myo-Tg mice; JBC, 2004). In the present study, to examine a possible cause-and-effect relationship between myo and NF-B activation in the cardiac hypertrophic process, we constructed lentiviral (L) vectors expressing short interfering (si)-RNAs to specifically inhibit the myo gene. One construct, L-si-109, showed the best silencing effects, at both mRNA (155.3 Ϯ 5.9 vs 42.5 Ϯ 5.5, p Ͻ0.001) and protein levels. Significant reduction was also observed in myo-induced protein synthesis [74.2 Ϯ 3.2 vs 23.6 Ϯ 6.2 (% over control), p Ͻ0.001]; associated with inhibition of ANF (181.8 Ϯ 6.8 vs. 68.6 Ϯ 5.3) and NF-B activation (60.8% over stimulated cells, p Ͻ0.001). To further establish the relationship between myo and NF-B in vivo, we delivered L-si-109 into 10-wk-old Myo-Tg mice, which were sacrificed after another 6 weeks. Our data showed that L-si-109-Tg treatment resulted in significant reduction in heart-weight-to-body-weight ratio (7.9 vs 5.6, p Ͻ0.001, nϭ5), associated with myo gene expression (55.4% over untreated Tg mice, p Ͻ 0.001), ANF expression (61.6% over untreated Tg mice, p Ͻ0.001) and attenuation of NF-B activation (44.42% over untreated Tg mice,p Ͻ0.001). Similar observations were made when L-si-p65 was delivered into Myo-Tg mice. Our data indicate that heart-weight-to-body-weight ratio was reduced from 8.5 to 6.5 (nϭ3), associated with significant reduction in NF-B activation (58.64 % over untreated Tg mice, pϽ0.001). These data suggest, for the first time, that inhibition of myo or NF-B specifically and separately using an RNA interference strategy attenuates cardiac hypertrophy and that myotrophin could be used as a therapeutic target for treatment of heart failure.
P61 Erk5 Activation Inhibits Inflammatory Responses via Peroxisome Proliferator-Activated Receptor ␦ Stimulation in Skeletal Muscle: Possible Involvement in Aging
Jun-ichi Abe, Chang-Hoon Woo, Michael P Massett, Tetsuro Shishido, Seigo Itoh, Bo Ding, Carolyn McClain, Wenyi Che, Sreesatya R Vulapalli, Chen Yan; Univ of Rochester, Rochester, NY Peroxisome proliferator-activated receptors (PPAR) decrease the production of cytokine and iNOS expression, which are associated with aging-related inflammation and insulin resistance. Recently, the involvement of the induction of heme oxygenase-1 (HO-1) in regulating inflammation has been suggested, but the exact mechanisms for reducing inflammation by HO-1 remains unclear. We found that overexpression of HO-1 and [Ru(CO)3Cl2]2, a carbon monoxide (CO)-releasing compound, increased both ERK5 kinase and transcriptional activity in C2C12 cells. [Ru(CO)3Cl2]2 activated PPAR␦ transcriptional activity via MEK5/ERK5 signaling pathway. The inhibition of NF-B activity by ERK5 activation was reversed by a dominant negative form of PPAR␦ suggesting that ERK5/PPAR␦ activation is required for the antiinflammatory effects of CO and HO-1. Finally, we found the concomitant reduction of HO-1 and ERK5, and induction of iNOS in skeletal muscle from 19 month old mice, which showed insulin resistance compared with 5 month mice. Interestingly, the ability of PPAR␦ binding to iNOS promoter was also significantly decreased in old mice using chromatin immunoprecipitation assay in vivo. Based on these data, we propose a new mechanism by which CO and HO-1 mediate anti-inflammatory effects via activating ERK5/PPAR␦, and ERK5 mediates CO and HO-1-induced PPAR␦ activation via its interaction with PPAR␦.
P62 Nuclear Ca 2؉ /CaM/CaMK Signaling Regulated ␤-Myosin Heavy Chain Gene Transcription in Pressure Overload-Induced Hypertrophic Heart of Rat
Jian Liu, Qi Zhou, Xinqiao Hosp, Chongqing, China; Peiyong Wang, Third Military Med Univ, Chongqing, China; Yingbin Xiao; Xinqiao Hosp, Chongqing, China Regulation of ␤ myosin of heavy chain (␤ MHC) gene expression by nuclear Ca 2ϩ /CaM/ CaMK signaling pathway was investigated in pressure overload-induced hypertrophic rat heart. The model of rat cardiac hypertrophy was established by abdominal aortic constriction. Velocity and isopyknic gradient centrifugation was used to fractionate rat cardiac nuclei. Compare with the control group, ␤ MHC mRNA gene expression was higher in the hypertrophic group and in cultured hypertrophic cardiac myocytes, and they were inhibited by pretreatment with calcium chelator BAPTA-AM, CaM inhibitor trifluoperazne in cultured cell (pϽ0.05). Nuclear run-off transcription assay showed ␤ MHC gene transcription was markedly enhanced in the hypertrophic group, and that was significantly inhibited by treatment of isolated cardiac nuclei with calcium chelator BAPTA-AM, CaM inhibitor trifluoperazne and CaM antagonist calmidazolium chloride, as well as CaMKII inhibitors KN-62 respectively (pϽ0.05). Western blot analysis revealed that nuclear CaM, CaMKII and CaMKIV were significantly increased, and the activities of CaMKII and CaMKIV in nuclei were also increased in the hypertrophic group (pϽ0.05). Thus, we conclude that ␤ MHC gene is regulated at the transcriptional level, which might be required for the nuclear translocation of CaM, CaMKII, CaMKIV and the activity increase of nuclear CaMKII and CaMKIV. The nuclear Ca 2ϩ /CaM/CaMK signaling pathways might be involved in the ␤ MHC gene regulation and the development of overload-induced cardiac hypertrophy. of the NOS dimer and NOS activity and reduced expression of O 2 -. In order to determine if the expression of arginase is causal in this loss of NOS coupling, adult mouse lungs were transfected with an AAV encoding arginase driven by either a Tie2 or ␣-sm muscle actin promoter. Transfection led to a 4-fold increase in arginase activity when compared to lungs transfected with the reporter gene AAV␤gal. Ten days after transfection, there was a marked increase in O 2 expression and a significant loss of NOS coupling that was prevented by treatment with BEC. Pulmonary arterial catheterization demonstrated significantly higher mean PA pressure at 6 weeks in AAV-arginase mice compared with AAV␤gal mice (19.8 Ϯ 1.1 mmHg compared to 13.9 Ϯ 0.9 mmHg, PϽ0.05). Arginase transfection was associated with a marked increase in ROS signaling, MMP activation, and pulmonary vascular remodeling. These results clarify the role of arginase in mediating pulmonary hypertension in vivo and provide the first evidence that arginase regulates NOS dimerization and activity. Several studies have demonstrated that the proinflammatory cytokine tumor necrosis factor ␣ (TNF-␣) has both injurious and cardioprotective effects, due to the actions of multiple TNF-responsive downstream signal transduction pathways. Currently, there is little known regarding the complex TNF-␣ signaling pathways that affect cardiomyopathy. One of the major TNF signaling pathways involves nuclear factor-B (NF-B), a pleiotropic transcription factor that activates genes involved in cellular processes including growth, apoptosis, inflammation, angiogenesis and cardiomyocyte function. It has been shown that NF-B activation is necessary for G-protein coupled and TNF-induced hypertrophy in vitro. Although it has recently been shown that activation of NF-B is required for hypertrophy in response to pressure overload and TNF overexpression in vivo, the definitive role of NF-B in non-cytokine induced cardiomyopathies has not been elucidated in vivo. We show that both TNF-␣ and NF-B are activated in cardiomyopathy caused by cardiac-specific transgenic overexpression of calcineurin (CnATg). In order to investigate the role of NF-B in murine cardiomyopathic models, we engineered transgenic mice with cardiac-specific expression of dominant negative IB␣. Although blockade of NF-B in double transgenic CnATg/IB mice was complete, we were unable to delineate significant in vivo physiological effects from this blockade. This result was in direct contrast to previous results with TNF-induced cardiomyopathy in which blockade of NF-B activity significantly abrogated cardiac hypertrophy, improved cardiac function and significantly improved survival. Blockade of NF-B in TNF-induced cardiomyopathy significantly increased Akt activity, which is thought to contribute to the dramatically improved cardiac phenotype. Interestingly blockade of NF-B did not increase activation of Akt in the calcineurin cardiomyopathic model. This suggests the existence of complex signaling networks in which the same signaling mediator(s) may play different roles dependent upon combinatorial effects of particular mediators. The potential role of other signaling mediators in calcineurin-induced cardiomyopathy is currently under investigation. Yeast two-hybrid analysis was used to screen a human heart library to isolate proteins that interact with the adult muscle specific ␤1D but not with ␤1A integrin. In addition to proteins known to bind the ␤1 cytoplasmic domain including RACK 1 and ␣-actinin, several novel candidates were isolated and identified. One protein identified was subunit 3 (CSN3/Sgn3) of the COP9 signalosome complex. This protein/protein interaction was specific for ␤1D integrin, as no binding to ␤1A integrin (cytoplasmic domain) was measurable by two-hybrid analysis. This study focuses on the characterization and independent verification of the interaction between ␤1D integrin and CSN3 protein. Both co-immunoprecipitation and immunolocalization of CSN3 and ␤1D integrin in cardiac myocytes is presented. To begin to unravel the role of this interaction, we have characterized the expression of CSN3 in both proliferating and differentiated cardiac and skeletal muscle cells. The interaction between CSN3 and ␤1D integrin may represent a new pathway for integrin signaling in striated muscle. Introduction: Various studies compare coronary artery disease (CAD) patients with controls in order to determine which polymorphisms are associated with a higher risk of disease. The results have often been contradictory. Moreover, the studies have evaluated isolated polymorphisms and not associations of polymorphisms, which is the way they occur in nature. Objective: our purpose was to evaluate the risk of CAD in patients with associated polymorphisms in the same gene or in different genes. Methods: we evaluated in 298 CAD patients and 520 healthy individuals the risk associated with ACE DD, ACE8 GG, AGT 174 MM and 235 TT, MTHFR 677 TT and 1298 AA polymorphisms. Then we evaluated the risk of associated polymorphisms in the same gene. Finally, for the isolate polymorphisms which were significant, we evaluated the risk of polymorphism associations at different functional levels Results: isolated polymorphisms presented with a higher frequency in the cases and are linked in a significant way to the CAD group (ACE DD Genotype [PϽ0.0001], ACE 8 GG [Pϭ0.015]; MTHFR 1298 AA [Pϭ0.011]). The association of polymorphisms in the same gene did not have an addictive or synergistic effect, nor did it increase the risk for CAD. The polymorphic associations in different genes (ACE DD or ACE 8 GG ϩ AGT 235 TT; ACE DD or ACE 8 GG ϩ MTHFR 1298 AA) increased the risk of CAD when compared with the isolated polymorphisms (OR 2.9 vs. 1.8). Conclusions: the association of mutated polymorphisms in the same gene did not increase the risk of the isolated polymorphism. The association of mutated polymorphisms in genes belonging to different enzymatic systems was always linked to an increased risk, when compared with the isolated polymorphisms. This study points to the possibility of understanding the CAD genetic risk from a global point of view and not by regarding each isolate polymorphism. In an effort to discover regulators of cardiac gene expression and growth, we devised a eukaryotic expression screen for cDNAs encoding activators of the atrial natriuretic factor (ANF) promoter, a cardiac-specific marker of hypertrophy and pathological remodeling of the adult heart. This screen revealed a family of activators of the ANF promoter, called calmodulinbinding transcription activators (CAMTAs), which are conserved from plants to humans. We show that CAMTAs are recruited to the ANF promoter, at least in part, by association with the cardiac homeodomain protein Nkx2-5 and function as inducers of cardiac growth. Overexpression of CAMTA2 in isolated neonatal cardiomyocytes by adenoviral-mediated delivery induces hypertrophic growth of cardiomyocytes. Transgenic mice overexpressing CAMTA2 in the heart display cardiac hypertrophy, which progresses to dilated cardiac myopathy. Mice lacking CAMTA2 display diminished hypertrophy in response to pressure overload and neurohumoral signaling. Through gain-and loss-of-function approaches in vivo and in vitro, we show that class II HDACs restrain the activity of CAMTA proteins. Nuclear export of class II HDACs in response to PKC/PKD signaling releases CAMTAs from HDAC-dependent repression with consequent expression of genes involved in cardiac growth. These findings uncover a role for mammalian CAMTA proteins as signal-responsive transcriptional activators of cardiac growth and targets for the repression of class II HDACs.
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P69 Cardiac Autophagy Is a Maladaptive Response to Hemodynamic Stress
Hongxin Zhu, Paul Tannous, Janet Johnstone, Yongli Kong, John M Shelton, James A Richardson, Beth Levine, Beverly A Rothermel, Joseph A Hill; UT Southwestern, Dallas, TX Background: Autophagy is a highly conserved mechanism of protein and organelle degradation linked to several neurodegenerative diseases. Nothing is known about the possible role of autophagy in heart failure. Methods and Results: Short-term nutrient deprivation, an established trigger of autophagy, induced dramatic increases in the ratio of LC3-II:LC3-I in ventricular lysates, indicative of increased autophagic activity. To determine the specific contribution of cardiomyocyte autophagy, we generated alphaMHC-GFP-LC3 transgenic mice. Short-term starvation induced a robust increase in the punctate localization of GFP-LC3 in myocytes, demonstrating cardiomyocyte autophagy and confirming the validity of our "autophagy reporter" mice. To test for autophagy in failing heart, we induced pressure overload by severe constriction of the thoracic aorta (sTAB). Fluorescence microscopy demonstrated autophagosome-localized GFP-LC3 in left ventricular myocytes 24h after banding which peaked at 48h and subsequently declined (though remaining elevated relative to control, pϽ0.05). EM revealed double-membrane autophagosomes in cardiomyocytes in failing heart. Lysosome activity was increased in failing LV as demonstrated by immunostaining for cathepsin D and LAMP-1, suggesting that diminished activity of distal lysosomal pathways was not responsible for autophagosome accumulation. To explore whether cardiomyocyte autophagy is beneficial or maladaptive, we studied mice with targeted disruption of Beclin-1, a gene required for autophagosome formation. Heterozygous disruption of Beclin-1 led to decreased autophagy in pressure-stressed cardiomyocytes. Heart failure-associated declines in LV systolic function were significantly attenuated in Beclin-1 mutants. Beclin-1 over-expressing transgenic mice manifested an amplified pathological response to sTAB. Compared with WT, Beclin-1 transgenic mice subjected to standard TAB manifested increased autophagic activity, impaired systolic performance, increased load-induced fibrosis, but similar levels of apoptosis. Conclusions: These findings implicate autophagy in the pathogenesis of load-induced heart failure and suggest it may be a target for novel therapeutic intervention.
P70 Extracellular Signal-Regulated Kinase Is Sufficient but Not Necessary for Cardiac Hypertrophy In Vivo
Nicole H Purcell, Jeffrey Robbins, Jeffery D Molkentin; Children's Hosp Med Ctr Cincinnati, Cincinnati, OH
The mitogen-activated protein kinases (MAPKs) function as central mediators of numerous biologic processes such as control of cellular growth, differentiation, and survival. The extracellular signal-regulated kinases (ERKs) constitute one major branch of the MAPK signaling cascade that is activated in cardiomyocytes through G protein coupled receptors, tyrosine kinase receptors, integrins, stretch, and other diverse stress stimuli. ERK1/2 are directly activated by MEK1, an upstream MAPKK that specifically phosphorylates the TxY motif in the activation loop of ERK1/2. Overexpression of activated MEK1 in the heart by transgenesis induced specific activation of only ERK1/2, which was associated with the early development and continued maintenance of concentric cardiac hypertrophy (Bueno et al., EMBO J. 2000; 19:6341-6350) . These results, in conjunction with other published accounts, have solidified the hypothesis that MEK1-ERK1/2 signaling is sufficient to mediate/initiate the cardiac hypertrophic response in vivo. However, the necessity or requirement of ERK1/2 in mediating cardiac hypertrophy in vivo has not been elucidated. Here we analyzed erk1-/-and erk2ϩ/gene-targeted mice, as well as mice expressing a bi-transgenic, tet-inducible MKP3 (DUSP6) cDNA in the heart to specifically inactivate ERK1/2 at anytime. Loss of erk1 or heterozygosity of erk2 did not alter the cardiac hypertrophic response following pressure overload or neuroendocrine agonist stimulation, despite having a significant reduction in total ERK activity in the heart. Moreover, tet-inducible expression of MKP3 in the heart, which completely inactivated all cardiac ERK activity (but not other MAPKs), did not alter the ability of the heart to hypertrophy following pressure overload stimulation. Thus, our results suggest that ERK1/2 are sufficient to induce the cardiac hypertrophic response, but they are not required to mediate it.
P71 The Cardiovascular Transcription Factor Kruppel-like Factor 5 Inhibits Apoptosis Through a Mechanism Involving Interaction with Poly(ADP-ribose) Polymerase-1 and Further Regulation by Acetylation
Toru Suzuki, Ryozo Nagai; The Univ of Tokyo, Tokyo, Japan Kruppel-like factor 5 (KLF5) is a proto-oncogenic transcription factor that is pathogenically induced to mediate the cardiovascular remodeling response to external stress (Nat Med 2002). KLF5 shows stimulatory effects on cell growth, and acetylation of KLF5 is important for this effect (Mol Cell Biol 2003) . Initial studies using KLF5-deficient mice showed that KLF5 protects against apoptosis as induced by arterial injury. Through analysis of the mechanisms of the anti-apoptotic actions of KLF5, we found that it functionally interacts with Poly(ADP-ribose) polymerase-1 (PARP-1), a nuclear enzyme involved in DNA repair. PARP-1 interacted with KLF5 specifically under apoptotic conditions in the endogenous setting, and domain-mapping experiments showed that the first zinc finger of KLF5, which is the site of acetylation, to mediate interaction. A non-acetylatable mutant of KLF5 did not interact with PARP-1, and acetylation of KLF5 as induced by apoptotic stimulus increased affinity with PARP-1. Functionally, pro-apoptotic activity of a proteolytic peptide of PARP-1 produced under apoptotic conditions was inhibited by interaction with wild-type KLF5 but not the non-acetylatable mutant. Collectively, our findings show PARP-1 to be a target of action of the cardiovascular transcription factor KLF5, and suggest that sequestering interaction of PARP-1 by KLF5 under apoptotic conditions with further regulation by acetylation to be a novel mechanism regulating cell death/survival in cardiovascular pathogenesis.
P72
Role of 14-3-3 Protein in Cardiomyocyte Survival
Jeffrey M C Lau, Anthony J Muslin; Washington Univ Sch of Med, St. Louis, MO The 14 -3-3 family of intracellular dimeric phosphoserine-binding proteins regulate signal transduction, cell cycle, apoptotic, and metabolic cascades. Previous work with global 14 -3-3 protein inhibitors suggested that these proteins play a critical role in antagonizing apoptotic cell death that occurs in response to provocative stimuli. To determine the specific role of one family member in apoptosis, mice were generated with targeted disruption of the 14 -3-3 gene. Although 14 -3-3 -/mice did not survive embryonic development, haploinsufficient mice appeared normal at birth and were fertile. Baseline cardiac structure and function was normal in 14 -3-3 ϩ/mice, however, cultured adult cardiomyocytes derived from 14 -3-3 ϩ/mice were sensitized to the development of apoptosis in response to treatment with hydrogen peroxide or UV irradiation. In addition, 14 -3-3 ϩ/mice were intolerant of experimental myocardial infarction and most animals died from acute ventricular rupture in the days following surgery. The 14 -3-3 ϩ/mice that survived myocardial infarction were sensitized to develop pathological ventricular remodeling with increased cardiomyocyte apoptosis in the infarct border zone when compared to wild type littermates. Analysis of the activity of signaling proteins in cardiac lysates revealed that ASK1, JNK and p38 MAPK activation was increased, but ERK MAPK activation was reduced, in 14 -3-3 ϩ/cardiac tissue. Treatment of 14 -3-3 ϩ/mice with a general p38 MAPK inhibitor, SB202190, significantly reduced the mortality rate observed after experimental myocardial infarction. These results demonstrate that 14 -3-3 plays a critical anti-apoptotic function in cardiomyocytes and therapeutic agents that increase 14 -3-3 activity may be beneficial to patients with MI.
P73 Withdrawn
P74 Enhanced Myocardial ERK Activation in Animal Models of Duchenne Muscular Dystrophy and Limb Girdle Muscular Dystrophy 2F
Stephen C Armstrong, Melody A Scott; Cardiovascular Rsch Inst, Sioux Falls, SD Background: Dystrophin associates with a protein complex (DAPC) which includes: an extracellular protein, ␣-dystroglycan; the transmembrane glycoproteins, ␤-dystroglycan and ␣, ␤, ␥, ␦ -sarcoglycans (SG); and caveolin-3 (Cav3). Dystrophin deficiency manifests as Duchenne or Becker muscular dystrophy and dilated cardiomyopathy (DCM). The Mdx mouse model demonstrates an absence of dystrophin and a decrease in other DAPC components. Mdx mice exhibit mild cardiomyopathy. ␦SG deficiency manifests as Limb Girdle Muscular Dystrophy (LGMD2F), with DCM occurring in patients. A hamster strain that is ␦SG deficient (TO2) was identified as a DCM model. We have confirmed chamber dilatation and systolic dysfunction in the TO2 model. This study examined kinase activation in the Mdx and TO2 models. Methods/ Results: Kinase phosphorylation and activation was determined by phospho-specific antibodies. Enhanced ERK activation was observed in the Mdx and TO2 models as compared to C57 and F1B control animals, respectively. ERK activation in these models was accompanied by an increase in Raf Ser259 phosphorylation. This was unexpected in that this Akt mediated phosphorylation event reportedly inhibits the ERK pathway. Additionally, an increase in FAK Tyr397 and Akt Tyr326 phosphorylation was observed in the Mdx model, indicating activation of tyrosine kinase pathways. Finally, an enhancement of GSK-3 phosphorylation was observed in the Mdx model. This corresponds with the finding of increased Raf Ser259 phosphorylation to suggest that the Akt pathway is activated in the Mdx and TO-2 models. Conclusion: This is the first report that correlates enhanced ERK activation and Raf Ser259 phosphorylation in the hearts of Mdx and TO2 animals. DAPC dissociation presumably reverses a negative regulation of the ERK pathway. This corresponds to studies which demonstrate enhanced myocardial ERK activation and cardiomyopathy in a Cav3 knockout mouse model. Raf Ser259 phosphorylation and increased ERK activation might indicate an Akt mediated blockade of the Ras-Raf pathway and the release of a sequestered pool of activated ERK subsequent to the dissociation of DAPC. ERK activation could function as contributor to the pathology of muscular dystrophy or as a compensatory response.
P75
Cardiac-Specific Deletion of the Small Rho GTPase Cdc42 Reveals Its Pivotal Function in Cardiac Hypertrophy
Marjorie S Maillet, Bastiano Sanna, Yi Zheng, Jeffery D Molkentin; Cincinnati Children's Rsch Foundation, Cincinnati, OH The low molecular weight GTPases of the Rho super-family are molecular switches cycling between a GTP-bound active state and GDP-bound inactive state. Rho GTPases play critical roles in gene expression, apoptosis and cytoskeleton regulation in various cells types. Previous in vitro studies in neonatal cardiomyocytes suggested that Rho GTPases are involved in hypertrophy induced by angiotensin II, phenylephrine or leukocyte inhibitory factor. However, very little is known concerning Rho GTPase family members functions in vivo, especially Cdc42. Here, we investigated the function of Cdc42 in the heart using a cardiac-specific gene-targeting strategy in which loxP sites flanking the Cdc42 locus were subjected to recombination with a cardiac-specific cre expressing transgene. Cdc42 protein levels in the heart were significantly reduced in Cdc42 fl/fl cre ϩ mice at 4 weeks of age. Interestingly, Cdc42 fl/fl cre ϩ mice displayed a mild baseline hypertrophic phenotype at 10 weeks of age (10% increase of HW/BW ratio and cell size when compared to aged match Cdc42 ϩ/ϩ cre ϩ wild type animals). When subjected to transverse aortic constriction (TAC) for 2 weeks, Cdc42 fl/fl cre ϩ mice developed significantly greater cardiac hypertrophy (HW/BW ratio increased by 80% when compared to sham operated animals) that was associated with reduced cardiac function. Cdc42 fl/fl cre ϩ mice subjected to TAC also developed severe intra-myocardial fibrosis compared with little fibrosis in control TAC operated mice. Cdc42 fl/fl cre ϩ mice also showed enhanced hypertrophy in response to isoproterenol (60 mg/kg/day) stimulation induced by subcutaneous alzet minipump placement for 14 days. Although the phenotype of these mice needs to be further characterized, especially the downstream hypertrophic mechanisms, these preliminary results suggest an important role of Cdc42 in cardiac baseline physiology and response to stress.
P76 Diacylglycerol Kinase Prevents Cardiac Remodeling by Mechanical Overload
Yasuchika Takeishi, Takeshi Niizeki, Mutsuo Harada, Takanori Arimoto, Isao Kubota; Yamagata Univ, Yamagata, Japan Background: Gq protein-coupled receptor (GPCR) signaling pathway including diacylglycerol (DAG) and protein kinase C plays a critical role in the development of cardiac hypertrophy and heart failure. DAG kinase (DGK) phosphorylates DAG and controls cellular DAG levels, and thus is thought to be acting as a regulator of GPCR signaling. We have previously reported that DGK inhibits GPCR agonist-induced cellular DAG accumulation, activation of the downstream signaling cascade and subsequent cardiomyocyte hypertrophy. In this study, we examined whether DGK modifies cardiac remodeling by mechanical overload. Methods and Results: Thoracic transverse aortic constriction (TAC) was created in transgenic mice with cardiacspecific overexpression of DGKzeta (DGK-TG) and wild-type (WT) mice. Increases in heart weight at 4 weeks after TAC were attenuated in DGK-TG mice compared to WT mice. Increases in inter-ventricular septal thickness, dilatation of the left ventricular cavity, and decreases in left ventricular systolic function were observed with echocardiography in WT mice at 4 weeks after TAC surgery. However, these structural and functional changes after TAC were attenuated in DGK-TG mice. Up-regulation of atrial natriuretic factor and beta-myosin heavy chain mRNA was observed after TAC in WT mice, but not in DGK-TG mice. Next, left anterior descending coronary artery was ligated in DGK-TG and WT mice. Left ventricular chamber dilatation, left ventricular systolic dysfunction, and increases in left ventricular weight and lung weight at 4 weeks after myocardial infarction were attenuated in DGK-TG mice compared to WT mice. In the non-infarct area, cardiac fibrosis and up-regulation of profibrotic genes such as transforming growth factor-beta 1, collagen type I, and collagen type III were observed at 4 weeks after myocardial infarction in WT mice. However in DGK-TG mice, cardiac fibrosis and profibrotic gene induction were blocked. The survival rate after myocardial infarction was higher in DGK-TG mice than in WT mice. Conclusion: DGKzeta suppresses cardiac structural remodeling after TAC and myocardial infarction. DGKzeta may be a potential novel therapeutic target to prevent cardiac remodeling in response to mechanical overload.
P77 Dnajb5, an Hsp40 Family Protein, Mediates Antihypertrophic Effects of Thioredoxin1 in the Heart
Tetsuro Ago, Junichi Sadoshima; UMDNJ-NJMS, Newark, NJ Thioredoxin1 (Trx1) plays an important role in reducing redox-sensitive proteins, thereby regulating critical cellular functions, such as growth and apoptosis. We have previously shown that cardiac hypertrophy by pressure-overload is suppressed in transgenic mice with cardiac specific overexpression of Trx1 (Tg-Trx1). However, the molecular mechanism by which Trx1 inhibits hypertrophy remains poorly understood. cDNA microarray analyses revealed that expression of DnaJb5, a Hsp40 family protein, is significantly upregulated in Tg-Trx1 hearts. Because another Hsp40 family protein (Mrj) was recently shown to inhibit the transcriptional activity of NFATc3 through recruitment of class II HDAC to the nucleus, we hypothesized that Trx1 attenuates NFAT activity through DnaJb5, thereby suppressing cardiac hypertrophy. Protein expression of DnaJb5 was increased in both Trx1-overexpressed cardiomyocytes and Tg-Trx1. Upregulation of DnaJb5 is mediated by HSF-1, a redox-sensitive transcription factor, since both expression and transcriptional activity of HSF-1 were enhanced in Trx1overexpressed cardiomyocytes and because shRNA-mediated knockdown of HSF-1 attenuated Trx1-induced upregulation of DnaJb5. Immunostaining and western blot analyses indicated that Trx1 and DnaJb5 are colocalized in the nucleus. In vitro pull-down binding assays indicated that DnaJb5 associates with Trx1 through TXNIP, a Trx1-binding protein. Both Trx1 and DnaJb5 attenuated phenylephrine (PE)-induced increases in the transcriptional activity of NFAT as well as hypertrophy without showing additive effects, suggesting that Trx1 and DnaJb5 are on the same pathway leading to inhibition of NFAT and hypertrophy. Furthermore, knocking-down of DnaJb5 significantly attenuated Trx1-induced inhibition of PE-induced cardiac hypertrophy. By making a genetic cross between Tg-Trx1 and transgenic mice harboring the NFAT luciferase reporter, it was found that both NFAT activation and cardiac hypertrophy by PE are significantly suppressed in the presence of Trx1 in vivo. In summary, Trx1 upregulates DnaJb5, colocalizes with DnaJb5 in the nucleus, and inhibits NFAT. DnaJb5 is a critical downstream effector of Trx1, mediating anti-hypertrophic effects in the heart.
P78
Deficiency of ␤1 Integrins Exaggerates ␤-Adrenergic Receptor-Stimulated Apoptosis and Heart Failure
Prasanna Krishnamurthy, Venkateswaran Subramanian, Mahipal Singh, Krishna Singh; East Tennessee State Univ, Johnson City, TN Background: Sympathetic nerve activity increases in the heart during heart failure. We hypothesized that ␤1 integrins play a protective role in chronic beta-adrenergic receptor (␤-AR) stimulated cardiac myocyte apoptosis and heart failure. Methods and Results: L-isoproterenol (iso; 400 g/kg/day) was infused in a group of wild-type (WT) and ␤1 integrin heterozygous knockout (hKO) mice. Alterations in LV structure and function, cardiac myocyte apoptosis and activity of signaling molecules was assessed following 7 and 30 days of iso-infusion. M-mode echocardiographic measurements demonstrated increased percent fractional shortening (%FS) in WT-iso following 7 and 30 days of iso-infusion. Interestingly, %FS was significantly reduced in hKO-iso group following 30 days of iso-infusion. Isovolumic relaxation time (IVRT) and isovolumic contraction time (IVCT) were significantly lower in both the iso-treated groups. However, the decrease in IVRT was significantly higher in hKO-iso vs WT-iso (PϽ0.05). Peak LV developed pressure (LVDP) and LV end diastolic pressure (LVEDP) measured using Langendorff-perfusion analyses were significantly increased in WT-iso when compared to sham and hKO-iso groups (PϽ0.05 vs WT-sham and hKO-Iso). The number of apoptotic myocytes was significantly higher in hKO-iso hearts when compared to WT-iso group at 7 and 30 days following iso-infusion (pϽ0.001 WT-iso vs hKO-iso). Myocyte cross sectional area and fibrosis were increased in both iso groups when compared to their respective shams. However, the increase in myocyte size and fibrosis was significantly lower in hKO-iso hearts (PϽ0.05 vs WT-iso). Western blot analysis indicated increased phosphorylation of JNK and ERK1/2 and protein expression of GRP78 following 7 days of iso-infusion. Interestingly, the increase in p-JNK was significantly higher in hKO-iso when compared to WT-iso group (PϽ0.01 vs WT-iso; nϭ4). Iso-infusion significantly increased the level of MMP-2 in hKO-iso hearts, whereas MMP-9 was significantly increased in WT-iso group. Conclusion: ␤1 integrins play a crucial role in ␤-AR-stimulated apoptosis with effects on left ventricular structure and function.
P79 Proapopotic Serine/Threonine Kinase Mst1 Prevents Cardiac Hypertrophy Through Phosphorylation of PERK
Soichiro Usui, Mari Odashima, Chull Hong, Stephen F Vatner, Junichi Sadoshima; UMDNJ-New Jersey Med Sch, Newark, NJ Mammalian sterile 20-like kinase1 (Mst1) is a ubiquitously expressed serine/threonine kinase, which plays an important role in mediating apoptosis. Overexpression of Mst1 in mice results in dilated cardiomyopathy (DCM) with increased myocyte apoptosis but without compensatory myocyte hypertrophy. The lack of compensatory hypertrophy despite cardiac dilation may be detrimental and contribute to progression of DCM. Thus, we examined the molecular mechanism by which the proapoptotic kinase inhibits compensatory cardiac hypertrophy. Overexpression of Mst1 significantly inhibited cardiac myocyte hypertrophy by phenylephrine (PE), an agonist for the ␣1 adrenergic receptor. Mst1 induced phosphorylation of eukaryotic translation initiation factor 2-␣ (eIF2-␣), a negative regulator of protein translation, and protein kinase R-like endoplasmic reticulum (ER) kinase (PERK), a kinase phosphorylating eIF2-␣, in cardiac myocytes. Activation of PERK and phosphorylation of eIF2-␣ are observed in the presence of ER stress. In fact, other markers of ER stress, such as CHOP and caspase12, were also stimulated by Mst1 in cardiac myocytes. Adenovirus-mediated expression of dominantnegative PERK (DN-PERK) abrogated both phosphorylation of eIF2-␣ and inhibition of PE-induced cardiac myocyte hypertrophy by Mst1. To examine whether Mst1 and PERK physically interact with one another, in vitro binding assays were conducted. GST-PERK-C terminal fusion protein was able to bind Mst1 in vitro. Furthermore, in vitro kinase assay indicated that recombinant Mst1 phosphorylates GST-PERK-C terminal, including the activation loop. Mst1 partially co-stained with protein disulfide isomerase, which is localized at ER. These results suggest that Mst1 directly interacts with PERK, thereby phosphorylating it. Activation of PERK plays an essential role in mediating Mst1-induced inhibition of cardiac hypertrophy by mimicking ER stress responses such as phosphorylation of eIF2 ␣. Mst1 not only stimulates apoptosis, but also initiates cross talk with the ER stress pathway, thereby inhibiting cardiac hypertrophy. Background: Disruption of leptin signaling pathway may contribute to obesity-related cardiac disease, as leptin deficient (ob/ob) mice display cardiac hypertrophy, impaired ␤-adrenergic signaling, increased cardiac apoptosis and reduced survival. Since leptin maintains a tonic level of neuronal nitric oxide synthase (NOS1) expression in the brain, we hypothesized that leptin deficiency would decrease cardiac expression of NOS1. As NOS1 inhibits xanthine oxidoreductase (XOR), NOS1 downregulation would increase XOR activity. The increase in reactive oxygen species (ROS) production associated with reduced NO production would create nitroso-redox imbalance, which could contribute to obesity-related cardiac disease. Methods and Results:
P80
Reduced Neuronal Nitric Oxide Synthase Expression Contributes to Increased Oxidative Stress and Nitroso-Redox Imbalance in Murine Model of Obesity
We studied 2-6 month old ob/ob and C57Bl/6 controls. Our results demonstrated that cardiac NOS1 protein abundance (Pϭ0.01) and mRNA expression (Pϭ0.03) were reduced in ob/ob, while endothelial NOS protein abundance and mRNA expression were unaltered. NO metabolites (nitrites and nitrates) production within the myocardium was consequently reduced in ob/ob mice (Pϭ0.02). Furthermore, ROS production was increased in ob/ob mice as GSH/GSSG ratio was decreased (Pϭ0.02), and this could be attributed, at least in part, to increased XOR activity measured by Amplex Red fluorescence assay kit (Pϭ0.04). XOR and NADPH oxidase subunits protein abundance were not changed in ob/ob mice. Leptin deficiency did not change the NOS1 subcellular localization studied by immunofluorescence, as NOS1 co-localized with the ryanodine receptor but not with caveolin-3. Conclusion: Leptin deficiency is linked to decreased cardiac expression of NOS1 and NO metabolite production, with a concomitant increase in XOR activity and ROS production, resulting in nitroso-redox imbalance. This finding is independent of NOS1 translocation to the plasma membrane. These data offer novel insights into potential mechanisms of myocardial dysfunction in obesity.
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Intrinsic Mechanism of Myotrophin-Driven Cardiac Hypertrophy in Neonatal Rat Cardiomyocytes
Biswajit Das, Sudhiranjan Gupta, Subha Sen; Lerner Rsch Inst, Cleveland, OH Myotrophin, an ankyrin repeat protein, is known to play an important role in the initiation of cardiac hypertrophy by stimulating protein synthesis in rat cardiomyocytes that leads to heart failure and is correlated with activation of the NFB signaling cascade (JBC, 1990; JCB, 2002; JBC, 2004) . But how myotrophin triggers such a signaling cascade for hypertrophic phenomena is not known. In the present study, using neonatal rat cardiomyocytes, we examined the localization and trafficking of myotrophin that was added to the external media. Alexa-488 conjugated recombinant myotrophin internalized within 5 min of its introduction. Within the next 20 -60 min, myotrophin translocated into the nucleus. NFB signaling was upregulated simultaneously. Incorporation of myotrophin into the cell increases protein synthesis (50.39% increase over control). Genistein (a tyrosine kinase inhibitor) pre-treatment significantly inhibited the incorporation of myotrophin into cytoplasm suggesting that internalization of myotrophin is through a tyrosine kinase-mediated pathway. Based on the solution structure of myotrophin, we have identified potential sites of the protein in two hairpin-like loops that is responsible for its stimulatory activity by activating NFB pathway. To dissect out this structure-function relationship of myotrophin, we have generated 10 myotrophin mutants to define their trafficking, ability to activate NF-B pathway and increased protein synthesis. Observations obtained from this study will enable us to understand how myotrophin stimulate cardiomyocytes and how myotrophin interacts with components of the NF-B pathway to initiate cardiac hypertrophy.
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Construction and Characterization of an Inhibitor-Resistant Na ؉ /H ؉ Exchanger Adenoviral Vector for Transfection of Cardiomyocytes Ersilia Coccaro, Mackenzie E Malo, Larry Fliegel; Univ of Alberta, Edmonton, Canada
The mammalian Naϩ/Hϩ exchanger isoform 1 (NHE1) is a ubiquitously expressed membrane protein. It contains a 500 amino acid membrane domain that transports ions and a 315 amino acid regulatory cytosolic domain that is a target for protein kinase mediated phosphorylation. NHE1 plays a critical role in ischemia and reperfusion (I/R) injury to the myocardium. NHE1 is also important in mediating myocardial hypertrophy and blockage of NHE1 activity prevents hypertrophy and I/R injury in animal models. We recently demonstrated that extracellular regulated kinase (Erk) mediated activation of NHE1 occurs during ischemia and reperfusion of the myocardium. However, the mechanisms by which phosphorylation acts are largely unknown. To understand the regulation of NHE1 we made four mutant NHE1 cDNA expression vectors with key phosphorylation sites mutated as follows; S693A; T718A, S723/726/729A; S766/770/771A; & T779A, S785A. Experiments in AP-1 cells have shown that mutant S766/70/71A contains amino acids that are important in regulation of NHE1 activity. However, regulation of NHE1 is tissue specific and myocardial NHE1 has different kinetic properties compared with other tissues. To examine the activity of the various NHE1 mutants in the myocardium we constructed adenoviruses which express the NHE1 mutants. NHE1 mutant proteins had additional mutations [Leu163Phe/Gly174Ser] that increased NHE1 resistance to HOE694 (a specific blocker of NHE1) 100-fold in comparison to endogenous NHE1. Inhibitor resistant NHE1 was inserted into the vector pAdTrack-CMV and recombined with pAdEasy-1 for production of recombinant adenovirus in HEK293A cells. Infection with adenovirus resulted in production of NHE1 protein that was detected by Western blot analysis. HOE694-resistant NHE1 activity was also detected while endogenous NHE1 was inhibited, confirming that NHE1 activity was the result of adenoviral expression. Our results show that adenoviral expression of NHE1 is a practical method for studying NHE1 in cardiomyocytes. Future studies will examine NHE1 activity of control and phosphorylation mutants over varying internal pH's and in response to Erk activation, to determine which amino acids mediate NHE1 activation in the myocardium. Vinculin (Vin) is a ubiquitously expressed actin binding protein that plays a dynamic role in the actin cytoskeleton assembly. Vin is located at intercalated discs (ICDs) as well as in cell-to-matrix adhesions. Metavinculin (MVin) is a muscle-specific splice variant of Vin that is mutated in patients with cardiomyopathy. Since global knockout (KO) of Vin is embryonic lethal and heterozygous global knockout of Vin predisposes mice to stress-induced cardiomyopathy, we generated cardiac-myocyte specific Vin KO mice. Cre expression and excision of the floxed Vin/MVin exon 3 was mediated by the ventricular myosin light chain-2 (MLC2v) promoter. Homozygous Cre-excision of Vin showed no indication of embryonic lethality (nϭ125). Younger Vin KO mice (6 -10 week-old) with preserved cardiac function nonetheless showed: A) cardiac arrhythmias ranging from supraventricular ectopic beats to non-sustained ventricular tachycardia (VT), and B) sudden death by telemetry-documented polymorphous non-sustained VT. Older Vin KO mice developed a cardiomyopathic phenotype. Specifically we found: 1) a 71% reduction of MVin protein levels vs. littermate homozygous floxed controls (F/F) (nϭ3); 2) histological fibrosis and LV dilation by age 12 weeks; 3) depressed cardiac function by 16 weeks (%FSϭ27.56 Ϯ 3.2 in Vin KO vs. 36.0 Ϯ 2.7 in F/F; Vcfϭ5.9 Ϯ 0.7 in Vin KO vs. 7.2 Ϯ 0.6 in F/F), nϭ10; 4) high mortality (97%) by 20 weeks vs. none in F/F (nϭ39); 5) altered cardiac ultrastructure with morphologically abnormal deeply serrated ICDs, reduced adherens junctions, increased separation of myofibrils adjacent to ICDs and Z-lines, and swollen mitochondria (nϭ5); and 6) a 55% reduction of cadherin protein expression and a 42% reduction of beta-1D integrin in whole heart lysate. Conclusion: This is the first report of tissue specific inactivation of the Vin gene. Analysis of this cardiac specific Vin KO model indicates that reduced Vin protein expression at the cell-to-cell junctions causes dissolution of the ICD (cell-to-cell cardiomyopathy) and therefore leads to both electrical as well as contractile dysfunction. This animal model provides new evidence of Vin's role in mechanical/electrical coupling of cardiac myocytes in the working myocardium.
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Myocyte-Specific Excision of the Murine Vinculin Gene Leads to
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Enhanced Na ؉ /H ؉ Exchanger Activity Contributes to Myocardial Ischemia/Reperfusion Injury and Cardiac Hypertrophy Fatima Mraiche, Istvan Baczko, Peter Light, Larry Fliegel; Univ of Alberta, Edmonton, Canada
The Naϩ/Hϩ exchanger isoform 1 (NHE1) is an integral membrane protein, found in the myocardium. Recent evidence suggests that NHE1 is an important contributor to myocardial ischemia/reperfusion (I/R) injury and a mediator of cardiac hypertrophy. To examine the effect of increased NHE1 expression, we created two transgenic models that express NHE1 in the mouse myocardium. The N-line overexpresses wild type NHE1 and the K-line overexpresses a slightly hyperactive human NHE1. Western blot analysis showed that NHE1 was targeted to the myocardium. NHE activity of adult ventricular cardiomyocytes was elevated in the K-line and N-line (350 Ϯ 12 and 210 Ϯ 2.5) vs. controls (100 Ϯ 3.3). We examined the sensitivity of field-stimulated N-line cardiomyocytes to I/R injury using a metabolic model of inhibition and reoxygenation. The increase in diastolic [Ca2ϩ]i associated with reoxygenation was larger in N-line cardiomyocytes (42 Ϯ 6.8%) vs. controls (22 Ϯ 5.5%, PϽ0.05). HOE 694 (5 M), an NHE1 inhibitor, attenuated this increase. To examine the effects of NHE1 expression on heart susceptibility to hypertrophy, we examined cell area and the heart weight to body weight ratio (HW/BW). The cell area of isolated cardiomyocytes was larger in the K-line (111 Ϯ 4.7) vs. controls (100 Ϯ 2.6, PϽ0.05). The K-line mice also had a greater HW/BW (130.4 Ϯ 4.6) vs. controls (100 Ϯ 3.8, PϽ0.05). Administration of phenylephrine via osmotic mini-pumps (50mg/kg/day) produced a further increase in the HW/BW in the K-line mice (150.9 Ϯ 10.7) vs. controls (117.9 Ϯ 7.0, PϽ0.05). However, angiotensin II (200ng/kg/min) had no effect on the HW/BW in the N-line or K-line mice. These results demonstrate that overexpression of NHE1 directly causes increased diastolic Ca2ϩ overload during cardiac I/R and that enhanced NHE1 activity increases cell area, heart weight to body weight ratio and susceptibility to hypertrophic stimuli.
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Cardiac-Specific SUR1 Expression Disrupts Cardiac Sarcolemmal ATP-Sensitive Potassium Channel Activity and Impairs the Cardiac Response to Systolic Overload
Xinli Hu, Xin Xu, Univ of Minnesota, Minneapolis, MN; Thomas Flagg, Washington Univ, St. Louis, MO; Ping Zhang, Univ of Minnesota, Minneapolis, MN; Colin G Nichols, Washington Univ, St. Louis, MO; Robert J Bache, Yingjie Chen; Univ of Minnesota, Minneapolis, MN A recent report described several patients with idiopathic cardiomyopathy who had mutations of ABCC9, the gene that encodes the regulatory subunit SUR2A of cardiac myocyte sarcolemmal ATP sensitive potassium channels (s-K ATP ), suggesting that impaired s-K ATP function might be a cause of cardiomyopathy. Consequently, this study examined whether K ATP dysfunction impairs the cardiac response to hemodynamic overload. We recently developed a strain of transgenic mice overexpressing the SUR1 subunit under transcriptional control of the alpha-myosin heavy chain promoter. SUR1-tg mice demonstrate diminished s-K ATP current density, essentially generating a cardiac specific K ATP knockdown model. Transgenic mice develop and grow normally without obvious cardiovascular defects or dysfunction. Although there was no significant difference in heart weight, lung weight, or left ventricular (LV) function between SUR1-tg mice and wild type littermates (WTL) under unstressed conditions, SUR1 over expression resulted in significant increases of myocardial p-mTOR, total-mTOR, p-S6K1, and p-JNK, while myocardial p-ERK1 and p-ERK2 were decreased. Myocardial total-S6K1, total-JNK, p-AKT, p-AMPK were unchanged in SUR1-tg mice. Most interestingly, female SUR1-tg mice demonstrated a markedly abnormal response to systolic overload following transverse aortic constriction (TAC). Thus, after TAC of 4 weeks duration, SUR1-tg mice developed more severe LV dysfunction (LV ejection fraction decreased to 49.9Ϯ5.0% in SUR1-tg mice vs. 72Ϯ4.9% in WTL; pϽ0.05), as compared to 84% in SUR1-tg mice after sham surgery. Consistent with the greater ventricular dilation and dysfunction in the SUR1-tg mice, 4 weeks after TAC the SUR1-tg mice had more severe (pϽ0.05) pulmonary congestion (with a 190Ϯ 20% increase in lung weight/body weight ratio) as compared to WTL (with a 44Ϯ31% increase in lung weight/body weight ratio). Within the 4 week observation period, TAC induced mortality did not differ between SUR2A-tg and WTL. The finding that disruption of s-K ATP channel function exacerbates systolic overload induced myocardial hypertrophy and heart failure indicates a critical role for s-K ATP channels in mediating the cardiac response to stress. We have shown that expression of a constitutively active or "unregulated" ␣5 integrin subunit, designated ␣5-1, in perinatal or adult mouse heart resulted in severe conduction defects, rapid onset cardiomyopathy and death. Expression profiling of hearts in which ␣5-1 integrin expression was induced de novo revealed dramatic increases in calreticulin mRNA and protein.
P86
Overexpression of Calreticulin in Adult Cardiac Myocytes Is Not the Cause of Lethality in Mice with Expression of "Activated" ␣5 Integrin
Interestingly, the phenotype of mice over expressing calreticulin neonatally resembled that of the ␣5-1 mice. This implicated calreticulin as a proximal mediator of the deleterious effects of ␣5-1 integrin. To answer this question, we used our conditional heart specific transgenic expression system to express high levels of calreticulin in neonatal and adult cardiac myocytes. Induction of increased calreticulin in neonates did lead to cardiac conduction abnormalities as previously reported. However, over expression of calreticulin in the adult heart for up to 2 months did not result in cardiomyopathy. Therefore, while calreticulin expression is increased in ␣5-1 transgenic mice, calreticulin is not the cause of the rapid onset heart failure.
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Adverse Effects on Cardiomyocyte Function of Removing the Inhibition of the Sarco(endo)plasmic Reticulum Ca 2؉ Transport ATPase by Phospholamban Virginie Bito, Peter Vangheluwe, William E Louch, Frank Wuytack, Karin R Sipido; K U Leuven, Leuven, Belgium Background. Replacement of the cardiac sarco(endo)plasmic reticulum Ca 2ϩ ATPase SERCA2a by its SERCA2b splice variant with a higher Ca 2ϩ affinity (SKO mice) induces left ventricular hypertrophy (LVH). Although phospholamban (PLB) inhibition was spontaneously increased and SERCA levels were reduced (50% vs. wild-type, WT) in the SKO heart, ablation of PLB (DKO mice) exacerbated LVH, reduced life span and evoked stress intolerance. To investigate whether the severe DKO phenotype relates to the observed further reduced cardiac SERCA2 content (33% vs. WT), we analyzed cardiomyocyte Ca 2ϩ handling. Methods. Cardiomyocytes were isolated from adult DKO and WT mice. [Ca 2ϩ ] i changes were monitored at 30°C under whole-cell voltage-clamp using K 5 -Fluo-3. Results. In both DKO and WT cardiomyocytes, the amplitude of the [Ca 2ϩ ] i transient showed a negative frequency dependence. At 8 Hz, the amplitude of the DKO Ca 2ϩ transient was significantly reduced (in nM: 151Ϯ31, n cells ϭ8 vs. 259Ϯ38 in WT, n cells ϭ12; PϽ0.05). [Ca 2ϩ ] i removal was faster in DKO at 1 Hz (t 1/2 in ms: 101Ϯ8 vs. 141Ϯ11 in WT; PϽ0.05), but normalized to WT values at 8 Hz (t 1/2 in ms: 83Ϯ6 vs. 81Ϯ3 in WT). At 1 Hz, diastolic [Ca 2ϩ ] i was similar in DKO and WT (in nM: 131Ϯ12 in DKO vs. 138Ϯ14 in WT) and increased with frequency in both groups. However, the increase in DKO at 8 Hz was significantly lower compared to WT ([Ca 2ϩ ] i in nM: 196Ϯ23 in DKO vs. 312Ϯ37 in WT, PϽ0.05). The SR Ca 2ϩ content was deduced from the Ca 2ϩ transient recorded after application of 10 mM caffeine. In DKO, the caffeine-evoked [Ca 2ϩ ] i transient at 1 Hz was larger compared to WT but in contrast to WT, it did not significantly increase at 8 Hz. Forskolin (10 M) increased the amplitude of the [Ca 2ϩ ] i transient and the rate of [Ca 2ϩ ] i removal in WT, but not in DKO. Conclusions. Increasing the Ca 2ϩ affinity of the SERCA2 pump by PLB ablation can adequately increase SR Ca 2ϩ uptake even in the context of reduced SERCA2 levels. However, normal SR Ca 2ϩ handling in DKO does not prevent LVH. In addition, the lack of increase in SR Ca 2ϩ content with frequency and the impaired ␤-adrenergic response are likely responsible for the stress intolerance and high mortality of the DKO mice.
P89 Compensatory Mechanisms Protect the Heart Against Changes in the Ca 2؉ Affinity of the Sarcoplasmic Reticulum Ca 2؉ Transport ATPase
Peter Vangheluwe, Karin R Sipido, Luc Raeymaekers, Frank Wuytack; K U Leuven, Leuven, Belgium
In S2 b/b mice, the cardiac sarcoplasmic reticulum Ca 2ϩ pump SERCA2a was replaced by SERCA2b, a higher Ca 2ϩ affinity isoform. Interestingly, the imposed high Ca 2ϩ affinity was countered by a spontaneous increase in phospholamban (PLB) inhibition, with beneficial effects on cardiac function. The 50% lower cardiac SERCA2 levels in S2 b/b may serve the same purpose, i.e. preventing excessive cytosolic Ca 2ϩ uptake at low Ca 2ϩ concentrations ([Ca 2ϩ ] c between 0.05-0.4 M). In fact, the low SERCA2 levels only moderately affected Ca 2ϩ uptake activity in this concentration range. We now (A) compared the compensatory response in heterozygous mice (HT) and (B) crossed our S2 b/b mice with mice overexpressing SERCA2b (M. Periasamy). We investigated if higher SERCA2 levels would further increase PLB inhibition. (A) In the wild-type (WT) heart, 2% of the SERCA2 content consists of SERCA2b, whereas SERCA2a makes up for the remainder. HT mice contain one SERCA2 allele from which only SERCA2b can be formed and one WT allele, of which the transcripts can be spliced to SERCA2a or SERCA2b mRNA. Expression of both alleles would allow a 50/50% SERCA2a/2b distribution in the HT heart. However, cardiac SERCA2a expression predominated (85%) over SERCA2b (15%). In addition, this selective suppression of SERCA2b correlated with an overall reduced SERCA2 content (-35% vs. WT). In contrast to homozygous S2 b/b , the lower SERCA2a levels in HT were compensated by a reduced PLB inhibition (2-fold less protein, but increased phosphorylation vs. WT). (B) Overexpression of SERCA2b in S2 b/b mice resulted in a 20% increase in cardiac SERCA2 content, a similar increase in PLB levels and a further reduced PLB phosphorylation vs. S2 b/b . Also, the increased SERCA2 levels did not counter hypertrophy, indicating that the hypertrophy in S2 b/b is not related to the low SERCA2 content. In conclusion, enforced expression of the higher Ca 2ϩ affinity SERCA2b was spontaneously countered by adjusting SERCA2b expression, PLB expression and PLB phosphorylation. These data support the view that the Ca 2ϩ -uptake activity at lower micromolar Ca 2ϩ concentrations is tightly controlled. Understanding these control mechanisms would open doors for new ways of adjusting the SERCA2 activity in the (diseased) heart. Ageing is associated with impairment of endothelial progenitor cells (EPC) and increasing risk for atherosclerosis. Insulin-like growth factor-1 (IGF-1) stimulates angiogenesis and has vascular protective properties, but little is known about its effect on age-related EPC dysfunction. We compared EPC number and function in healthy male volunteers (57.4 Ϯ 1.4 years) before and after a ten day treatment with recombinant growth hormone (0.4 mg/day) with that of younger male subjects (27.5 Ϯ 0.9 years). Older subjects had lower IGF-1 levels which were increased by growth hormone treatment (126.0Ϯ7.2ng/ml vs 241.1Ϯ13.8ng/ml; pϽ0.0001). In older subjects, circulating CD133 ϩ /VEGFR-2 ϩ EPC were significantly lower, EPC function was attenuated, EPC senescence was increased and EPC telomerase activity was reduced compared with the younger group. Growth hormone treatment in elderly subjects increased circulating EPC, that displayed improved colony forming and migratory capacity, showed enhanced incorporation into tube-like structures, and increased telomerase activity comparable to that of the younger group. IGF-1 stimulated EPC differentiation, migratory capacity and the ability to incorporate into forming vascular networks in vitro via the IGF-1 receptor. IGF-1 treatment significantly attenuated precipitant EPC senescence of older study subjects. IGF-1 increased telomerase activity, expression, phosphorylation and activity of endothelial nitric oxide synthase in EPC in a phosphoinositide-3(PI-3)-kinase/Akt-dependent manner. Small interference RNA-mediated functional knockdown of eNOS in cultured EPC abolished the IGF-1 effects. Growth hormone-mediated increase of IGF-1 reverses EPC dysfunction in older subjects by a PI-3-kinase/Akt/eNOS mediated pathway and may be a novel therapeutic strategy against vascular disorders with impairment of EPC. With the advent of clinical trials for cardiac regeneration employing adult stem cells, it becomes essential for both safety and efficacy to know the spatial distribution of cells delivered in vivo in animal models and in humans. Quantum dots (QDs) are extremely bright semiconductor nanoparticles with unique spectral properties that permit sensitive detection excluding autofluorescence. We have developed an approach to uniformly load QDs into adult human mesenchymal stem cells (hMSCs) via endocytosis. This optimized loading procedure avoids perinuclear aggregation, which can compromise hMSC viability. Both unloaded hMSCs and those with intracellular QDs proliferate similarly. QD-loaded hMSCs can be transfected to overexpress exogenous genes similarly to unloaded cells. Further, by tracking loaded hMSCs through multiple divisions in vitro, we confirmed that dilution of QDs per cell did not hinder signal detection over 44 days (at least 6 divisions). QDs did not cross gap junctions between hMSCs and were not taken up by cardiac myocytes in culture, suggesting that false positives should not pose a serious concern. We have imaged and enumerated QD-loaded hMSCs through the full thickness (100m) of an extracellular matrix patch, which is difficult with traditional cell tracking agents such as EGFP. Finally, we injected 100,000 QD-loaded hMSCs into the left ventricular wall of the rat heart. One hour later, cardiectomies were performed and 222 10-m-thick sections were obtained and imaged for fluorescence. Computer algorithms were developed to "stack" the fluorescent images and recreate the three-dimensional distribution of the injected stem cells. More than 85% of the stem cells were within 1500 m of the centroid of the stem cell mass, while only 2% of the cells were further than 2000 m from the centroid. Given their ease of loading, absence of effects on proliferation and the low likelihood of false positives, these results suggest it is feasible to use QDs to label, track, enumerate and reconstruct the three-dimensional distribution of hMSCs following in vivo delivery to the mammalian heart. A virtue of such reconstructions is that they can also be used to validate detection via MRI and other non-invasive imaging approaches.
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Age-Dependent Impairment of Endothelial Progenitor Cells Is Corrected by Growth Hormone-Mediated Increase of Insulin-like Growth Factor-1
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Identification of a Progenitor Cell Population from Human Skeletal Muscle that Is Superior to Committed Skeletal Myoblasts for Cardiac Cell Therapy
Masaho Okada, Thomas R Payne, Bo Zheng, Hideki Oshima, Nobuo Momoi, Kimimasa Tobita, Bradley B Keller, Bruno Pé ault, Johnny Huard; Univ of Pittsburgh/Children's Hosp of Pittsburgh, Pittsburgh, PA Skeletal myoblast transplantation is being investigated for human cardiac repair; however, a recent Phase 2 cardiac cell therapy trial based on autologous skeletal myoblasts has ceased to enroll new patients due to a lack of efficacy. Here our objective was to identify and isolate a progenitor cell population from human skeletal muscle biopsies that was superior to committed skeletal myoblasts for cardiac cell therapy. After the human skeletal muscle biopsy was digested, we used fluorescence-activated cell sorting (FACS) to isolate various fractions of mononuclear cells based on their expression of the myogenic marker CD56 and the endothelial markers CD34 and CD144. We obtained 3 different cell populations: 'myogenic' cells (committed skeletal myoblasts) (CD56 ϩ /CD34 -/CD144 -), 'endothelial' cells (CD56 -/CD34 ϩ / CD144 ϩ ), and 'myogenic-endothelial' cells (CD56 ϩ /CD34 ϩ /CD144 ϩ ). Each sorted cell population was then expanded in culture. These cells were then injected (3ϫ10 5 cells/heart) into the ischemic myocardium of SCID mice after acute myocardial infarction. Two weeks later, echocardiography was performed to assess left ventricular (LV) heart function (nϭ5 mice/ group). The hearts injected with myogenic-endothelial cells displayed significant improvement in cardiac contraction, as measured by percent fractional shortening and percent fractional area change, when compared not only with control saline-injected hearts (PϽ0.05), but also with endothelial cell-or myogenic cell-injected hearts (PϽ0.05). However, we did not observe improvement in LV cardiac contraction after transplantation of either the myogenic or endothelial cells when compared to control saline-injected hearts. Histologically, the transplantation of myogenic-endothelial cells regenerated significantly more new skeletal myocytes and induced significantly more neoangiogenesis (i.e., blood vessel density) in the infarct zone than did the transplantation of the myogenic and endothelial cell types (PϽ0.05). In conclusion, these findings suggest that human myogenic-endothelial cells represent a novel cell population that offer superior therapeutic benefit after myocardial infarction when compared to committed skeletal myoblasts or endothelial cells.
P93 Thymus Explants During Correction of Congenital Heart Defects: A New Source of Multilineage Stem Cells
Matthias Siepe, Thomas Severin, Univ Hosp, Freiburg, Germany; Andreas R Thomsen, Roland Bosse, CellGenix Technology Transfer GmbH, Freiburg, Germany; Friedhelm Beyersdorf, Christian Schlensak; Univ Hosp, Freiburg, Germany Introduction: Stem cell transplantation and tissue engineering are attractive future strategies for functional myocardial repair. Multi-lineage stem cells (MLSC) are well qualified for this purpose and have mainly been isolated from the bone-marrow so far. In the present study we aimed to isolate MLSC from the thymus gland of infants undergoing cardiac defect repair, where partial thymectomy represent a standard procedure for better cardiac access. Methods: After sternotomy, the thymus gland of 10 neonates/children undergoing cardiac surgery was removed. Tissue was minced, digested and cultured. Multi-lineage potential was tested every three culture passages using differentiation cultures towards the osteogenic, chondrogenic and adipogenic lineage. Surface antigen expression was investigated in detail by FACS-analysis and results were compared with MLSC from the bone-marrow. Results: While the majority of isolated cells were non-adherent lymphocytes, we observed two types of adherent cells in primary culture. The epithelial cell colonies were refractory to passage. The remaining cells showed almost unlimited proliferation. Throughout the proliferation phase of more than 40 doublings a multi-lineage potential was re-evaluated. Full differentiation potential is maintained during this proliferation phase as confirmed by differentiation cultures and FACS-analysis. The thymic MLSC showed similar characteristics as compared to bone-marrow derived MLSC. Conclusions: The human thymus gland is an alternative source for isolation of MLSC in neonates and young children undergoing cardiac surgery since the thymus is routinely resected during pediatric cardiac surgery. Children who might undergo further cardiac surgeries might profit from the use of thymic MLSC for tissue engineering. Background: Optimal cell sources and scaffold chemistry for cardiovascular tissue engineering remain unknown. We investigated seeding endothelial progenitor cell (EPC)-derived endothelial cells on a novel elastomeric scaffold, polyglycerol sebacate (PGS). We hypothesize that EPC proliferation and ECM formation could be enhanced by pre-coating PGS scaffolds with ECM proteins. Methods: Characterized ovine peripheral blood EPC were seeded onto scaffolds for 3 days followed by 14 days in a laminar fluid flow system. We pre-coated the scaffolds with laminin (LM), fibronectin (FN), fibrin, collagen types I/ III (Coll I/III), or elastin (EL) (nϭ5; controlϭ uncoated, unseeded scaffolds). Results: EPC were CD31 ϩ , vWF ϩ , and ␣-SMAprior to seeding. Both coated and uncoated scaffolds revealed CD31 ϩ and vWF ϩ cells throughout the scaffold with primary surface expression. ␣-SMA ϩ cells were found both on the surface and in the "interstitium" of the scaffold. A range of ␣-SMA ϩ cells was observed: uncoated Ͻ EL, Ͻ LM Ͻ FN Ͻ Coll I Ͻ Fibrin ϽColl III. The presence of ␣-SMA ϩ cells correlated with enhanced and uniform expression of LM and FN within the surface and "interstitium" of pre-coated scaffolds comparable to native valve. Enhanced FN was observed: uncoatedϽ Coll IIIϽ Coll IϽ ELϽ FibrinϽ LM. In contrast, Coll I/III were expressed in the surface. In addition, both CD31 ϩ and ␣-SMA ϩ cells produced Coll I. Biochemical assays demonstrated increased DNA (uncoated Ͻ Coll I ϭ LM ϭ EL Ͻ Fibrin Ͻ Coll III Ͻ FN) and collagen content (LM ϭ EL Ͻ Fibrin Ͻ FN). Flexure testing demonstrated decreased effective stiffness of the seeded scaffolds, regardless of whether the PGS was pre-coated or uncoated (5.49 Ϯ 0.38 vs. 8.13 Ϯ 0.17 kPa, pϽ 0.05). A range of cellularity was observed: uncoated Ͻ ELϽ LMϽ Coll IϽ FibrinϽ Coll III Ͻ FN. Overall, the most enhanced histology was seen in FN pre-coated scaffolds. CONCLUSION: PGS offers the advantages of low stiffness and elasticity, allowing for large deformations. Pre-coating offers the additional advantage of controlling scaffold surface chemistry. Circulating EPC appear to have the potential to provide both interstitial and endothelial functions, and can produce ECM on PGS allowing a single cell source for construction of autologous heart valves.
P94 Protein Precoating of Elastomeric Tissue-Engineering Scaffolds: Extracellular Matrix Formation and Phenotypic Changes of Circulating Endothelial Progenitor Cells
P95 AAV SDF-1 Augmented Myoblast Therapy for Cardiac Failure
Bijoy D Thattaliyath, Faris Al-Mousily, Sean Germain, Christina Pacak, Stacy Porvasnik, Melissa Lewis, Glenn Walter, Barry J Byrne; Univ of Florida, Gainesville, FL During the past few years the number of patients with cardiac failure has increased following improved therapy and survival of patients following myocardial infarction(MI). Currently there is no approved modality of treatment to repair the resulting damage of ischemic injury. This study was done to evaluate the transplantation of AAV (Adeno-associated virus) SDF-1(Stromal Derived Factor) modified human myoblast versus normal myoblasts in improvement of cardiac function. SDF-1 is essential for cardiogenesis and vasculogenesis during development. SDF-1 levels are elevated post-ischemic injury and may have a role in the repair and regeneration of the damaged myocardium. We hypothesize that increased levels of SDF-1 with myoblasts will drive stem cells to the myocardium and promote repair process. Materials and Methods: MI is created in 8 weeks old nude rats. Baseline cardiac MRI is performed 3 weeks post-infarction. Superparamagnetic iron oxide (SPIO) labeled myoblasts are injected with or without AAV-SDF-1 transduction into the infracted myocardium. Hydrogel is used in the study groups to improve cell retention at the site of transplant. Cardiac function is reassessed by MRI at 1, 4 and 8 weeks post-transplant. Control animals receiving no myoblasts or non-transduced myoblast transplants are also followed by the same protocol. The images are analyzed using CAAS MRV software. End-diastolic and end-systolic volumes are used to calculate ejection fraction, cardiac output and wall thickening. The transplanted tissues are analyzed with antibodies specific to skeletal and cardiac muscle lineage. Results We have been able to successfully transplant human myoblasts in the intra-myocardially post-infarction in nude rats. The SPIO labeled cells were able to be tracked till the end of the study (8 weeks). Rats treated with AAV SDF-1 by itself did not show any significant improvement of cardiac function. The cardiac output improved 8 weeks post-myoblast transplant compared to the media injected controls. The AAV SDF-1 transduced myoblast with and without hydrogel showed significant improvement in cardiac function. Conclusion: AAV transduced myoblasts with SDF1 will be beneficial in improvement of cardiac function compared to using only myoblasts. The diabetic heart is targeted by both coronary and non-coronary pathology that eventually results in cardiac failure. Cardiac function in diabetes can be improved by physical exercise among other interventions. However, the exercise induced benefits on cardiac cycle volume profiles and hemodynamics in diabetes are poorly understood. The importance of this information is underscored by the evidence that diabetic heart disease is associated with both systolic and diastolic left ventricular (LV) dysfunction. We used a non-invasive approach, MRI, to characterize the effects of exercise training on cardiac function in diabetic rats. Twelve animals were randomized into three groups (nϭ4 per group; sedentary control -SC; sedentary diabetic -SD; and exercised diabetic -ED). At the termination of study, EKG gated cardiac MRI was performed with a 9.4T scanner to resolve LV cardiac cycle events. The systolic hemodynamic indices were derived from the LV volumetric data. The decrease in LV end diastolic volume in diabetes was prevented by exercise training (end diastolic volumes were 626.70Ϯ10.01, 413.94Ϯ8.33, and 584.10Ϯ 7.80 l in the SC, SD and ED groups, respectively). Exercise training also prevented the increase in LV end systolic volume in diabetes (end systolic volumes were 208.37Ϯ4.24, 224.13Ϯ2.81, and 200.49 Ϯ 1.73 l in the SC, SD and ED groups, respectively). Accordingly the LV stroke volume and ejection fraction in diabetes were improved by exercise (stroke volume was 418.33Ϯ8.48, 189.81Ϯ8.70 and 383.56Ϯ8.33 l; and ejection fraction was 66.74Ϯ0.58, 45.80Ϯ1.24, 65.65Ϯ0.60 %, in the SC, SD and ED groups, respectively). The LV output was 0.12Ϯ5.37e -3 , 0.05Ϯ2.42e -3 , and 0.09Ϯ2.65e -3 l/min, in SC, SD and ED groups, respectively, indicating that exercise training was able to prevent the decline in LV output that accompanies a sedentary lifestyle in diabetes. The time derivatives of LV volume in the exercised diabetic group approached the control levels. These results suggest that early intervention in the form of exercise training prevents cardiac dysfunction in diabetes.
P96 Exercise Training Improves Cardiac Function in Diabetic Rats: Noninvasive Assessment Using High-Resolution Magnetic Resonance Imaging
P98 Withdrawn
P99 HNO Inotropy Is Reduced in G␣q Overexpressing Cardiomyocytes Displaying Altered Cellular Redox Conditions and Reduced RyR 2 Protein Expression
Carlo G Tocchetti, Gianfrancesco Cormaci, Miguel A Aon, Eiki Takimoto, Johns Hopkins Univ, Baltimore, MD; Jeffrey P Froehlich, Univ of Maryland, Baltimore, MD; Gerald W Dorn, II, Univ of Cincinnati, Cincinnati, OH; Hector H Valdivia, Univ of Wisconsin, Madison, WI; Sandro Betocchi, Massimo Chiariello, Federico II Univ, Naples, Italy; David A Kass, Nazareno Paolocci; Johns Hopkins Univ, Baltimore, MD Nitroxyl (HNO) enhances ryanodine receptor (RyR 2 ) and SERCA2a activity to induce/sustain positive inotropy in control myocytes. HNO targets critical reduced thiols in the contractile machinery. Hence, in heart failure, lowered abundance of cardiac reducing equivalents and/or expression of Ca 2ϩ handling proteins should result in blunted HNO inotropy. To test this, myocytes were isolated from G␣q overexpressing mice, displaying hypertrophy/cardiac failure and ␤-adrenergic desensitization, and from control FVBN mice (WT), suspended in Tyrode's solution (1mM Ca 2ϩ ) and field stimulated (.5 Hz, 23°C). Sarcomere shortening (SS) was assessed by real-time image analysis. We characterized G␣q cardiac redox status, i.e. intracellular reduced glutathione with two-photon microscopy and expression of glutathione (GSR) and thioredoxin reductase (TrxR). RyR 2 protein expression was evaluated by western blot. G␣q myocytes displayed reduced intracellular thiol content (-14% in fluorescence a.u. vs controls, nϭ35 each, pϽ.005), with marked upregulation of tissue GSR and TrxR. RyR 2 protein amount was reduced in G␣q cells ( Fig.) . G␣q cells did not respond to isoproterenol (ISO, 10nM): SS was ϩ19Ϯ14% vs 250Ϯ75% ⍀⌻ (ϭ.02 ⌫␣). Conversely, HNO donated by Angeli' salt increased SS: 22Ϯ11% and 40Ϯ11%, at 250 and 500M AS, respectively (both pϽ.05 vs base). Yet, HNO action was less effective in G␣q as compared to controls: 61Ϯ15% and 103Ϯ19% (both pϽ.05 vs G␣q). Thus, HNO inotropy is blunted in G␣q myocytes, and reduced level of intracellular thiols and/or viable RyR 2 may contribute to this. We also postulate that changes in RyR 2 redox status may further concur to blunt HNO efficacy in HF. The possibility to regenerate dead myocardium by cell therapy using either extra-cardiac or cardiac stem cells is the object of an intense investigation. Whereas much work has been done to assess the potential of injected cells to form new myocardium, little is known about the spontaneous recruitment of stem cells through the circulation. Host-derived cardiomyocytes were found in human sex-mismatched heart transplantations, however the relative proportion of this phenomenon was estimated very high by some authors and negligible by others. In heterotopic heart allo-transplantation, we previously demonstrated that circulating cells engraft the heart transplants but do not significantly contribute to cardiac repair. Possible fusion events, as opposed to transdifferentiation, had been hypothesized but not proved. Here, we took advantage by the use of xeno-transplantations, in which markers of both donor and recipient cells are available, to address this issue. Xeno-transplantations were performed using GFP ϩ transgenic rats as hosts, and either Syrian hamsters (nϭ8) or transgenic mice expressing the lacZ reporter gene under the control of the cardiac troponin I promoter (nϭ6), as heart donors. All transplants, which were retrieved 15 days after surgery, contained a large quantity of GFP ϩ inflammatory cells. In 7 of 8 hamster-to-rat heart transplants GFP ϩ mature cardiomycytes were found, with percentages ranging from 0.0001% to 0.034%. No more than 15 GFP ϩ cardiomyocytes were detected in all mouse-to-rat transplants. We also found rare small GFP ϩ cells expressing markers of cardiac progenitor cells, such as GATA-4 and MEF2C, in all xenografts. All GFP ϩ cardiomyocytes identified in our study co-expressed GFP (the host's marker) and either hamster-specific antigens or the LacZ marker of mouse origin (the donor's markers). Thus, using both an immunological and a genetic approach, we conclusively demonstrate that in our experimental model circulating cells do not significantly contribute to form new myocardium, rather they generate hybrid cardiomyocytes by cell fusion.
P100
Host-Derived Circulating Cells Generate Hybrid Cardiomyocytes by Cell Fusion in Heterotopic Heart Xenotransplantations
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P103 Mononuclear Cord Blood Cells or Unrestricted Somatic Stem Cells Do Not Improve Survival or Heart Function After Myocardial Infarction in Rats
Steffen Rabald, Carl-Ludwig-Inst for Physiology, Leipzig, Germany; Manja Kamprad, Inst of Immunology, Leipzig Univ, Leipzig, Germany; Michael Cross, Leipzig Univ, Leipzig, Germany; Heinz G Zimmer, Alexander Deten; Carl-Ludwig-Inst for Physiology, Leipzig, Germany
In this study the effect of mononuclear cord blood cells (MN-CBCs) and unrestricted somatic stem cells (USSCs) on survival and heart function after myocardial infarction (MI) was analyzed. Methods: In a first trial, MI was induced in 14 w old male spontaneously hypertensive rats (SHR) by ligation of left coronary artery (nϭ60). After 24 h, 3x10 6 MN-CBCs (nϭ23) or medium (nϭ23) was injected via a tail vein. Right and left ventricular (RV and LV, resp.) function was measured with Millar-tip catheters after 8 w. Additional 12 infarct hearts were examined 6 or 24 h after CFSE-labeled cell or medium injection (each nϭ3). In a second trial, 1x10 6 or 5x10 5 MN-CBCs (nϭ14) or USSCs (nϭ15), resp., were directly injected into the MI border zone 24 h after MI in female Sprague-Dawley rats (SD). Medium-injected MI-rats served as controls (nϭ18). Heart function was monitored by echo for 12 weeks, after which catheterization was performed. Results: Labeled cells were detected in the border zone adjacent to the infarct area at 6 and 24 h after i.v.-cell injection as well as 1 w after direct injection. Cumulative survival, however, was comparable in cell and medium treated MI (SHR) rats (57 vs. 61%, resp.) and MI size not significantly different (51Ϯ2 vs. 53Ϯ2%). Moreover, LV end-diastolic pressure and RV systolic pressure, indicating severely impaired heart function, were similar (table). Also the other hemodynamic parameters as well as the histological analyses did not provide evidence for improved myocardial pump function or cardiac remodeling after MI by cell therapy. Similarly, heart function measured by echo or catheterization (table) as well as cardiac remodeling were comparable between SD-MI rats after direct cell injection and MI-CTRLs. Conclusion: Despite detection of the cells in the border zone of MI 6 and 24 h after i.v.-injection of 1 w after direct injection neither MN-CBCs nor USSCs did improve survival or heart function after myocardial infarction in rats. To evaluate the effect of overlapping stents on the integrity of the drug-eluting coating of TAXUS ® Express ® (Boston Scientific Corporation, Natick, MA) stents a short-term study was carried out in healthy swine to assess and compare the outcomes from implantation of single versus completely overlapped TAXUS ® Express ® stents. Methods: Slow Release (8.8%) TAXUS Express stents were deployed into coronary arteries of healthy female domestic swine in a single (32 mm length) or complete overlap (16 mm length) configuration (targeting 100%). At termination (Յ4 hours or 48 hours), tissue was digested from the samples, and single (nϭ9) and overlapped pairs (nϭ9) of stents were visually inspected (inner diameter and outer diameter) at 32X magnification with a light microscope and an area reticule. Coating integrity for overlapping versus single TAXUS Express stents was assessed both qualitatively (stent-to-stent polymer interactions such as protrusions) and quantitatively (total coating displacement area). Results: There were no observations of coating loss, protrusions, or any unusual coating features on either single or overlapped pairs of stents deployed in vivo. Overlapped stents did not exhibit any stent-to-stent polymer interactions. Quantitatively, there were no differences in the area measurements of displaced (bare) coating between overlapping and single TAXUS Express stents. Displaced area per stent (mean Ϯ standard deviation) was 0.07Ϯ0.03% and 0.05Ϯ0.03% for overlapping and single stents, respectively. The displaced areas remained over ten-fold below manufacturing specifications for coating integrity. Conclusions: Results from stent coating studies in vivo demonstrated the robust quality of the Slow Release formulation coating on TAXUS Express stents placed in a completely overlapping configuration. All overlapped TAXUS Express stents had intact coatings with low amounts of detectable defects that were well below manufacturing specifications. These results indicate that implanting TAXUS Express stents in an overlapping configuration does not result in the loss of coating integrity.
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P105 Histological Assessment of Myocardial Infarct Size in the Mouse Chronic Infarction Model: Infarct Length Measurement Is More Accurate than Infarct Area Measurement
Junya Takagawa, Yan Zhang, Richard E Sievers, Neel K Kapasi, Maelene L Wong, Yerem Yeghiazarians, Randall J Lee, William Grossman, Matthew L Springer; Univ of California, San Francisco, San Francisco, CA Efficacy of potential cell-or gene-based treatments for myocardial infarction (MI) is frequently assessed by histological measurement of infarct size (IS) in rodent models. In experiments involving an acute MI setting, measurement of the infarcted area in tissue sections of the left ventricle (LV) is a standard approach to determine IS. This approach has also been used in a chronic infarct setting, taking infarct area measurements several weeks post-MI. However, we hypothesized that wall thinning due to cardiac remodeling would invalidate the correlation between a severe infarct and a large infarct scar area measurement, reducing the legitimacy of this approach in a chronic setting. To address this issue, we assessed LV ejection fraction (LVEF) in 23 infarcted mouse hearts and ranked them according to increasing severity. The scar was measured in multiple sections per heart by a blinded investigator using several strategies, the numbers obtained were combined to express IS as percentage of total LV volume, and the values were compared to the functional measurements for each heart. Our measurement strategies consisted of calculation of the ratio of (1) summed infarct areas to summed LV myocardial areas (Area Measurement: AM), (2) summed epicardial and endocardial infarct arc lengths to summed epicardial and endocardial LV circumferences (Length Measurement: LM), and (3) summed midline infarct arc lengths to summed midline LV circumferences (Midline Length Measurement: MLM). Linear correlation analyses showed that IS from all three measurement approaches correlated significantly with LVEF and wall motion score index. However, the IS derived from AM was significantly smaller than those from the other measurements, and the range of values obtained was compressed 0.4-fold, substantially compromising the accuracy of this approach. We conclude that area-based IS measurements underestimate the extent of the infarct and substantially reduce the sensitivity of this measure compared to measurements based on infarct arc lengths. We further conclude that the estimation of myocardial and infarct midlines provide comparable accuracy to the more cumbersome tracing of epicardial and endocardial lengths and circumferences.
P106
Improvement of Cardiac Function by Ultrasound-Guided Injection of Bone Marrow Cells into Mouse Myocardium 3 Days Postinfarction
Yan Zhang, Junya Takagawa, Richard E Sievers, Maelene L Wong, Christian Heiss, Mohan N Viswanathan, Neel K Kapasi, Jianqin Ye, Elyse Foster, William Grossman, Matthew L Springer, Yerem Yeghiazarians; Univ of California, San Francisco, San Francisco, CA Considerable interest has focused on intra-myocardial delivery of bone marrow cells (BMCs) and endothelial progenitor cells (EPCs) as a potential treatment for myocardial infarction (MI). However, preclinical experiments have been limited to treatment within hours of an MI, in contrast to human trials, in which cell therapy has been performed several days later after patient stabilization and autologous cell harvesting. We compared the therapeutic effects of different putative stem and progenitor cells in a mouse MI model using a novel percutaneous echo-guided injection approach to deliver cells 3 days post infarction. Methods: After induction of MI, echo-guided injection of cells or saline control (HBSS) into myocardium at the infarct border zone was performed at day 3 post-MI in the following groups (nϭ8/group): mouse BMCs (mBMCs) into C57BL/6 mice, human BMCs (hBMCs) into immunodeficient SCID mice, mBMCs into SCID, human EPCs into SCID, and HBSS into both C57BL/6 and SCID as controls. High-resolution echocardiography was performed blinded at baseline, 2 days post-MI (before injection), and day 28 post-MI. Results: Left ventricular ejection fraction (LVEF) was uniformly reduced from 57.2Ϯ4.0% to 38.4Ϯ3.7% (pϽ0.0001) after MI in all groups. Mice injected with mBMCs showed the best effect with significant improvement in global LVEF (37.8Ϯ2.3 vs 44.4Ϯ6.3%, pϭ0.03) at day 28, and there was a tendency toward less dilation of cardiac dimensions compared with that before injection. The global systolic function of the group injected with mBMCs was significantly better than that of its corresponding control group (44.4Ϯ6.3 vs 31.1Ϯ10.4%, pϽ0.0005). EPC injection showed a non-significant trend toward improvement of LVEF and less LV dilation, while the LVEF of its corresponding control group continued to decrease, resulting in a significant difference between the EPC group and its controls at day 28 (41.5Ϯ4.3 vs 32.1Ϯ6.3%, pϽ0.0005). Conclusions: Unfractionated mBMCs attenuated ventricular remodeling and improved LV function when delivered several days post MI. However, different cell types affected LV function to varying extents. The novel approach allowed us to assess the efficacy of cell implantation in the mouse at a clinically relevant time after MI. There is no consensus on precisely when to inject stem/progenitor cells for treatment of acute myocardial infarction. We therefore determined the attraction of infarcted myocardium from 45 rat hearts for human umbilical cord blood progenitor cells (HUCBC) at 1, 2, 2.5, 3, 6, 12, 24, 48, and 96 hours after LAD occlusion to determine the optimal time to transplant HUCBC after infarction. Our assay is based on migration of fluorescent DAPI labeled HUCBC from wells in an upper chamber of a Boyden apparatus through a semi-porous membrane into wells in a lower chamber that contained either normal or infarcted myocardium. 100,000 DAPI-labeled HUCBC were placed in separate wells above the membrane that corresponded to normal or infarcted homogenate in the lower wells. The greatest HUCBC migration occurred to infarcted myocardium at 2 hours and at 24 hours after LAD occlusion in comparison with normal controls. 76,331Ϯ3384 HUCBC migrated to infarcted myocardium at 2 hrs and 69,911Ϯ2732 at 24 hrs after LAD occlusion (both pϽ0.001) and significantly exceeded HUCBC migration to normal heart. The HUCBC migration remained greatest at 2 and 24 hours after LAD occlusion when the number of migrated cells was adjusted for infarct size. Injection of 10 6 HUCBC in Isolyte into infarcts of non-immunosuppresed rats at 1-2 hours (nϭ10) or at 24 hours (nϭ5) after LAD occlusion resulted in infarct sizes one month later of 6.4Ϯ0.01% and 8.4Ϯ0.02% of the total LV muscle area, respectively, in comparison with infarct sizes of 30.7Ϯ0.02% (nϭ10) in infarcts treated with only Isolyte (pϽ0.005). Infarcts treated with only Isolyte increased myocardial concentration of tumor necrosis factor alpha (TNF␣) from 6.9Ϯ0.8% to 51.3Ϯ4.6%, monocyte chemoattractant protein (MCP-1) from 10.5Ϯ1.1% to 39.2Ϯ2.0%, monocyte inflammatory protein (MIP) from 10.6Ϯ1.6% to 23.1.0Ϯ1.5% and interferon gamma (INF␥) from 8.9Ϯ0.3% to 25.0Ϯ1.7% between 2 and 12 hours after LAD occlusion in comparison with controls (all pϽ0.001). In contrast, the concentrations of these cytokines in infarcts treated with HUCBC did not significantly change from controls. We conclude that: 1) infarcts significantly attract HUCBC, 2) HUCBC can substantially reduce infarct size, and 3) HUCBC can limit expression of cytokines in acute infarcts.
P107 Human Umbilical Cord Blood Mononuclear Progenitor Cells Are Attracted to Infarcted Myocardium and Significantly Reduce Myocardial Infarction Size
P108 Small Molecules and the Pharmacology of Cardiac Cell Fate
Jay W Schneider, Eric N Olson; UT Southwestern Med Ctr, Dallas, TX Developing a pharmacologic agent that could trigger cardiac fate exclusively and promote functional cardiac differentiation is an essential step towards safe and effective embryonic stem (ES) cell-based repair and regeneration of the cardiovascular system. We have studied the pharmacology of cardiac fate decisions and differentiation in ES and embryonal carcinoma (EC) cells, using both known drugs and novel synthetic compounds. Our results show that the first step in ES cell differentiation, a physiologic transition from embryonic to somatic cell cycle, is epigenetically regulated and inducible by histone deacetylase inhibitors. To identify specific small molecule inducers of cardio-mesodermal fate in ES/EC cells, we screened a large (200K) chemical library for drugs that could activate Nkx2.5 and myocardin, two of the earliest signature genes of this lineage. This screen has yielded an extraordinary collection of chemically interesting small molecules capable of activating cardiac genes in ES/EC cells which fall into several dozen distinct structural classes. Among the most promising hits , substituted aryl sulfonyl hydrazones activated pro-differentiation ERK signaling and the cardiac gene program in P19CL6 EC and SM1 ES cells. A second class of molecules, bearing an isoxazole core structure, also strongly activated Nkx2.5 and myocardin in stem cells. Isoxazoles were also potently neurogenic in cultured hippocampal neural progenitors cells and in the mouse brain in vivo. The cardiogenic and neurogenic effects of isoxazoles involve calcium signaling and activation of MEF2, a transcriptional regulator shared by neural and cardiac gene programs. Further characterization of sulfonyl hydrazones, isoxazoles and many additional promising cardiogenic candidates and their corresponding target proteins in stem cells will lead to discovery of new molecular tools to elucidate the biology of the cardiac fate decision in ES cells.
P109 Cell Fusion Was Not Essential for Cardiomyogenesis from Bone Marrow Stem Cells
Atsushi Kitagawa, Kenji Okada, Yutaka Okita, Kobe Univ Graduate Sch of Med, Kobe, Japan; Richard D. Weisel, Donald A.G. Mickle, Ren-Ke Li, Toronto General Hospital, Toronto, ON Objective: It is well known cell fusion is essential for cardiomyogenesis from bone marrow stem cells(BMSCs) in vitro or in vivo. In this study we investigated other cardiac environmental factors using fetal cardiac milieu instead of cell fusion system and evaluated cardiomyogenesis from BMSCs. Methods: 5.0 x 10 6 BMSCs were prepared from a 3-week-old rat with 5cc Isocove's Modified Dubellco Medium including 10% fetal bovine serum. Then supernatant having no cell, made from rat fetal hearts was added into BMSCs culture, which was incubated for seven days without any treatment like 5-azacythidine . Then, culture media was changed twice a week and observed for three weeks. We compared myotubes from BMSCs between bone marrow cells culture alone (BM group, Nϭ84) and those incubated with fetal heart supernatant (BF group, Nϭ69) by microscopy, electron microscopy, immunostaining, and RT-PCR. Results: From day 9 to 21, more myotubes were found in the BF group than in the BM group (19.5% vs 3.5% Ͻpϭ 0.03Ͼ). These myotubes were long shaped and multinucleated, most of which were beating spontaneously. Under electron microscopy, myofilaments and Z-bands were found. In immunohistochemical study, these myotubes were stained positive by anti Troponin-I and MF20 antibodies specific for cardiomyocyte. In RT-PCR analysis, MEF-2C, GATA-4 and NKx2-5 genes contributing to cardiomyogenesis in embryo, revealed in these myotubes. Conclusions: Cell fusion was not absolutely required for cardiomyogenesis from BMSCs under cardiac environmental factors like fetal cardiac milieu. This study system could enable BMSCs to differentiate into cardiomyocytes more effectively before transplanted into heart.
P110
Long-Term Effect of Gene Therapy for Chronic Ischemic Myocardium Using Platelet-Derived Endothelial Cell Growth Factor in Dogs
Wei Li, Kuniyoshi Tanaka, Koichi Morioka, Atsushi Takamori, Mitsuteru Handa, Narihisa Yamada, Xiaodong Shen, Sawaka Tanabe, Akio Ihaya; Univ of Fukui, Faculty of Med Science, Fukui, Japan
Objective -We previously reported the 2-week benefits of platelet-derived endothelial cell growth factor (PD-ECGF) gene therapy in chronically ischemic myocardium. This study further examined the long-term effects and safety. Methods -Twenty-four beagle dogs were randomly divided into 3 groups and chronic myocardial ischemia was created by stenosing the origin of the LAD using an ameroid constrictor. Two weeks later, a second thoracotomy was performed and a total of 5 mg of pCIhTP (pCIhTP, nϭ8) or pCILacZ plasmid DNA (pCILacZ, nϭ8) was diluted in 2 ml of saline and injected directly into 6 sites supplied by the LAD. Saline group (nϭ8) received saline alone. All lived dogs were followed up to 6 months. Echocardiography was used to trace the myocardial function (%EF) and myocardial blood volume at different time points as indicated in the results. Results -Myocardial infarction was decreased in the pCIhTP group. Myocardial blood volume and %EF decreased in all 3 groups after ameroid implantation, but recovered 2 weeks in the pCIhTP group, and maintained a higher level during the examination period (Figure, * pϽ0 .005, pCIhTP vs. pCILacZ and saline). Histologic analysis demonstrated that angiogenesis occurred after PD-ECGF gene treatment. There was a decreased expression of the proapoptotic proteins, active caspase-3 and Bax, and the number of apoptotic myocardial cells was lower in the pCIhTP group. Mitochondrial count was higher in pCIhTP group. Histologic examination demonstrated that no abnormal histologic changes or neoplasms were found in any organs. Conclusions -We conclude that a therapeutic approach using the PD-ECGF/TP gene to treat chronic ischemia is effective and safe.
P111 Withdrawn
P112
Ischemia-Induced Angiogenesis Is Impaired in Aminopeptidase A Knockout Mice
Ryuji Kubota, Yasushi Numaguchi, Chinatsu Hattori, Xiuyang Ma, Masakazu Ishii, Kazuhiko Yokouchi, Michitaka Tsuzuki, Yasuhiro Ogawa, Kenji Okumura, Toyoaki Murohara; Nagoya Univ, Nagoya, Japan Some studies suggested that aminopeptidase A (APA), a membrance-bound metallopeptidase degreading bioactive peptidase such as angiotensin II, is associated with angiogenesis of tumors. Although the role of APA on ischemia-induced angiogenesis is unknown. We examined whether ischemia-induced angiogenesis is altered in APA knockout (APAKO) mice. Methods and Results:APAKO mice and Wild type mice (C57BL/6J) were subjected to unilateral hindlimb ischemia. After surgery, Laser Doppler Perfusion Imaging demonstrated decreased blood flow recovery in APAKO mice, especially within 2 weeks (Ischemic/Non ischemic limb at 1, 2, pϽ0.01, at 4 weeks; pϽ0.05 vs wild type mice, Figure) . Tissue capillary density at two weeks decreased in APAKO mice, and Aorta Ring Assay revealed mean length of sprouting micro vessels was significantly shorter in APAKO mice. (Table) Tube Formation Assay showed endothelial cells isolated from aorta of APAKO mice were tend to form less endothelial network. These results suggested that angiogenesis was impaired in APAKO mice. Conclusion:Aminopeptidase A would be a functional target of ischemia-induced angiogenesis. 
CAPILLARY DENSITY AND AORTA RING ASSAY
P114
Treatment of Bone Marrow Mononuclear Cells with Erythropoietin and Platelet-Derived Growth Factor-BB Promotes Cellular Proliferation and Expression of Mesenchymal and Endothelial Cell Surface Markers In Vitro when Compared with Traditional Growth Factors
Jordan J Lancaster, Nicholle M Johnson, Southern Arizona VA Med Ctr, Tucson, AZ; Mohamed A Gaballa, Sarver Heart Ctr, Tucson, AZ; Hoang M Thai, Steven Goldman; Southern Arizona VA Med Ctr, Tucson, AZ Objective: Autologous bone marrow cells are being used in clinical trials for cell-based therapy after myocardial infarction. We developed an in vitro assay to determine if growth factor stimulation would promote specific stem cell growth prior to infusion into a recipient. Methods: Bone marrow mononuclear cells (BMMNCs) are harvested from 5-6 week old male Sprague-Dawley rat's femurs. The contents are flushed with sterile 10% FBS in DMEM-LG. Bone spicules and clots are allowed to settle; the cell suspension is decanted and centrifuged at 1200 rpm (room temperature). Cells are re-suspended in red blood cell lysis buffer, centrifuged, and washed twice in 20ml of PBS before plating 1x10 5 cells per well in 24 well plates. Each well is exposed to one of seven of the following growth factor combinations (10 ng/ml): 1) Control (10% FBS ϩ DMEM-LG), 2) platelet-derived growth factor-BB (PDGF-BB), 3) epidermal growth factor (EGF), 4) granulocyte colony stimulation factor (G-CSF), 5) erythropoietin (EPO), 6) EPOϩG-CSF, or 7) EPO ϩPDGF-BB. Media is changed daily for ten days, a sample is removed and the cells counted to calculate total number of cells. This process was repeated in a separate group of BMMNCs grown to confluency. At passage three, immunohistochemistry is used to detect the presence of CD34, CD44, CD45, CD90, VE-Cad, and Pan-ECA. Results: Growth factor stimulation produced a transient increase in the number of cultured BMMNCs from day one to day five, and decreased thereafter to day 10. At day five EPO treated cells had an increase (PϽ0.05) in number compared to all other groups: (1) 295,500Ϯ27,081 (nϭ6), (2) 227,250Ϯ7,663 (nϭ4), (3) 225,333Ϯ30,492 (nϭ3), (4) 303,000Ϯ31,815 (nϭ3), (5) 795,666Ϯ78,846 (nϭ4), (6) 712,333Ϯ88,214 (nϭ3), (7) 913, 000Ϯ35,355 (nϭ4) . Cells grown in EPOϩPDGF-BB demonstrated expression of mesenchymal (CD44ϩ, CD90ϩ, CD45-) and endothelial (CD34ϩ, VE-Cadϩ) cells markers. Conclusion: EPO in combination with PDGF-BB stimulates BMMNC growth 3 fold over no treatment, and express mesenchymal and endothelial cell markers. These data suggest that EPOϩPDGF-BB could be explored as growth factor treatment in patients undergoing cell-base therapy after myocardial infarction.
P115 In Vitro Analysis of Signaling by the Selective Corticotropin-Releasing Factor Receptor Agonist Urocortin 2 in Isolated Adult Cardiomyocytes
Stephen J Perry, Sachiko Junger, Jordan E Pomeroy, Robert E Petroski, Dimitri E Grigoriadis, Richard A Maki; Neurocrine Biosciences Inc, San Diego, CA Urocortin 2 (UCN2) is one of a family of neuropeptides that activates the corticotropin-releasing factor 2 (CRF 2 ) receptor and is currently under development as a novel therapy for acute decompensated heart failure (ADHF). UCN2 has been reported to possess cardioprotective properties not observed with existing ADHF therapies and acts by simultaneously increasing cardiac output and decreasing blood pressure. To date, little is known of the mechanisms through which UCN2 induces inotropy and lusitropy. Here we show that UCN2 signals through the Gs-coupled CRF 2 receptor on isolated adult rat cardiomyocytes (ARCMs) and compared the potency and efficacy of this peptide to the known inotrope dobutamine, a beta-1 adrenergic agonist. Treatment of ARCMs with either UCN2 or dobutamine stimulated cyclic AMP accumulation and the phosphorylation of PKA substrates. The effects of UCN2 were completely blocked by the selective CRF 2 receptor antagonist astressin-2B while those of dobutamine remained unaffected confirming selective activation of the CRF 2 receptor. UCN2 was Ͼ1000-fold more potent than dobutamine at stimulating cyclic AMP accumulation (EC 50 ϭ 1.4nM), while dobutamine was 2.6-fold more efficacious. By recording simultaneous calcium flux and sarcomere contractions in isolated ARCMs we also demonstrated that UCN2 treatment produced a dose-dependent slow increase (Ͼ10 minutes to reach maximum) in peak calcium release, sarcomere shortening, tau and time between peak calcium and peak contraction (EC 50 ϭ5nM), with no significant change in diastolic calcium concentration demonstrating the direct inotropic and lusitropic actions of UCN2. These data demonstrate that the direct inotropic and lusitropic activity of UCN2 on ARCMs occurs through selective activation of a CRF 2 receptor-dependent cyclic AMP/PKA pathway.
P116
␤-Blockers Switch Mitogen-Activated Protein Kinase Signaling in Adult Mouse Cardiac Myocytes
Manoj C Rodrigo, Philip M Swigart, Bat-Erdene Myagmar, John Cha, Bo-Qing Zhu, Che-Chung Yeh, Michael Mann, Joel Karliner, Paul C Simpson; UCSF and VA Med Ctr, San Francisco, CA Beta-adrenergic receptor (AR) antagonists (beta blockers) increase survival in heart failure, but the signaling mechanisms remain uncertain. Among the mitogen activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK) is anti-apoptotic, whereas the MAPK p38 can be pro-apoptotic. Here we tested the hypothesis that beta-blockers switch catecholamine signaling to MAPKs in cardiac myocytes. Myocytes from adult male C57BL/6J mice were cultured overnight in serum-free medium, then stimulated acutely with the natural catecholamines norepinephrine (NE) or epinephrine (EPI) (2 uM). MAPK phosphorylation (activation) was measured by immunoblot. NE or EPI alone markedly decreased ERK phosphorylation (NE 13Ϯ5% of vehicle, EPI 4Ϯ5% of vehicle; nϭ3; pϽ0.05). The beta-AR agonist isoproterenol (1 uM) had a similar effect (15Ϯ7% of vehicle). NE or EPI alone increased p38 phosphorylation by 6-fold (nϭ2). In sharp contrast, NE or EPI in the presence of the beta-blocker propranolol (2 uM) caused robust ERK activation (NE 389Ϯ70%, EPI 448Ϯ127%; nϭ4; pϽ0.05). ERK activation was mimicked by the alpha-1-AR agonist phenylephrine (20 uM; 302Ϯ56%). NE or EPI in the presence of propranolol had no effect on p38. When myocytes were treated acutely with beta-blockers alone, propranolol had no effect on ERK activity. However, the beta-blockers timolol or metoprolol alone activated ERK (timolol EC50ϭ23 nM, Emaxϭ248Ϯ2%, nϭ3, pϽ0.05; metoprolol EC50ϭ27 nM, Emaxϭ216Ϯ44%, nϭ2) . In cultured adult mouse cardiac fibroblasts, in contrast with myocytes, NE or EPI alone activated both ERK (5-fold) and p38 (2-fold). In conclusion, the natural catecholamines NE and EPI alone inhibit anti-apoptotic ERK and activate pro-apoptotic p38 via a beta-AR in adult mouse cardiac myocytes. Beta-blockers switch catecholamine signaling in myocytes to ERK activation via an alpha-1-AR. In addition, certain beta-blockers (timolol and metoprolol but not propranolol) activate ERK directly in the absence of catecholamines. Switching MAPK signaling towards ERK might contribute to the cardioprotective effects of beta-blockers. Blockade of ␤-adrenergic receptors (␤ARs) through receptor antagonists (␤-blockers) has evolved to one of the most effective and most frequently used therapeutic regimens in cardiovascular medicine. Polymorphisms of these receptors occur frequently, but there is limited and controversial evidence, whether and how these affect the patients response to ␤-blocker treatment. In this study, we generated a mutant of the ␤ 1 -AR into which the cyanand the yellow-emitting variants of the green fluorescent protein (CER and YFP) were inserted at the C-terminus extremity and in the third loop of the receptor respectively. Using fluorescence resonance energy transfer (FRET), the ␤ 1 -AR sensor allowed the direct monitoring of conformational changes of the receptors during pharmacological stimulation. After stimulation by its endogenous agonist norepinephrine, the human ␤ 1 AR was activated (decrease of the FRET ratio of about 4%) at a surprisingly slow speed (about 500 ms) followed by activation of its G-protein Gs and formation of cAMP. Commonly used ␤-blockers such as metoprolol, bisoprolol and carvedilol acted as inverse agonists at the human ␤ 1 AR actively inducing a conformational change opposite to that of agonists. The frequently occurring hyperfunctional Arg389 variant of the ␤ 1 AR (associated with a poor prognosis in heart failure patients) displayed similar behaviour to agonists and several antagonists as the Gly389 variant. However, the Arg389 receptor displayed a marked supersensitivity to the ␤-blocker carvedilol compared to the Gly389 variant which we confirmed on the second messenger level (cAMP ϩ300%). Expression of both receptor variants in cardiac myocytes confirmed the importance of the Arg389-sensitivity to carvedilol for cardiac rate control.
P117 Direct Determination of ␤1-Adrenergic Receptor Activation Reveals Differential Antagonist Sensitivity of Naturally Occurring Receptor Variants
P118 Forkhead Transcription Factors, Foxc1 and Foxc2, Directly Regulate VCAM-1 Gene Expression in Endothelial Cells
Myengmo Kang, Derrick Gregory, Tsutomu Kume; Vanderbilt Univ Med Ctr, Nashville, TN Objective Ϫ Although it is known that the induction of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells promotes leukocyte-endothelium interaction at sites of atheroma initiation leading to the development of atherosclerosis, the precise molecular mechanisms underlying transcriptional regulation of the VCAM-1 gene are incompletely understood. Foxc1 and Foxc2, closely related forkhead transcription factors, have been shown to play important roles in embryonic blood vessel development and endothelial functions in postnatal life. We investigated their potential regulation of VCAM-1 gene expression. Methods and Results Ϫ We found that transcripts of VCAM-1 are significantly upregulated by overexpressing Foxc in endothelial cells. Importantly, consistent with this finding, there are three Foxc-binding elements (FBEs) conserved between mouse and human in the VCAM-1 promoter region, and we confirmed by gel shift and chromatin immunoprecipitation (ChIP) assays that Foxc proteins can bind to these FBEs in vitro and in vivo. Luciferase assays using a series of deletion and mutant constructs for the VCAM-1 promoter further demonstrate that Foxc1 and Foxc2 regulate the promoter activity of VCAM-1 via the FBEs. Most significantly, endothelial cells isolated from adult Foxc2 heterozygous mutant mice show a significant reduction in VCAM-1 transcription compared to wild-type endothelial cells. Conclusions Ϫ Our results indicate that Foxc transcription factors directly regulate VCAM-1 gene expression in endothelial cells and that they may play a pivotal role in the development of atherosclerosis.
P119 Genetic Polymorphisms of the Renin-Angiotensin System in End-Stage Renal Disease and Evolution of Coronary Artery Disease
Rima Lal, Badan S Sehrawat, Kamal Sud, Madhu Khullar; Post Graduate Inst of Med Education and Rsch, Chandigarh, India Cardiac disease is the leading cause of death in patients having end -stage renal disease (ESRD). Genes encoding for angiotensinogen (AGT), angiotensin -converting enzyme (ACE), are candidates for cardiovascular and renal diseases. The impact of renin -angiotensin system (RAS) gene polymorphism on the prognosis of coronary artery disease in ESRD is still debated. METHODS: Genotyping was performed in 100 ESRD patients and 100 control subjects for the AGT-M235T, AGT A-6G, ACE insertion/deletion (I/D) and the angiotensin II type I receptor gene(AT1R) A1166C polymorphisms using polymerase chain reaction. Intimal medial thickness (I MT) was measured in all the patients. RESULTS: The frequency of DD genotype was significantly higher in the ESRD patients than the controls (PϽ0.001). Genotype frequencies of AGT M235T, AGT A -6G, and AT1R A1166C polymorphisms did not differ significantly between ESRD patients and controls. No association of Intimal medial thickness (IMT) of coronary artery was observed with any genotype in the ESRD patients. A strong association of ACE DD genotype and AGT MM genotype was observed in ESRD patients (pϽ0.001). The AGT MT genotype was found to be associated with AGT A -6G AG genotype only in ESRD population. Thus, polymorphism in genes of the RAS system may influence interindividual differences in the development and course of ESRD, but are not associated with IMT.
P120 Proteomic Identification of Cardiomyocyte Specific Biomarkers of Oxidative Injury
Qin M Chen, Lifang Xie; Univ of Arizona, Tucson, AZ Numerous lines of evidence indicate a role of oxidative stress in initiation and progression of heart failure. Among the main cell types within the heart, cardiomyocytes (CMCs) undergo hypertrophy or apoptosis, while cardiac fibroblasts (CFs) are responsible for fibrosis during the process of heart failure. In an effort to identify cell type specific biomarkers of oxidative injury, we isolated CMCs and CFs from rat hearts and treated cells with sublethal doses of H 2 O 2 for detection of secreted protein factors in the conditioned media by ESI-LC-MS/MS based proteomics. Comparison between the profiles of secreted proteins among the two cell types leads to the finding that H 2 O 2 at sublethal doses caused an elevation in the level of Cystatin C protein in the conditioned medium from CMCs but not from CFs. RT-PCR analyses of Cystatin C mRNA and Western blot analyses of Cystatin C protein confirm that H 2 O 2 induces dose dependent Cystatin C elevation in CMCs but not CFs. To validate the potential of using Cystatin C as a cardiac injury biomarker in association with oxidative stress in vivo, cardiomyopathy was induced by chronic administration of doxorubicin (Dox) in the absence of liver or kidney injury. Elevated Cystatin C was detected at the protein level in the plasma and heart tissue and at the mRNA level in heart tissue from Dox treated animals. We also tested the level of circulating Cystatin C in a myocardial infarction model induced by left descending coronary artery ligation. An increase in the level of Cystatin C protein was detected in the plasma of myocardial infarcted mice. These data suggest that Cystatin C can be useful as a biomarker of cardiomyocyte injury associated with oxidative stress in vitro and in vivo.
P121 Molecular Characterization of a Calcium ATPase Gene in an Animal Model of Cardiomyopathy
Eunice N Ndegwa, Michelle M Corley; Tuskegee Univ, Tuskegee, AL Cardiovascular disease, principally heart disease and stroke, is the United states leading killer for both men and women among all racial and ethnic groups. Among the core heart diseases, cardiomyopathy is the most common heart muscle disease usually necessitating a heart transplant Despite the diverse etiologies of cardiomyopathy, the Ca2ϩ cycling defect is a physiological hallmark of all forms of cardiomyopathy. Therefore,the genes involved in Ca2ϩ cycling have been considered responsible for cardiomyopathy. The calcium ATPase protein involved in regulation of calcium in and out of the intracellular calcium stores is thought to be altered in cardiomyopathic patients. The pathophysiological presentation of dilated cardiomyopathy in an avian model of cardiomyopathy (turkey) is similar to the human heart. Therefore, the purpose of this study was to identify and analyze the calcium ATPase gene in furazolidone induced cardiomyopathic turkeys. Primers were designed (Primer 3 software) from the chicken calcium ATPase mRNA to target the turkey genome. Total RNA was isolated from chicken (control), furazolidone induced and non-induced turkey heart tissues. A one step Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) was performed. The expected 195 bp cDNA fragment for the calcium ATPase gene was observed in ethidium bromide stained gels with a Ultra Violet Gel Documentation system, indicating successful amplification of the calcium ATPase gene from turkey heart.
P122 Increased Mitochondrial Uncoupling Protein 3 Is Associated with the Cardiomyopathy in the Dystrophic Mouse Heart
Wen Zhang, Michiel ten Hove, A Elisabeth Sang, Kay E Davies, Stefan Neubauer, Kieran Clarke; Univ of Oxford, Oxford, United Kingdom Patients with muscular dystrophy have heart failure and abnormal cardiac high-energy phosphate metabolism. Uncoupling protein 3, a muscle-specific form, is involved in the regulation of energy metabolism. Here, we tested the hypothesis that adult dystrophic mdx mouse hearts have cardiac dysfunction and abnormal energy metabolism associated with increased levels of mitochondrial uncoupling protein 3. Non-invasive, in vivo high-resolution cine magnetic resonance (MR) imaging was carried out in control and mdx mice using an 11.7 T MR magnet. High energy phosphate compounds were measured in isolated mouse hearts perfused in the Langendorff mode using 31 P MR spectroscopy (MRS). Mitochondrial uncoupling protein 3 levels were measured by Western blotting in control and mdx mouse hearts. Cine MR images showed that mdx mouse hearts had 18% (0.27 Ϯ 0.02 vs. 0.33 Ϯ 0.01 l/ms, P Ͻ 0.05) lower left ventricular peak filling rates, but the same left ventricular mass, end-diastolic volumes, end-systolic volumes, stroke volumes, ejection fractions and cardiac outputs. 31 P MRS showed that mdx mouse hearts had 40% (11.6 Ϯ 1.1 vs. 18.7 Ϯ 1.1 mM, P Ͻ 0.01) lower phosphocreatine concentrations, with the same ATP concentrations, as control mouse hearts. Mdx mouse hearts had 1.5-fold (P Ͻ 0.05) higher mitochondrial uncoupling protein 3 than their controls. We conclude that adult dystrophin-deficient mdx mouse hearts had left ventricular diastolic dysfunction associated with decreased phosphocreatine levels and increased mitochondrial uncoupling protein 3. study aims to characterize and determine the central regulatory role of mitochondria on tissue redox status and oxygenation. Methods and Results: In vivo electron paramagnetic resonance was performed to measure tissue redox status and oxygenation in the ischemic and reperfused myocardium. In vivo fluorometry was performed to measure tissue NADH and reactive oxidant species. High-performance liquid chromatography-electrochemical method was performed to measure tissue reduced/oxidized glutathione ratio levels. It was found that tissue reduction rate was increased 100% (0.042 to 0.084 min -1 ) during ischemia and decreased 33% (0.042 to 0.028 min -1 ) after reperfusion compared to the non-ischemic myocardium. There was an overshoot of tissue oxygenation after reperfusion. Tissue NADH level was increased to 1.8 fold (1.0 to 1.8) during ischemia and 1.2 fold (1.0 to 1.2) after reperfusion. There was a brief burst generation of ROS at the beginning of reperfusion. Tissue GSH/GSSG levels showed a 48% (50.0 to 74.0) increase during ischemia and a 29% (50.0 to 35.5) decrease after reperfusion. Conclusions: In conclusion, the higher reduction rate in the ischemic myocardium was consistent with the lower oxygenation, lower ROS generation, higher NADH content, and higher GSH/GSSG level. The lower reduction rate in the reperfused myocardium was consistent with the higher oxygenation, higher ROS generation, lower NADH content, and lower GSH/GSSG level. The restrained mitochondria respiration due to hypoxia during ischemia caused an increase of tissue NADH and therefore shifted the tissue to a more reduced state. The ROS generated at the beginning of reperfusion may contribute to the oxidative redox status in the postischemic myocardium by regulating mitochondria respiration. Hypertensive cardiac hypertrophy is an independent risk factor for increased cardiovascular morbidity and mortality and effective reversal of hypertrophy is considered to be beneficial. We examined the effects of hypertension on cardiac mitochondria and systemic oxidative stress using a two kidney one-clip model of hypertension in C57 black mice. At four weeks after surgery mean arterial blood pressure was significantly increased in the two kidney one-clip model to 148.2 Ϯ 8.5 mmHg (nϭ9) and further increased to 181.2 Ϯ 4.1 mmHg at 8 weeks (nϭ8) compared with 107.8 Ϯ 6.9 mmHg in sham operated controls (nϭ5; PϽ0.05). At 8 weeks, heart weight: body weight ratio was 33.3% greater in the hypertensive mice (nϭ15) compared with sham operated controls (nϭ13; PϽ0.05). Mitochondrial size distribution assessed with electron microscopy indicated that the average size of mitochondria were significantly smaller in hearts from the test group compared with age-matched controls at 8 weeks. Urinary isoprostane production, an indicator of oxidative stress was significantly (PϽ0.05) increased in the test group at 4 weeks (nϭ12). At 8 weeks post surgery oxygen consumption with complex I substrates was increased 75.9 Ϯ 10.5% (nϭ3) and complex II substrates was increased 38.1 Ϯ 19.6% (nϭ3) compared with mitochondria from sham controls (nϭ4; PϽ0.05). By 12 weeks oxygen consumption by the mitochondria, cardiac mass, blood pressure and urinary isoprostanes had returned to near control values. We assessed individual complex activities and superoxide production by the mitochondria. At 4 weeks post surgery superoxide production assessed with the fluorescent indicator dihydroethidium, was increased 70.9 Ϯ 1.0% (nϭ4) compared with sham controls (nϭ5; PϽ0.05). More importantly the increase in superoxide production persisted to 12 weeks post surgery (39.7 Ϯ 0.7% increase) in the test group despite normalizing of cardiac mass and blood pressure. In addition mitochondrial complex I and complex III activities were significantly depressed at 12 weeks post surgery (nϭ4; PϽ0.05). These data suggest that effective reversal of hypertension and cardiac hypertrophy may not be sufficient to prevent further morbidity associated with persistent mitochondrial dysfunction.
P124
Evidence of Persisting Mitochondrial Dysfunction in a Model of Reversible Cardiac Hypertrophy
P125 Volatile Anesthetics Maintain the Antiapoptotic Association of Hexokinase with Mitochondria
Coert J Zuurbier, Peter J Keijzers, Anneke Koeman, Harry B van Wezel, Markus W Hollmann; Academic Med Ctr, Univ of Amsterdam, Amsterdam, The Netherlands Background: Recent evidence suggests that hexokinase mitochondria association attenuates cell death, and that blood glucose and insulin levels are associated with clinical outcome. In this study, we examined how these parameters of glucose metabolism are affected by anesthetics per se, i.e. at similar hemodynamic conditions and without surgical stress. Methods: In fed rats, the effects of pentobarbital (PENTO), isoflurane (ISO), sevoflurane (SEVO), ketamine-medetomidine-atropine (KMA) and sufentanil-propofol-morphine (SPM) on the cardiac cellular localisation of hexokinase (HK) and levels of blood glucose and insulin were determined and compared with values in non-anesthetized animals (control). The role of mitochondrial and sarcolemmal KATP-channel and ␣2-adrenergic receptor in isofluraneinduced hyperglycemia (IIH) was also evaluated. Results: Cytosolic HK relative to total HK increased in the following sequence: control (35.5 Ϯ 2.1%), SEVO (35.5 Ϯ 2.7%), ISO (36.6 Ϯ 1.7%), PENTO (41.2 Ϯ 2.0%), SPM (43.0 Ϯ 1.8%) and KMA (46.6 Ϯ 2.3%). PENTO (5.3 Ϯ 0.2 mM) and SPM (5.1 Ϯ 0.2 mM) were without effect on blood glucose as compared to control (5.6 Ϯ 0.1 mM). All other anesthetic agents induced hyperglycemia: 7.4 Ϯ 0.2 mM (SEVO), 9.9 Ϯ 0.3 mM (ISO) and 14.8 Ϯ 1.0 mM (KMA). Insulin levels were significantly elevated with PENTO (2.13 Ϯ 0.13 ng/ml) as compared to control (0.59 Ϯ 0.22 ng/ml), but were unaffected by the other anesthetics. Blocking the mitoKATP-channel with 5-hydroxydecanoate acid (10 mg/kg) did not prevent IIH and diazoxide (10 mg/kg) was without effect on blood glucose levels. However, glibenclamide (1 mg/kg) prevented IIH. Although inhibition of the ␣2-adrenergic receptor by yohimbine (6 mg/kg) did induce hypoglycemia, it did not prevent IIH. Conclusions: At similar hemodynamic conditions and without surgical stress, volatile anesthetics and KMA induce hyperglycemia. For ISO, hyperglycemia is a result of impaired insulin release due to sarcolemmal KATP-channel activation. Most importantly, isoflurane and sevoflurane maintain the anti-apoptotic hexokinase binding to mitochondria. The latter may be an important mechanism contributing to isoflurane and sevoflurane-induced cardioprotection.
P126 Permeability Transition Pore Opening in High-Conductance Mode May Be a Cause of Mitochondrial Abnormalities in Heart Failure
Victor Sharov, Anastassia Todor, Hani Sabbah; Henry Ford Health System, Detroit, MI Background: Increased mitochondrial permeability transition pore (MPTP) opening in transitory high conductance mode can create reversible mitochondrial damage during ischemia/ reperfusion. We showed earlier that mitochondria of viable cardiomyocytes (CM) in heart failure (HF) also exhibit both structural and functional abnormalities. We hypothesized that MPTP opening in transitory high conductance mode can be a cause of mitochondrial functional abnormalities described in viable CM in HF. Methods: CM were isolated from LV myocardium of 7 dogs with HF produced by intracoronary microembolizations. CM isolated from 7 normal dogs were used as a control. Calcium tolerant CM with intact sarcolemma were loaded with calcein AM alone or in combination with 0.2 M Cyclosporine A (CsA) and dynamic of calcein exit from mitochondria were measured using fluorometer with excitation filter NB490 and emission filter SC515. CoCl 2 was added to quench cytosolic and nuclear calcein fluorescence. Sarcolemma was skinned with 0.005% digitonin and state-3 mitochondrial respiration (V ADP ) in the presence 5 mM malate, 5 mM pyruvate and 1 mM ADP with and without 0.2 M CsA was measured with Clark electrode. V ADP was blocked with 0.35 mM atractiloside (V AT ). Respiratory control ratio (RCR) was calculated as V ADP /V AT . Propidium iodide was used to monitor sarcolemma integrity. Results: In 200 min after loading with calcein AM, mitochondria of failing CM show only 50% of maximal level of calcein fluorescence while in normal control CM calcein fluorescence remains unchanged. CsA does not affect the exit of calcein from mitochondria of normal CM and significantly slows down the exit of calcein from mitochondria of failing cardiomyocytes. CsA does not affect V ADP and RCR in normal control cardiomyocytes while significantly increases V ADP and RCR in failing CM. Conclusions: Exit of calcein (m.w. 1.0 kDa) from mitochondria of viable failing CM with intact sarcolemma suggests an existence of reversible transitory MPTP opening in high conductance mode. Attenuation of calcein loss and improvement of V ADP and RCR achieved with CsA (0.2 M) show that transient MPTP opening in high conductance mode in failing CM could be a cause of mitochondrial functional abnormalities described in failing heart.
P127 Multiprotein Complex Contains Proteins of the Mitochondrial Permeability Transition Pore and the Mitochondrial ATP-Sensitive K ؉ Channel
Hossein Ardehali, Northwestern Univ, Chicago, IL; Steven P Jones, Univ of Louisville, Louisville, KY; Eduardo Marban; Johns Hopkins Univ, Baltimore, MD Mitochondria are primary intracellular sites for respiration and apoptosis. The process of apoptosis involves opening of the mitochondrial permeability transition pore (mPTP), which in turn leads to release of proapoptotic proteins. Another mitochondrial channel, ATP-sensitive potassium channel or mitoK ATP , has been shown to exert protective effects. The structure of mitoK ATP is not known, but is thought to contain at least 5 mitochondrial proteins. Since there is evidence for pharmacological overlap between these two channels and that one protein (adenine nucleotide translocator) is shared between their putative structures, we hypothesized that there is physical interaction between protein members of these two channels. Using co-immunoprecipitation, antibodies against ATP synthase or inorganic phosphate carrier (PIC) pull down Bax and Bcl-2 and vice versa. ATP synthase also associates with other Bcl-2 family members, such as Bak, Bad, Bid, BclX L/S . PIC antibody also pulls down voltage dependent anion channel (VDAC). We then studied whether the opening of mPTP can be modulated by agents targeting other proteins in this complex. We first induced mPTP opening by treating isolated cardiac myocytes with a cell-permeable form of the VDAC binding domain of hexokinase (HK) II peptide. This peptide has been shown to dislocate HK form the mitochondria, and subsequent mPTP opening and apoptosis. Exposing myocytes to this peptide caused a dose-dependent (0 -20 M) reduction of mitochondrial membrane potential, consistent with mPTP opening. This effect was reversed by the ANT inhibitors, bongkrekic acid (BA, 0.05 mM) or atractyloside (Atr, 0.1 mM), but not by cyclosporine A or diazoxide. Our results suggest that there is a macromolecular complex in the mitochondria which contains the proteins of mPTP and mitoK ATP . Furthermore, the opening of mPTP by dislocating HK form the mitochondria leads to an opened conformation of mPTP that is insensitive to cyclosporine, but is reversed by ANT modulators.
P128 Oral Sodium Salicylate Inhibits Cardiac Mitochondrial Respiration
Enas Kandil, Dallas VA Med Ctr, Dallas, TX; Luke Szweda, Oklahoma Med Rsch Foundation, Oklahoma City, OK; Hesham Sadek; UT Southwestern Med Ctr, Dallas, TX Background: A potential detrimental effect of salicylates intake in congestive heart failure has been recently recognized. The Warfarin/Aspirin Study in Heart failure demonstrated that the aspirin group had significantly more hospital admissions due to heart failure when compared to the warfarin or control groups. Mitochondrial dysfunction plays an important role in the progression of heart failure by intensifying the energy supply/demand mismatch state. In a previous in-vitro study, we demonstrated that salicylates inhibit cardiac mitochondrial respiration. In the current study, we investigated the effect of oral Salicylate administration of cardiac mitochondrial function. Methods: Rats were randomized to receive water supplemented with sodium salicylate at 50 mg/kg/day (FDA approved arthritis treatment dose of salicylate) or regular drinking water (5 rats in each group). Subsarcolemmal cardiac mitochondria were assayed for mitochondrial respiration and electron transport chain activity. Results: At 1 week state 3 mitochondrial respiration was significantly inhibited (29 -43.4% inhibition depending on the respiratory substrate used). State 4 respiration was unchanged when compared to control mitochondria. Mitochondrial respiratory chain activities were unaffected by sodium salicylate treatment. Conclusion: Therapeutic doses of sodium salicylate significantly inhibit cardiac mitochondrial respiration with no effect on mitochondrial coupling. This inhibitory effect can potentially have deleterious effects in the setting of heart failure. Future studies to identify susceptible enzymes will provide important mechanistic information.
P129 Tauroursodeoxycholic Acid Reduces Apoptosis Following Myocardial Infarction in the Rat
Andrew L Rivard, Clifford J Steer, Betsy T Kren, Univ of Minnesota, Minneapolis, MN; Cecilia M Rodrigues, Rui E Castro, Univ of Lisbon, Lisbon, Portugal; Richard W Bianco, Walter C Low; Univ of Minnesota, Minneapolis, MN Introduction: Black bear bile extracts have been used in traditional Chinese medicine to treat liver and eye related illnesses for centuries. Recent analysis of the cellular effects of ursodeoxycholic acid (UDCA) and its taurine conjugated counterpart (TUDCA) have demonstrated antiapoptotic properties through regulation of Bcl-2 family and survival signaling proteins (Bax, Bad, phosphatidylinositol-3-kinase). In this study we assessed the hypothesis that TUDCA administered to Lewis rats prior to a myocardial infarction would exhibit antiapoptotic effects and improve cardiac function. Methods: Prior to ligation of the left anterior descending (LAD) coronary artery, TUDCA, nϭ11, (50mg/ml, 400mg/kg, IV) or PBS, nϭ15, was given over 40-minutes. Animals were sacrificed at 24 hours after ligation for transferasemediated dUTP-biotin nick end-labeling (TUNEL) and immunoassay caspase-3 activity. Additional TUDCA (nϭ4) or PBS (nϭ3) treated rats underwent pre-operative,1-week, and 4-week transthoracic ultrasounds to assess shortening fraction (SF) and infarct area. Results: TUNEL labeling of the cardiac tissue revealed a significant reduction in apoptotic cells in rats given TUDCA prior to ischemic injury (pϭ0.05). In support of the reduction in apoptosis, caspase-3 activity in the TUDCA treated animals was lower (pϭ0.02). By four weeks there was a smaller infarct area in the TUDCA group compared to the PBS group (0.05 vs 0.13 cm 2 , pϭ0.11). Furthermore, there was improvement in the SF. Conclusions: The results provide evidence for TUDCA as a viable treatment for reducing apoptosis in an experimental model of myocardial infarction. Additional studies will distinguish the functional result of improved cell survival following infarction. Possible clinical applications of this antiapoptotic drug include treatment of acute myocardial infarction.
P130
Sulfaphenazole, a CYP2C9 Inhibitor, Protects Against Ischemia-Reperfusion-Induced Injury in Isolated Rat Heart
Damodar Kumbala, Mahmood Khan, Vijay Kumar Kutala, Periannan Kuppusamy; Davis Heart Lung Rsch Inst, Columbus, OH The cardioprotective effect of Sulfaphenazole, a potent and selective inhibitor of cytochrome p450 isoform, CYP2C9, was investigated using isolated rat heart model of ischemia-reperfusion (I/R) injury. Isolated rat hearts were perfused with Krebs-Henseliet buffer, subjected to 30-min of global ischemia, followed by 45 min of reperfusion. Hearts were perfused with Sulfaphenazole (400 M) for 15 min before the onset of ischemia and throughout reperfusion. Control hearts subjected to I/R showed significant decrease in contractile function (left ventricular developed pressure, and rate pressure product), increased lactate dehydrogenase in coronary effluent and significant myocardial infarction (46% of risk area). Sulfaphenazole significantly enhanced recovery of heart function and decreased infarct size, and attenuated lactate dehydrogenase and suppressed I/R-induced free radical generation. Sulfaphenazole treatment also showed increased nitric oxide generation. The present study demonstrated that Sulfaphenazole significantly protected hearts against I/R-mediated cardiac dysfunction and injury. The protective effect could be due to the combined effects of CYP2C9 inhibition, antioxidant and as well as enhanced nitric oxide generation.
P132
Effects of Levosimendan plus Noradrenaline on Coronary Blood Flow, Myocardial Infarct Size, and the Extent of the No-Reflow Phenomenon in an Experimental Model of Ischemia-Reperfusion
Efstratios I Charitos, Panagiotis Papazoglou, Elias J Tsolakis, Antonios Xatziiliadis, Stavros Stavrakis, Ioannis Venetsanakos, Anargiros Ntalianis, Charalampos Pierrakos, John N Nanas; Univ of Athens, Athens, Greece Background: Positive inotropic agents have been used in clinical practice for the treatment of patients with cardiogenic shock. The aim of our study was to examine the effect of high doses of levosimendan plus noradrenaline on coronary blood flow (CBF), myocardial infarct size (MIS), and on the extent of the no-reflow phenomenon (NRP) in an experimental model of ischemia-reperfusion. Methods: A randomized study was conducted in an experimental model of ischemia-reperfusion. In seventeen piglets, 25-35 kg, after mid-thoracotomy, ischemia was provoked by ligation of the mid portion of the left anterior descending (LAD) coronary artery for 60 minutes, followed by 120 minutes of reperfusion. The animals were randomized 10 minutes before reperfusion into 2 groups: Group A, in which no medical intervention was made, and Group B, in which levosimendan was administered (loading dose 24 g/kg, followed by continuous infusion 0.4 g/kg/min) with noradrenaline (0.05 g/kg/min) until the end of reperfusion. CBF was measured by a transit time probe at the site of LAD ligation, and expressed as a percentage of baseline CBF. The extent of NRP was measured with thioflavine stain, and expressed as a percentage of the myocardial area at risk (AAR). Myocardial infarct size (MIS) was measured with triphenyltetrazolium chloride stain (TTC) and expressed as a percentage of the AAR. Results: Eight animals were included in Group A, and 9 in Group B. A trend towards increased CBF was observed in Group B during reperfusion. A trend towards reduction of the extent of NRP was observed in Group B (Group A: 60.9Ϯ11.4%, Group B: 50.5Ϯ17.6%, pϭ0.209). The MIS did not differ between groups (Group A: 77.1Ϯ8.8%, Group B: 80.5Ϯ6.0%, pϭ0.401). Conclusions: In this porcine experimental model of ischemiareperfusion, high doses of levosimendan plus noradrenaline increased CBF during reperfusion, did not cause further damage to microcirculation, and did not affect MIS. According to the results of this study, high doses of levosimendan can be safely used in patients with acute myocardial infarction complicated by refractory cardiogenic shock.
P133 Myocardial Apoptosis Induction in Cardiac Surgery Patients Depends on Cardioplegic Solution Type
Uwe M Fischer, Albert Antonyan, Wilhelm Bloch, Khosro Hekmat, Uwe Mehlhorn, Thorsten Wahlers; Univ of Cologne, Cologne, Germany
Objectives: Experimental studies suggest that myocardial apoptosis induction during cardioplegic arrest and reperfusion is not only mediated by oxygen free radicals but also depends on cardioplegic solution type. We studied apoptosis signal-pathway induction in patients subjected to cardioplegic arrest (CA) on cardiopulmonary bypass (CPB) using warm blood and cold crystalloid cardioplegia. Methods: In twelve patients we collected myocardial biopsies form the right atrial cannulation site before and at termination of CPB. Seven patients had CABG, five patients had aortic valve replacement (AVR). For CABG we used warm blood cardioplegia (Calafiore), while AVR hearts were arrested with crystalloid solution (Bretschneider). LV specimen were immuno-cytochemically stained against activated caspase-3 (apoptosis key-enzyme), and 8-isoprostaglandin-F 2 ␣ (oxidative stress marker). Cardiomyocytes were then quantitatively investigated using TV densitometry (gray units: U). Results: Caspase-3 activity significantly increased in CABG (17.8Ϯ2.1 to 30.0Ϯ1.9 U, pϭ0.003) while it remained unchanged in AVR (29.3Ϯ10.2 to 32.2Ϯ12.4 U, pϭ0.16). 8-Isoprostan-F 2 ␣ formation remained unchanged in AVR but increased significantly in CABG (by 10.9Ϯ4.9 U, pϭ0.03). While cardioplegic arrest was significantly longer in AVR (68Ϯ8 min vs. 38Ϯ6 min, pϭ0.03), reperfusion period on CPB was longer in CABG (30Ϯ4 vs 15Ϯ4 min, pϭ0.01). However, there was no correlation between duration of cardioplegic arrest or reperfusion on CPB and caspase-3 activity and 8-isoprostaglandin-F 2 ␣ formation in either group. Conclusions: High potassium warm blood cardioplegia initiates cardiomyocyte apoptosis rather than low sodium, low calcium crystalloid cardioplegia.
P134 Protective Actions of Adiponectin on Cardiac Remodeling After Myocardial Infarction
Noriyuki Ouchi; Boston Univ Sch of Med, Boston, MA Ischemic heart disease is the leading cause of morbidity and mortality in the United States. Obesity-linked diseases are closely associated with the development ischemic heart disease. However, the link between obesity and the development of ischemic heart disease is poorly understood at a molecular level. Adipose tissues secrete adipokines that directly or indirectly affect obesity-linked disorders. Adiponectin is an anti-atherogenic and anti-diabetic adipokine that is downregulated in patients with obesity-linked diseases including type 2 diabetes and ischemic heart disease. Recently, we demonstrated that adiponectin protects against acute myocardial ischemia-reperfusion injury (Shibata et. al. Nature Med. 2005) . However, the role of adiponectin in the regulation of chronic cardiac remodeling in response to myocardial infarction has not been investigated. To test the role of adiponectin in regulating cardiac remodeling after chronic ischemia, myocardial infarction was created in adiponectin-deficient (APN-KO) and wild-type (WT) mice by the permanent ligation of left anterior descending (LAD) artery. APN-KO mice showed impaired left ventricular function coupled to increased apoptosis and inflammation, and decreased angiogenesis in the heart after LAD ligation compared with WT mice. Treatment with adenoviral vector expressing adiponectin improved cardiac function, diminished myocardial apoptosis and promoted angiogenesis in both WT and APN-KO mice that underwent permanent LAD ligation. These observations suggested that adiponectin serves as a functional link between adipose tissue and the heart, and thereby influence the extent of cardiac remodeling following chronic myocardial ischemia. In cultured cardiac myocytes, adiponectin inhibited apoptosis under the conditions of hypoxia, which was reversed by dominant negative AMPK. Adiponectin inhibited LPS-induced TNF-alpha production in cardiac myocytes, which was blocked by inhibition of cyclooxygenase (COX)-2-dependent pathway. These data suggest adiponectin protects the heart from chronic cardiac injury through both AMPK-and COX-2-dependent mechanisms. Adiponectin could represent a molecular target for treatment of obesity-related myocardial disease. Background: Recent studies report that aldosterone (Aldo) is produced by failing human hearts and induces apoptosis through calcineurin-dependent pathway which is inhibited by calcium (Ca 2ϩ ) channel blockade. Aldo antagonism by spironolactone (Spiro) reduces heart failure morbidity and mortality by unclear mechanisms. Thus, we hypothesized that canrenone (CRN), Spiro major active metabolite, cardiac protective mechanism could be mediated by cardiomyocyte apoptosis inhibition obtained by modulation of intracellular Ca 2ϩ handling. Methods: CRN was isolated from potassium canrenoate and identified by gas chromatography/mass spectrometry and nuclear magnetic resonance ( 1 H-NMR and 13 C-NMR). Adult rat cardiomyocytes were isolated and loaded with Indo-1 for simultaneous measurements of intracellular Ca 2ϩ transient and contractility. L-type Ca 2ϩ channel current was measured using patch-clamp technique in whole cell configuration. Cellular viability and apoptosis were analyzed by propidium iodide, annexin V and caspase-3 activation (anti-rabbit caspase-3 antibody) fluorescence quantified by flow cytometry. Results: CRN (50 M) reduced cardiomyocyte shortening (3.26 Ϯ 0.45% of resting length vs 5.18 Ϯ 0.61% of resting length in controls; nϭ14; pϽ0.01), intracellular Ca 2ϩ transient amplitude (0.3 Ϯ 0.03M vs 0.5 Ϯ 0.04M in controls; nϭ13; pϽ0.001), sarcoplasmic reticulum Ca 2ϩ content (146.0 Ϯ 8.7 mol/l of cytosol vs 172.8 Ϯ 12.9 mol/l of cytosol in controls; nϭ6; pϽ0.01) and L-type Ca 2ϩ channel current (4.6 Ϯ 1.5 pA/pF vs 7.5 Ϯ 1.8 pA/pF in controls; nϭ5; pϭ0.03). CRN inhibited cardiomyocytes apoptosis induced by Aldo, as analyzed by the percentage of annexin V positive cells (control 5%, 50M CRN 3%, 10 M Aldo 76%, and CRNϩAldo 10% -p Ͻ 0.001), and caspase-3 activation (control 17.50%, CRN 15.66%, Aldo 90.91%, and CRN ϩ Aldo 18.83% -p Ͻ 0.001). Conclusion: CRN protects cardiomyocytes against apoptosis induced by Aldo. This effect is probably mediated by reducing Ca 2ϩ availability to trigger Ca 2ϩ dependent pathways that induce apoptosis.
P135 Antiapoptotic Action of Canrenone (Spironolactone Major Active Metabolite) in Aldosterone-Induced Apoptosis: A Calcium-Dependent Pathway
P136 Intracellular Zinc Protects Isolated Rat Hearts from Ischemia/Reperfusion Injury: Involvement of Protein Kinase C
Gulnura Karagulova, UMDNJ, New Brunswick, NJ; Yuankun Yue, Mohamed Boutjdir, Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY; Abel Moreyra, Irina Korichneva; UMDNJ, New Brunswick, NJ Background: In addition to its structural role, zinc is an essential component of redox signaling. We have determined that zinc ions play a role of lynchpins in redox switches of Ser/Thr kinases structurally presented by cysteine-rich sequences in the regulatory domains. Oxidative stress triggers zinc release from protein kinase C (PKC) molecule, the event possibly linked to zinc depletion of cardiac tissue under ischemia/reperfusion (I/R). We now examined if replenishment of intracellular zinc at reperfusion improves myocardial recovery after a period of ischemia. Methods and Results: We analyzed the recovery of left ventricular developed pressure (LVDP), heart rate, and the incidence of arrhythmias in isolated adult rat hearts subjected to 15 or 30 minute global ischemia followed by 45 min of reperfusion. After 15 min ischemia at 30 min reperfusion the baseline LVDP of 101.37 Ϯ10.98 mmHg recovered by 83.83%. 10 -5 M zinc ionophore, pyrithione improved myocardial recovery up to 100% at the same time reducing incidence of arrhythmias more than two-fold. The effect was particularly dramatic at 30 min global ischemia yielding the improvement of LVDP recovery from 15.58% to 74.95% with arrhythmias diminished 8-fold. The effect was dose-dependent with 500 M zinc being toxic. Improved recovery was not observed with non-permeable ZnCl2 and was attenuated by 10 -5 M zinc chelator TPEN. Importantly, the recovery depended on the activation status of PKC. 50 nM PMA added prior pyrithione prevented the protection supporting our published data and suggesting that irreversible PKC activation leads to irreversible zinc release. Analysis of heart tissues revealed that proteolysis of PKC␦ was prevented by pyrithione. Incubation of isolated cells with TPEN accelerated 4 -5 fold PKC downregulation induced by activators, PMA or hydrogen peroxide Conclusions: Myocardial zinc homeostasis is an important factor reflecting the protein redox status and serving a valid biomarker of stressed tissue. Replenishment of vanished intracellular zinc protects myocardium from oxidative stress preserving functionality of PKC as one of the potential zinc-dependent targets.
P138 Negative Effects of the Atkins Diet on Ischemic Myocardial Metabolism and Function
Thomas N Masters, Alexander A Fokin; Carolinas Med Ctr, Charlotte, NC Ischemic cardiac muscle utilizes primarily carbohydrates for energy production rather than its normal dependence on lipids. With the increased popularity of the high fat, high protein and low carbohydrate diets (Atkins Diet), the reduced carbohydrate availability could be contraindicated during a myocardial ischemic episode. This study investigated the effects of an Atkins Diet in a canine model and compared the cardiac response to a normal dietary group. Eight animals were maintained on a control diet (Group I) and eight animals on an Atkins Diet (Group II). After 6 weeks, anesthetized animals were surgically prepared to measure the myocardial uptake of glucose (Glu), free fatty acids (FFA), lactate (Lac), pyruvate, oxygen and hemodynamic parameters (end systolic elastance (EES), LV pressure, HR and dp/dt) while increasing the heart rate (50%, 25 minutes) before and after ␤-blockade (propranolol, 0.3 mg/Kg, 15 min). In Group I, pacing before ␤-blockade caused an increase in FFA (25%) and Lac (125%) uptake, and no change in Glu. Fifteen minutes after ␤-blockade, FFA uptake was reduced from 3.65 to 1.71 Eq/min/100g (LV weight) and was unchanged during pacing. Lac uptake increased 1.15 to 2.27 mg/min/100g following ␤-blockade and from 1.25 to 5.15 mg/min/100g during pacing. In Group II, FFA uptake was elevated and remained during pacing while both Glu and Lac were significantly reduced. Following ␤-blockade, Lac, Glu and FFA uptakes were markedly reduced following ␤-blockade and pacing. Hemodynamically in Group II, EES was significantly elevated during pacing before ␤-blockade, but after, there was a marked reduction in EES and during pacing, there was little functional activity. In conclusion, increasing cardiac work (pacing) elevated FFA and/or carbohydrate uptake before ␤-blockade in Groups I and II. After propranolol (which decreases myocardial FFA uptake with an increased carbohydrate utilization and RQ's near 1.0), pacing plus the Atkins Diet reduced carbohydrate availability concomitant with a decreased FFA uptake. The resulting deterioration of myocardial functional activity was predictable and was supported by the present experiments. Therefore, the Atkins Diet with cardiac ischemia or extreme exercise would be contraindicated.
P139 Abnormal Activation of the Ubiquitin Proteasome System Is a Novel Mechanism that Mediates Doxorubicin-Induced Cardiotoxicity
Satoru Kobayashi, Yuan Huang, Troy Lackey, Jinbao Liu, Xuejun Wang, Timothy D O'Connell, Qiangrong Liang; South Dakota Health Rsch Foundation, Sioux Falls, SD Doxorubicin (DOX) is a highly effective antitumor agent known to cause severe cardiotoxicity that culminates in congestive heart failure. A prevailing theory for DOX cardiotoxicity is the DOX-induced generation of reactive oxygen species (ROS), which has been supported by the ability of numerous antioxidants to reduce DOX cardiotoxicity in animal studies. However, clinical trials show very limited effect of antioxidant therapy in humans, suggesting that additional mechanisms might be involved in the pathogenesis of DOX-induced heart failure.
Here we show that the Ubiquitin Proteasome System (UPS) is activated by DOX in neonatal rat cardiomyocytes (NRC) and adult mouse cardiomyocytes (AMC) as demonstrated by a GFP reporter that is sensitive to UPS-mediated degradation. DOX induces apoptosis in NRC and AMC as shown by increased cleavage of poly (ADP-ribose) polymerase (PARP), DNA laddering, and TUNEL or Annexin-V positive cells. Importantly, DOX-induced UPS activity leads to the depletion of cardiac survival factor GATA4 as well as its down stream targets Bcl2 and BclxL. Inhibition of UPS function with specific proteasome inhibitor MG262 or MG132 protects NRC and AMC from DOX-induced apoptosis. Furthermore, MG262 prevents DOX-induced degradation of GATA4 and a loss of Bcl2 and BclxL. Interestingly, several antioxidants are able to block DOX-induced ROS generation but they do not have any effect on UPS activity or GATA4 depletion, suggesting that the UPS-mediated GATA4 depletion is not dependent on ROS. Rather, it is a direct effect of DOX that acts in parallel with ROS leading to DOX cardiotoxicity. Moreover, we have shown that MG262 reduces ROS production possibly due to its ability to preserve GATA4 protein levels. Together, these findings suggest that the abnormal activation of the UPS is a novel mechanism that mediates DOX-induced cardiotoxicity. Given the limited effect of antioxidants on reducing DOX cardiotoxicity, a more promising therapeutic modality might be to use DOX and a proteasome inhibitor in combination. This can be easily implemented in clinical settings since the proteasome inhibitor bortezomib has been shown to enhance the antitumor activity of DOX in humans.
P141 Withdrawn
P142
Effects of Angiotensin II Type 1 Receptor Antagonist on Transforming Growth Factor-␤1 and Myocardial Remodeling in Rats with Developing Heart Failure
Hadyanto Lim, Methodist Univ of Indonesia, Medan, Indonesia; Kasiman Sutomo, North Sumatra Univ, Medan, Indonesia; Santoso Teguh, Univ of Indonesia, Jakarta, Indonesia; Harun Rasyid Lubis, North Sumatra Univ, Medan, Indonesia; Chuen Neng Lee, National Univ Hosp, Singapore, Singapore; Yahwardiah Siregar, North Sumatra Univ, Medan, Indonesia; Kappusamy Kalaiselvi, Yi Zhun Zhu; National Univ of Singapore, Singapore, Singapore Background : Excessive changes of myocardial remodeling after myocardial infarction cause detrimental effects on cardiac function and result in chronic heart failure. The angiotensin II type 1 receptor antagonist losartan suppresses the myocardial remodeling and reduces the mortality in patients with chronic heart failure. Aim : To determine its effects on left ventricular remodeling, function and gene expression in developing heart failure following left coronary ligation (CAL). Methods : Wistar rats were assigned to one of the four groups : 1. sham-operated (n ϭ 12); 2, coronary artery ligation (n ϭ 17); 3, CAL ϩ losartan (nϭ13); 4, sham ϩ losartan (n ϭ 12). Losartan (10 mg/kg/day) was administered orally to rats from the 1st to 6th week after the operation and subsequently examined left ventricular (LV) hemodynamics, myocardial transforming growth factor beta1 (TGF-beta1 mRNA, collagen type I and collagen type III mRNAs gene expression. Results : At the end of 6 weeks, the survival rate of group 2 and 3 were 65% (11/17) and 92% (11/12), respectively. The heart weight and left and right ventricular weights to body weights ratio were found to have significantly increased in group 2 compared with group 3. Myocardial TGF-beta1 mRNA, collagen type I and collagen type III gene expression levels were increased by 1.4-fold, 1.82-fold and 1.73-fold in group 2, respectively, and were blunted by losartan. TGF-beta1, collagen type I and type III mRNAs in cultured vascular smooth muscle (VSM) cells were increased by 1.5-fold, 1.8-fold and 1.5-fold, respectively, and were dose-dependently blocked by losartan (5 micro M, 10 micro M, 50 micro M). Conclusions : The findings indicate that the mechanisms by which angiotensin II type 1 receptor antagonist attenuates myocardial remodeling and improves function may be attributable by direct inhibition of the TGF-beta1 mRNA, collagen type I and collagen type III mRNAs gene expression levels. We suggest that targeting myocardial TGF-beta1 mRNA represents an attractive approach toward treating postinfarction heart failure.
P143 Mast Cell-Deficient Mice Produce Less Circulating Il-6 and Exhibit Less Cardiac Tissue Damage than Their Littermates Following Myocardial Ischemia Reperfusion Injury
Kausik Bhattacharya, Western Infirmary, Glasgow, United Kingdom; Kristin Karewell, Man Huang, Duraisamy Kempuraj, Theoharis C Theoharides; Tufts Univ Sch of Med, Boston, MA BACKGROUND Myocardial ischemia reperfusion (IR) injury complicates all forms of coronary artery revascularization. Circulating interleukin-6 (IL-6) has been implicated in cell death following a variety of stimuli. To date macrophages, platelets, neutrophils and the endothelium have been shown to release IL-6 after IR injury. Cardiac mast cells have been implicated in IR; however, their involvement has never been quantified. In this randomized prospective study, we compared cardiac tissue susceptibility and serum IL-6 changes between the mast cell deficient (W/W v ) mice and their normal littermates (ϩ/ϩ). METHODS Thirty male W/W v mice and their ϩ/ϩ littermates were anaesthetized with 2.5% isofluorane. The left coronary artery (LCA) was ligated for 30 minutes or a sham procedure was performed. After 6 hours of reperfusion, the animals were sacrificed. The muscle viability was assessed on fresh whole-mount slices by the nitroblue tetrazolium (NBT) histochemical assay and serum IL-6 concentrations measured with ELISA. RESULTS Cardiac muscle viability was significantly higher in W/W v than the ϩ/ϩ mice. Serum IL-6 levels were higher in the ϩ/ϩ sham mice (163 Ϯ11 pg/ml, nϭ6) than the W/W v mice (65Ϯ11 pg/ml, nϭ6) , p Ͻ 0.001. The IL-6 levels increased significantly after reperfusion only in the ϩ/ϩ mice (245Ϯ14 pg/ml, nϭ8, p ϭ 0.001), while it remained similar in the W/W v mice (71Ϯ17 pg/ml, nϭ8, p ϭ 0.783). CONCLUSIONS These results show that the absence of mast cells reduces the myocardial damage associated with IR injury. Furthermore, there is an attenuation is the inflammatory response, as measured by serum IL-6 levels, following this local insult. This finding entertains the prospect of developing prophylactic therapy -targeting selective inhibition of cardiac mast cell activation, in clinical situations involving medical or surgical myocardial revascularization.
P144 "Postconditioning" the Human Heart: Multiple Balloon Inflations During Cardiac Catheterization May Confer Cardioprotection
Chad E Darling, Eric B Pearlman, Patrick B Solari, Craig S Smith, Mark I Furman, Karin Przyklenk; Univ of Massachusetts Med Sch, Worcester, MA Background: Growing evidence from experimental models suggests that relief of myocardial ischemia in a stuttering manner (i.e., 'postconditioning' [PostC] with brief cycles of reperfusion/ reocclusion) limits infarct size. However, the potential clinical efficacy of PostC has, to date, been largely unexplored. Objectives: Our aim was to test the hypothesis that CK release (i.e., clinical surrogate of infarct size) would be attenuated in ST-elevation myocardial infarction (STEMI) patients receiving multiple balloon inflations-deflations during cardiac catheterization and angioplasty. Methods: To obtain initial insight into this issue, we conducted an IRB-approved, retrospective chart review of all STEMI patients with single vessel occlusion (LAD or right coronary) that presented to our institution from November 2004 -March 2006. Exclusion criteria were: pre-infarction angina; previous MI; cardiogenic shock; arrest; or evidence of spontaneous reperfusion (defined as TIMI-2 flow or greater). Patients were prospectively divided into 2 subsets: those receiving 1-3 balloon inflations (nϭ54: considered the minimum range to achieve patency and stent placement) versus those in whom 4 or more inflations were applied (nϭ59: treatment at the discretion of the invasive cardiologist). Primary endpoints were peak CK release and length of hospital stay. Results: Patients who required Ն 4 inflations-deflations, presumably due to more complex coronary lesions, had a length of hospital stay that was modestly (but significantly) prolonged. Nonetheless, peak CK release was lower (pϽ0.05) in patients receiving 4 or more inflations versus 1-3 inflations. Conclusion: These data, albeit not conclusive, are consistent with the concept that relief of sustained ischemia in a stuttered manner (analogous to postconditioning) may evoke cardioprotection in the clinical setting. 
1-3 Inflations
P145
Regulation of Cardiac Periostin and Pleiotrophin Gene Expression by Myocardial Infarction and Pressure Overload
Virva Joensuu, Jaana Rysa, Jani Aro, Mika Ilves, Hanna Leskinen, Heikki Ruskoaho; Univ of Oulu, Oulu, Finland Periostin (PN) and pleiotrophin (PTN) are extracellular matrix (ECM) proteins, PN being involved in cell adhesion, while PTN is a diverse ECM-and cell surface-associated growth factor. However, little is known about the role of these initially osteoblasts-associated proteins in adverse myocardial remodeling after myocardial infarction and in response to pressure overload. Here we determined the effect of myocardial infarction as well as the acute and chronic pressure overload on left ventricular (LV) PN and PTN gene expression. Post-infarction LV remodeling process, characterized by thinning of the wall in the infarcted area, eccentric hypertrophy and ventricular chamber dilation was associated with elevated PN mRNA levels at 24 hours (1.6-fold, PϽ0.05). On the other hand, PTN gene expression significantly decreased at 24 hours post-infarction, but afterwards there was a tendency for PTN mRNA levels to increase during LV remodeling process. In a model of acute pressure overload in conscious rats, a significant increase (2.8-fold, PϽ0.01) in LV PTN mRNA levels was seen in response to 4 hrs of intravenous administration of arginine 8 -vasopressin (0.05 g/kg/h). Furthermore, infusion of angiotensin II (Ang II) (30 g/kg/h) subcutaneously by osmotic minipumps for 72 hours significantly increased LV PN mRNA levels (5.6-fold, PϽ0.05). In addition, a significant 1.7-fold increase in PTN mRNA levels was observed after 2 weeks of Ang II infusion (PϽ0.05). Finally, to study the effect of chronic hypertension to PTN expression, we compared PTN mRNA levels in 12, 16, and 20 months old spontaneously hypertensive rats (SHR) to their age-matched normotensive control Wistar-Kyoto rats (WKY). An increase in PTN gene expression in SHR compared to WKY was observed at each time point, the greatest elevation being 2.1-fold (PϽ0.01) at 12 months. These results suggest that PN and PTN are involved in myocardial infarction and pressure overload induced cardiac ECM remodeling process. Interestingly, PTN gene expression was also rapidly upregulated in response to acute pressure load well before the development of left ventricular hypertrophy. C-fos gene transcription regulation by nuclear calcium handling system-Ca 2ϩ -ATPase, IP 3 receptor, ryanodine receptor in nuclei and the changes of nuclear calcium handling system were investigated in pressure overload-induced hypertrophic heart of rat. The model of rat cardiac hypertrophy was established by abdominal aortic constriction. Velocity and isopyknic gradient centrifugation was employed to fractionate rat cardiac nuclei. RT-PCR showed c-fos gene expression increased by 75.8% (0.58Ϯ0.16 vs 0.33Ϯ0.12, pϽ0.05) in the hypertrophic group. Nuclear run-off transcription assay showed c-fos gene transcription was markedly enhanced by 40.7% (144.6Ϯ1.6 vs 91.3Ϯ3.5, pϽ0.01) in the hypertrophic group, which was significantly attenuated in both control and hypertrophic group by treatment of isolated cardiac nuclei with Ca 2ϩ -ATPase inhibitor thapsigargin, and ryanodine receptor antagonist ruthenium red, as well as IP 3 receptor antagonist heparin respectively (pϽ0.01). The inhibited transcriptional effects of thapsigargin (decreased by 70.8%, 42.3Ϯ1.3 vs 144.6Ϯ1.6) and heparin (decreased by 72.2%, 39.9Ϯ1.3 vs 144.6Ϯ1.6) on c-fos gene were stronger than the effect of ruthenium red (decreased by 20.1%, 115.0Ϯ1.8 vs 144.6Ϯ1.6). Compare with the control group, the activity of Ca 2ϩ -ATPase in cardiac nuclei was decreased by 51.9% (4.7Ϯ0.5 vs 9.8Ϯ0.4 mol/min⅐mg, pϽ0.01); [ 3 H] ryanodine binding assay of ryanodine receptors on nuclear envelope showed Maximal number of binding sites (B max) and dissociation constant (Kd) of ryanodine binding decreased by 57.8% (121.5Ϯ11.3 vs 288.0Ϯ39.0 fmol/mg protein, pϽ0.01) and by 54.4% (2.5Ϯ0.8 vs 5.5Ϯ1.9 nmol/L, pϽ0.05) respectively; [ 3 H] IP 3 binding assay revealed Bmax and Kd of IP 3 Rs on nuclear envelope were increased by 1.1 (828.8Ϯ77.8 vs 395.6Ϯ35.8 fmol/mg, pϽ0.05) and by 2.15-fold (18.1Ϯ2.7 vs 6.3Ϯ1.3 fmol/mg, pϽ0.05) respectively in the hypertrophic group. These results indicated that c-fos gene transcription regulation involved in the change of nuclear calcium handling system, which might at least partly take part in developing overload-induced cardiac hypertrophy
P148 Gene Expression Changes in Human Trabeculae Treated with the ␤-Adrenergic Receptor Agonist Isoproterenol
Carmen C Sucharov, Bradley Nelson, Jennifer Morrison, Wayne Minobe, Michael Bristow; Univ of Colorado HSC, Denver, CO ␤-adrenergic signaling plays an important role in the natural history of dilated cardiomyopathy (DCM), exerting both compensatory effects on cardiac function and promoting the development and progression of the DCM phenotype. Activation of ␤-adrenergic receptors (␤ 1 -AR and ␤ 2 -AR) during periods of cardiac stress initially results in increases in heart rate and contractility, effectively improving cardiac output, but then ultimately harms the failing heart by altering gene expression patterns and cardiac morphology. Of the changes that are observed in failing hearts, increases in ␤ myosin heavy chain (␤MyHC), skeletal ␣-actin, and atrial natriuretic peptide (ANP), with coordinate decreases in ␣ myosin heavy chain (␣MyHC) and sarcoplasmatic reticulum ATPase 2a (SRCA2a), are perhaps the most widely recognized. Gene expression studies in response to ␤-AR stimulation have been done mostly in animal models, with the exception of one study performed by our group (Lowes et al), in which treatment of heart failure patients with b-blocker therapy results in a partial reversal of the fetal gene program. Here we show that by treating isolated human trabeculae with the ␤-AR agonist isoproterenol for 48 hours, changes in the fetal gene program are observed, with up-regulation of ANF, BNP and skeletal ␣-actin. Briefly, individual trabeculae of uniform size (1 to 2 by 6 to 8 mm) were isolated from the free wall of the right ventricle and placed in muscle bath chambers containing Tyrode's buffer equilibrated with 95% O 2 /5% CO 2 and kept at 37°C. Trabeculae were suspended between plastic mounting clips and treated with 10 -7 M isoproterenol for 48 hours, and gene expression was measured by RT-PCR. These results suggest that human trabeculae are a valid model system to analyze changes in gene expression in response to hypertrophic agonists in human subjects. cardiology. However, only few data exist on the impact of RAPA on vascular function. Aim of our study was to investigate the influence of RAPA on vascular function of human internal thoracic arteries (ITA). Methods: Samples of ITA were obtained from 35 patients, undergoing elective coronary artery bypass surgery. Specimen were cut into rings and suspended in organ baths, containing 10 ml Krebs-Henseleit solution for isometric tension recording. After an equilibration period of 2 hours rings were then challenged with 1mol of the contractile agonist noradrenaline (NA). During active tone kept by NA the relaxant compound acetylcholine (ACh) was tested (1mol). Arteries were then incubated with different concentrations of RAPA (10fmol, 1nmol, 0.1mol, 1 mol, 10 mol) for 20 h. In all experiments at least one arterial ring was used as time-matched, "non-treated" control. After that period testing with NA and ACh was repeated on the same rings. Results: The maximal contractile response for 1mol NA was similar between the different concentrations of RAPA and the controls. Comparing the ACh induced relaxation in relation to the NA (1mol) induced precontraction before versus after incubation in each group, we found a concentration dependent decrease in relaxation, being significant for 1mol and 10mol RAPA compared to the control (in %: control: 46.0Ϯ4.6; 1mol :30.7Ϯ2.8, pϭ0.011; 10mol: 12.9Ϯ1.2, pϽ0.001) . Conclusion: To our knowledge these are the first data investigating the influence of RAPA on vascular reactivity in human tissue in vitro. Our results revealed, that contractility induced by NA revealed no direct effect of RAPA on muscular contractile function. However relaxation of ITA induced by ACh is concentration-dependently decreased by RAPA indicating impaired endothelial function after only short exposure to RAPA.
P150
Lack of microRNA Regulation in Myocardial and Skeletal Muscle in Response to Cardioplegic Arrest and Cardiopulmonary Bypass
Basel Ramlawi, Cesario Bianchi, BIDMC-Harvard Med Sch, Boston, MA; Gary L Latham, Asuragen Inc, Austin, TX; Neel R Sodha, Munir Boodhwani, BIDMC-Harvard Med Sch, Boston, MA; Julie Krosting, Heidi Peltier, Asuragen Inc, Austin, TX; Frank W Sellke; BIDMC-Harvard Med Sch, Boston, MA Introduction: MicroRNAs(miRNAs) are small, non-coding RNAs that regulate the expression of complementary messenger RNAs (mRNA). The expression of miRNAs in myocytes in response to stress has not been studied. We quantified the abundance of several miRNAs in patients in response to cardioplegic arrest (CA) and cardiopulmonary bypass(CPB). Methods: Right atrial(RA) and skeletal muscle(SKM) was harvested from similar cardiac surgical patients (Nϭ6) before and after CA/CPB. RNA was extracted using Ambion's MELT Total RNA Isolation System. Total RNA was analyzed by TaqMan real-time RT-PCR of select mRNA and miRNA targets. CYR61 and DUSP1 were studied as genes known to be upregulated by CPB as positive controls. GAPDH was used as a negative control. miRNAs were selected based on data in the literature showing abundant expression in muscle tissue. Biological replicates and technical triplicates were performed for all samples. pϽ0.05 was significant. Results: Both CYR61 and DUSP1 were significantly upregulated (pϭ0.03 and pϭ0.04 respectively) while GAPDH expression was not altered by CPB. There was no significant difference in the regulation of miRNAs tested following CA/CPB for the 18 targets that were assayed by qRT-PCR. Conclusions: No miRNA targets were identified that were differentially expressed in response to the ischemia reperfusion stress following CA/CPB in patients. Background: The tunica media is the largest layer of the aortic wall that integrates and stabilizes it. It consists of elastin and collagen fibers and of smooth muscle cells (SMCs). SMCs assumed to initiate apoptosis in aneurysm formation of the aorta in patients with bicuspid aortic valve (BAV). However, a location in apoptosis signaling within SMCs in the aortic media is unkown. This study investigated the alteration of the aortic wall in patients with BAV and first approved the use of therapeutical strategies maintaining apoptosis inhibition. Methods: Tissue samples of aneurysmal and normal human aorta were collected from 40 patients during surgery (15 patients with BAV and aneurysm, 5 BAV without aneurysm, 15 patients with aneurysm and normal aortic valve (TAV) and 5 TAV without aneurysm). Histological and immunohistochemical techniques were used to study structural alterations. To define the molecular biologic condition in this tissue cell culture, quantitative RT-PCR and Western Blot were performed. Apoptosis parameter, the activities of matrix metalloproteinases and the levels of their inhibitors were measured. Results: Light and scanning electron microscopy of the aneurysmal tissues lacks any well known typical structure of the aortic wall. There was 6 to 15-fold increase of MMP-2 and MMP-9 in aneurysmal tissues obtained from BAV (70%). 6 to 9-fold increase of MMP-2 in aneurysmal tissues obtained compared to nonaneurysmal aortic tissue. In situ TUNEL, bcl-2 and bax gene expression showed no significant differences in all groups. However, in vitro treatment of cells obtained from aneurysmal tissues resulted in abundant detection of necrotic cells measured by Annexin V-PIstaining. Conclusions: Reduced elastin in tissues of ascending aortic aneurysm in BAV seems to be related to MMP elevation, whereas apoptosis may be an early mechanism leading to unbalance of the MMPs.
P152 Distinct Regulation of Thrombospondin-1 Gene Expression in Loaded Hearts
Erja Mustonen, Jaana Rysa, Jani Aro, Jutta Puhakka, Hanna Leskinen, Heikki Ruskoaho; Univ of Oulu, Oulu, Finland
The heart responds to pressure overload by concentric hypertrophy, while post-infarction remodeling is associated with thinning of the wall in the infarcted area, followed by eccentric hypertrophy, ventricular chamber dilation and extracellular matrix (ECM) remodeling. Thrombospondin-1 (TSP-1) is a secreted ECM glycoprotein with diverse functions, such as inhibition of angiogenesis and activation of transforming growth factor-␤1. However, the role and mechanisms regulating TSP-1 gene expression in the heart are unclear. Here we first studied TSP-1 gene expression during left ventricular (LV) remodeling process after experimental myocardial infarction in rats. TSP-1 mRNA levels were elevated at day 1 and protein levels at 2 and 4 weeks following the myocardial infarction. To study whether also pressure overload affects TSP-1 gene expression, we infused angiotensin II (Ang II) in rats. Subcutaneous infusion of Ang II (30g/kg/h) by osmotic minipumps for 6, 12 and 72 hours and 2 weeks increased LV TSP-1 mRNA levels up to 2 weeks, the maximal increase being observed at 6 hours (19.4-fold, pϽ0.001). Ang II type 1 receptor (AT 1 ) antagonist losartan (400 g/kg/h) completely inhibited the activation of TSP-1 gene expression by Ang II at 6 hours. Finally, arginine 8 -vasopressin (AVP) infusion into young (3 months old) and old (20 months old) conscious spontaneously hypertensive rats (SHR) and their age-matched normotensive control Wistar-Kyoto (WKY) rats was used to study whether diastolic hypertensive heart failure influences acute pressure overload induced increases in TSP-1 gene expression. A significant increase in LV TSP-1 mRNA levels were seen after 30 minutes and 4 hours of AVP infusion (0.05 g/kg/min) in young and old SHR and WKY rats, this increase being greater in SHR. These results indicate that TSP-1 is rapidly up-regulated in response to pressure load well before the development of left ventricular hypertrophy and fibrosis. Moreover, TSP-1 may have a role in the post-infarction remodeling process.
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Mao-to, Japanese Herbal Medicine, Prolonged the Survival of Viral Myocarditis in Mice by Reduction of Cardiac TNF-␣ Expression
Tsugiyasu Kanda, Zhu Shijie, Takashi Takahashi, Kanazawa Med Univ, Kahoku Ishikawa, Japan; Hiroyuki Sumino, Gunma Univ, Maebashi, Japan; Junji Moriya, Jun'ichi Yamakawa, Seiichiro Saegusa; Kanazawa Med Univ, Kahoku Ishikawa, Japan Mao-to, Japanese herbal medicine, has anti-viral and anti-autoimmune effects. Immunomodulative agents are tried , but the effects were limited. We examined the beneficial effects of Mao-to on the severity of acute myocarditis induced by encephalomyocarditis (EMC) virus in mice with the modification of cardiac tumor necrosis factor-alpha (TNF) gene expression. The C3H mice were randomly divided into 5 groups (nϭ30 of each). Group N included uninfected control mice. Group A, B, C and D were inoculated intraperitoneally with EMC virus. Group A was orally administered saline starting on day 0 to day4. Group B was orally administered Mao-to (500mg/kg/day) starting on day 0 to day4. Group C was orally administered with Mao-to at the same dose as group B starting on day 2 to day6. Group D was orally administered with Mao-to at the same dose as group B starting on day 4 to day 8. The 14 days survival was observed after viral inoculation. Body weight (BW) and organ weight containing heart (HW), bilateral lungs, thymus and spleen were examined on days 0, 2, 4, 6 and 14. Cardiac expression of TNF protein and mRNA was examined by immunohistochemistry and qualitative RT-PCR. The survival rates on day 7 were 18.2% in group A, 18.2% in group B, 63.6% in group C, 23.3% in group D. Increase of survival rates on day 14 in group C (36.4%) was statistically significant compared with that in group A, B and D (0% , 0% , 0% of each, PϽ.01). The HW and HW/BW ratio in group C on day 6 was significantly (PϽ.05) lower than those in group A, B or D. Myocardial injury and inflammation in group C were significantly (PϽ.05) reduced compared with those in group A and B on day 6. The lung weight/ BW ratio in group C on day 4 and 6 was significantly (PϽ.05) lower than those in group A. Cardiac expression of TNF protein and mRNA was significantly (PϽ.05) reduced in group C in comparison with in group A, B or D on day 6. Oral administration of Mao-to starting on day 2 is beneficial for improvement of mortality resulting from acute viral myocarditis in mice with reduced expression of cardiac TNF. These findings suggest crucial implication for starting time of herbal medicine in a murine model of viral myocarditis.
P154
MicroRNA Function During Cardiac Hypertrophy
Eva van Rooij, Lillian B Sutherland, Ning Liu, Robert D Gerard, Eric N Olson; UT Southwestern Med Ctr at Dallas, Dallas, TX Diverse forms of cardiac injury evoke a hypertrophic response characterized by an increase in cardiomyocyte cell volume, enhanced protein synthesis, assembly of sarcomeres and activation of a fetal cardiac gene program. Pathological hypertrophy is a major predictor of heart failure and cardiac sudden death. MicroRNAs (miRNAs), which target specific mRNA transcripts for degradation and translational repression, have emerged as key regulators of cell growth, differentiation and death. We have explored the possible involvement of miRNAs in cardiomyocyte hypertrophy and heart failure. Microarray analysis revealed over a dozen miRNAs that were significantly induced or repressed in cardiac tissue from mice that were either exposed to transverse aortic constriction or cardiac-specific over-expression of activated calcineurin, stimuli that induce cardiac hypertrophic remodeling. The changes in expression of these miRNAs were recapitulated in failing human hearts. The potential functions of these hypertrophic miRNAs have been investigated by their cardiac over-expression in vivo and in vitro. Selected cardiac miRNAs have also been inactivated in mice by gene targeting. The functional significance of discreet miRNAs as modulators of the cardiac hypertrophic response will be presented.
P155
Effect of Erythropoietin on Neointima Formation in Rat Carotid Artery Model of Vascular Injury
Maram K Reddy, Vinod Labhasetwar; College of Pharmacy, Univ of Nebraska Med Ctr, Omaha, NE
Effect of Erythropoietin on Neointima Formation in Rat Carotid Artery Model of Vascular Injury Maram K Reddy and Vinod Labhasetwar Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198
Various cyotoxic or cytostatic gene and drug therapies targeting vascular smooth muscle cells (VSMCs) have demonstrated some efficacy in inhibiting VSMCs proliferation and neointima formation following angioplasty and/or stent implantation; however, re-endothelialization of the injured artery is critical to its long-term patency. Previous studies have shown that the bone marrow (BM)-derived endothelial progenitor cells (EPCs) are recruited at the vascular injury site and contribute to endothelial recovery. Recombinant human erythropoietin (EPO) has been shown to induce proliferation and mobilization of EPCs and also possesses anti-inflammatory and anti-apoptotic properties. Therefore, we hypothesized that the exogenous administration of EPO would mediate the process of vascular repair by facilitating re-endothelialization and thus could inhibit neointima formation. To test our hypothesis, animals were injected EPO intraperitoneally (5,000 IU/Kg) 6 hr prior to vascular injury and then on every alternate day for one week in a rat carotid artery injury model and morphometric analysis of arteries was carried out at three weeks. Although the EPO treated animals demonstrated nearly complete and continuous arterial re-endothelialization (90% endothelial cell coverage vs. Ͻ 20% in saline control), the treatment also resulted in excessive neointima formation (Intima/Media ratio 2.1 Ϯ 0.09 vs. 1.6 Ϯ 0.02, nϭ5, pϽ0.001), resulting in significant reduction in lumen area (0.16 mm 2 Ϯ 0.01 vs 0.3 mm 2 Ϯ 0.02, nϭ5, pϽ0.001). The mechanism of excessive neointima formulation in the EPO treated group was shown to be due to excessive neoangiogenic response in the injured artery as represented by CD31-positive structures (103 Ϯ 10/mm 2 vs. 35 Ϯ 5.2/mm 2 saline control, pϽ0.001). Nonetheless, our results explained a common occurrence of vascular access stenosis in patients on EPO treatment during hemodialysis and suggest the cautious use of EPO in patients who are at a risk of vascular injury.
P156 Detection and Monitoring of Brain Recovery After Therapeutic Hypothermia in a Post-Cardiac Arrest Rodent Model: A Quantitative EEG Study
Xiaofeng Jia, Matthew A Koenig, Hyun-Chool Shin, Gehua Zhen, Romergryko G Geocadin, Nitish V Thakor; Johns Hopkins Med Inst, Baltimore, MD Objective: To test the hypothesis that quantitative electroencephalogram (qEEG) can objectively assess functional electrophysiological recovery of brain after hypothermia in an asphyxial cardiac arrest rodent model. Methods: Twenty-eight rats were subjected to 7-minute (nϭ14) and 9-minute (nϭ14) asphyxia-cardiac arrest. One half of each group (nϭ7) was randomly subjected to hypothermia one hour after CPR (Tϭ33 o C for 12 hours) and the other half (nϭ7) to normothermia (Tϭ37 o C). Continuous monitoring of blood pressure, EEG, and core body temperature and intermittent arterial blood gas (ABG) analysis were undertaken. Neurological recovery after CPR was assessed by serial Neurological Deficit Score (NDS) and qEEG analysis. Information Quantity (IQ), a validated measure of relative EEG entropy, was employed to monitor electrical recovery of the brain. Result: After cardiac arrest, the hypothermia-treated group demonstrated better brain recovery (higher IQ) compared to normothermic controls (PϽ0.001). The 72-hour functional recovery by NDS of the hypothermia group was also significantly better compared to the normothermia group (PϽ0.01). IQ during the hypothermia maintenance period has the highest correlation within the first 24 hours (Pearson correlation 0.746, 2-tailed significance Ͻ0.001) with 72-hour functional recovery by NDS. Conclusion: The qEEG IQ measure was able to detect the effects of hypothermia during the first 24 hours which was corroborated by the functional recovery by NDS at 72 hours. These results demonstrate the potential utility of objective measures such as qEEG-IQ to track the response to hypothermia and other potential therapies during the early phase of recovery from cardiac arrest.
P157 Withdrawn
P158 Atorvastatin Activates Cyclooxygenase-2 in the Heart via S-Nitrosylation by Inducible Nitric Oxide Synthase
Yochai Birnbaum, Yumei Ye, Yu Lin, Sheldon Freeberg, Juan Martinez, Jose R Perez-Polo, Barry F Uretsky; Univ of Texas Med Branch, Galveston, TX Background: Atorvastatin (AT) increases myocardial expression of phophorylated Ser-1777 endothelial nitric oxide synthase (P-eNOS), inducible NOS (iNOS) and Cycloxygenase-2 (COX2). Although AT increases the expression of COX2 in eNOS -/mice, there is no increase in COX2 activity as occurs in wild-type (WT) mice. In the rat, COX2 activation occurs by iNOS mediated S-nitrosylation. Aim: To investigate whether the difference in COX2 activity between the AT-treated WT and eNOS -/is related to S-nitrosylation. Methods: WT, eNOS -/-, and iNOS -/mice received AT 10 mg/kg/d (ATϩ) or water alone (AT-) for 3 days. Hearts were harvested and subjected to ELISA and immunoblotting. S-nitrosylation of COX2 was assessed by the "Biotin Switch" assay. To verify that the immuno-precipitates contained COX2, membranes were stripped and blots with anti-COX2 antibodies. Results: COX2 expression in the AT-groups was very low. AT increased COX2 expression in WT (4,287Ϯ104%) and eNOS -/-(4,354Ϯ101%), but not iNOS -/mice (101Ϯ3%). However, myocardial 6-keto-PGF 1␣ levels (81.4Ϯ0.2 vs. 15.7Ϯ0.1 pg/ml; pϽ0.001) were increased by AT only in WT mice, but not in eNOS -/-(16.5Ϯ0.1 vs. 15.6Ϯ0.1 pg/ml) or iNOS -/-(15.9Ϯ0.2 vs. 15.3Ϯ0.1 pg/ml) mice. The "Biotin Switch" assay shows that COX2 was S-nitrosylated only in WT mice. Although eNOS is activated by AT in the iNOS -/mice, there is no S-nitrosylation and activation of COX2. Conclusions: COX2 is activated by S-nitrosylation only in WT mice. Although iNOS is intact in eNOS -/mice, it is not activated and therefore, does not S-nitrosylate the AT-induced upregulated COX2.
P159 Pioglitazone and Atorvastatin Augment Myocardial Production of 15-Epi-Lipoxin A 4 in the Rat Heart
Yochai Birnbaum, Yumei Ye, Yu Lin, Sheldon Y Freeberg, Shawn P Nishi, Juan D Martinez, Ming-He Huang, Barry F Uretsky, Jose R Perez-Polo; Univ of Texas Med Branch, Galveston, TX Background: Both statins and thiazolidinediones have anti-inflammatory properties. However, the exact mechanisms underlying these effects are unknown. We investigated whether ATV and PIO increase myocardial content of lipoxin A 4 and 15(R)-epi-lipoxin A 4 (15ELX), both arachidonic acid products with strong anti-inflammatory properties. Methods and Results: Experiment 1: Rats received 3-day pretreatment with: 1) water; 2) PIO 10 mg/kg/d; 3) ATV 10 mg/kg/d; or 4) PIOϩATV. Experiment 2: Rats received: 1) water; 2) PIOϩATV; 3) PIPϩATV and valdecoxib, a selective COX2 inhibitor; 4) PIOϩATV and zileuton, a selective 5-lipoxygenase inhibitor; or 5) zileuton alone. There were 4 rats in each group. Heart were harvested and analyzed for myocardial lipoxin A 4 and 15ELX levels, and COX2 and 5-lipoxygenase protein expression. ATV (1.10Ϯ0.02 ng/mg; pϽ0.001 vs. sham) and PIO (0.98Ϯ0.02 ng/mg; pϽ0.001 vs. sham) significantly increased myocardial 15ELX levels compared to the sham-treated group (0.51Ϯ0.02 ng/mg). Myocardial 15ELX were significantly higher in the PIOϩATV group (1.29Ϯ0.02 ng/mg; pϽ0.001 vs. each other group). Both valdecoxib and zileuton abrogated the PIOϩATV increase in 15ELX, whereas zileuton alone had no effect. PIO, ATV and their combination resulted in a small increase in myocardial lipoxin A 4 levels, which was not statistically significant. ATV alone, or in combination with PIO markedly augmented COX2 expression. The effect of PIO on COX2 expression was smaller. Myocardial expression of 5-lipoxygenase was not altered by PIO, ATV and their combination. Conclusions: Both PIO and ATV increases myocardial levels of 15ELX, an arachidonic acid product with anti-inflammatory properties. This finding may explain the anti-inflammatory properties of both PIO and ATV.
Withdrawn P160 P161 A Role for Interleukin-Converting Enzyme in Heart Failure
proapoptotic caspases are of central importance. In contrast, the role of proinflammatory caspases is unclear. Interleukin converting enzyme (ICE, caspase-1) has been described as a proinflammatory caspase that generates active IL-1beta. This study aims to elucidate the cardiac function of ICE. Gene array analysis in a murine heart failure model showed upregulation of myocardial ICE. We confirmed this both in a murine heart failure model as well as in human heart failure (Immunoblot, ϩ123Ϯ14%, pϽ0.0001). To investigate if the upregulation of ICE is causally involved in heart failure, we generated transgenic mice with cardiomyocyte specific overexpression of ICE. These mice reveal a strong induction of cardiomyocyte apoptosis starting at one month of age (TUNEL, ϩ407Ϯ118%, pϽ0.01). This is followed by fibrosis and cardiomyocyte hypertrophy (cross-sectional area, ϩ62Ϯ4%, pϽ0.05). Importantly, cardiomyocyte hypertrophy is not paralleled by an increased ventricular weight. ICE-TG hearts ultimately displayed left ventricular dilatation and wall thinning. Additionally, these mice exhibit a impaired cardiac function as seen in decreased dp/dtmax values (7370Ϯ1300 (WT) vs. 4550Ϯ1020 mmHg/s (TG)) and increased LVEDP-values (ϩ763Ϯ335%)). These alterations are not due to increased IL-1beta formation. Adenoviral expression of ICE in primary rat cardiomocytes potently induced both activation of caspase-3 (Immunoblot, ϩ99%Ϯ17%, pϭ0.001) and -9 and cardiomyocyte apoptosis (TUNEL, ϩ776Ϯ42% vs. LacZ control virus), that could be prevented by an ICE-specific inhibitor. To test the role of endogenous ICE for cardiomyocyte apoptosis we employed ischemiareperfusion as a strong apoptotic stimulus in ICE-deficient mice. Depletion of endogenous ICE protects from cardiomyocyte apoptosis (3-fold reduction,ICE-KO vs. WT,pϽ0.05). In contrast to previous findings which imply a proinflammatory role of ICE, these data infer a primary proapototic role for ICE in cardiomyocytes. Our findings indicate a functional role for ICE in cardiomyocyte apoptosis.
P162
ANP-cGMP-PKG Signaling Blocks TGF-␤1-Induced Myofibroblast Transformation and Phospho-Smad3 Nuclear Translocation, but Not Smad3 Phosphorylation, in Mouse Cardiac Fibroblasts
Yiu-Fai Chen, Dajun Wang, Dongqi Xing, Peng Li, Xu Cao, Suzanne Oparil; Univ of Alabama at Birmingham, Birmingham, AL Background: We have shown that atrial natriuretic peptide (ANP) modulates the development of pressure overload-induced cardiac hypertrophy; and ANP, via the cGMP-protein kinase G (PKG) signaling, has direct anti-fibrogenic actions on heart by modulating expression of extracellular matrix (ECM) molecules in cardiac fibroblasts (CFs). Transforming growth factor (TGF)-␤1, via the Smad signaling, stimulates ECM expression and fibrosis in heart under stress conditions. Methods: To test the specific hypothesis that activation of ANP-cGMP-PKG signaling interrupts TGF-␤1 signaling by inhibiting TGF-␤1-induced phospho-Smad3 (pSmad3) nuclear translocation and myofibroblast (MF) transformation in CFs, quiescent mouse CFs were pre-treated with ANP (1 uM) or 8-Br-cGMP (a cGMP analog, 1 mM) for 30 min, and then exposed to TGF-␤1 (1 ng/ml) for 30 min (for Western blot and nuclear translocation) or 24 hrs (for MF transformation). pSmad3 protein levels were assessed by Western analysis. CFs were stained with anti-pSmad3 antibody to assess pSmad3 nuclear translocation by confocal microscopy. Numbers of MFs were assessed using ␣-smooth muscle actin (␣-SMA) staining. Separate groups of CFs were pretreated with KT5823 (a PKG inhibitor, 1 uM) 30 min before exposure to ANP or cGMP. Results: ANP and cGMP inhibited TGF-␤1-induced nuclear translocation of pSmad3, but did not inhibit TGF-␤1-induced phosphorylation of Smad3. Nearly all cells in TGF-␤1 treated CFs were ␣-SMA positive and contained organized ␣-SMA filaments, indicating complete transformation of CFs to MFs. Pretreatment with cGMP completely inhibited TGF-␤1-induced MF transformation (21% of total cells), but did not change basal (23% of total cells) MF numbers. KT5823 blocked the effects of ANP and cGMP. Conclusion: These results delineate a specific molecular mechanism by which activation of ANP-cGMP-PKG signaling pathway has direct anti-fibrogenic actions on heart by inhibition of TGF-␤1-induced pSmad3 nuclear translocation, MF transformation and expression of ECM molecules in CFs. We hypothesize that interaction between the ANP and TGF-␤1 signaling pathways at this level may play an important role in the pathogenesis of cardiac fibrosis and remodeling under stress conditions.
P163 Withdrawn
P164
BRCA1-Associated Protein 2: A Novel Modulator of ERK-MAPK Signaling in Heart Failure
Tim Seidler, Peter Schott, Cornelia Grebe, Manuel Keller, Albrecht Schmidt, Harald Kogler, Gerd Hasenfuss; Univ of Goettingen, Goettingen, Germany Mitogen activated protein kinase (MAPK) signalling can profoundly modulate hypertrophy and heart failure. BRCA1 Associated Protein 2 (BRAP) was recently identified as an important modulator of Ras dependent MAPK activation in non-cardiac cells. We identified BRAP to be differentially regulated upon load induced heart failure in a proteomics study. Thus, the aim of this study was to analyse the role of BRAP in the myocardium. Adenoviruses for overexpression of BRAP and Raf-BXB, a constitutively active MAPK, were created to study the effects of BRAP in isolated rat cardiac myocytes. Using Real-Time PCR and Western Blot, BRAP expression was analyzed in two rat models (Monocrotaline (MCT)-and pulmonary banding-induced) RV hypertrophy. Further, the expression of BRAP was analysed in non-failing and failing human myocardium. Transgenic mice, overexpressing BRAP cardiac-specifically, were created and analysed. BRAP was found to be upregulated in the hypertrophied RV myocardium of both animal models (BRAP/GAPDH mRNA ratio MCT 0.0051Ϯ0.0009 vs. control 0.0031Ϯ0.0003, pϽ0.002 (nϭ9); pulmonary banding 0.0047Ϯ0.0008 vs. control 0.0032Ϯ0.0002, pϽ0.02 (nϭ7)). Western blot results confirmed the mRNA data. Likewise, BRAP was expressed at significantly higher levels in human failing myocardium (DCM). In isolated myocytes, BRAP overexpression profoundly suppressed MEK and ERK MAPK signalling under baseline conditions and following Raf-BXB-stimulation. This suggests an inhibitory effect of BRAP on both adaptive hypertrophy and anti-apoptotic signalling. Three independently created BRAP-transgenic (TG) mouse lines in two different genetic backgrounds exhibited grossly enlarged hearts, compared to wildtype littermates (WT). Echocardiography confirmed dilation (left ventricular end-diastolic diameter 4.57Ϯ0.17 vs. 3,57Ϯ0.04 mm; pϽ0.05 BRAP vs. WT; pϽ0.05; TG vs WT) and significant reduction of fractional shortening (14Ϯ3% vs. 40Ϯ0.4%; BRAP TG vs. WT; pϽ0.001). Kaplan-Maier analysis showed a significantly decreased survival with 50% of mice dying before the age of 24 weeks. These data indicate that BRAP is differentially expressed in heart failure and controls cardiac size and function via inhibition of the ERK MAPK pathway.
P165 Angiotensin II Receptor Imbalance Associated with Neonatal Cardiac Growth Restriction Is a Prelude to Adult Cardiac Hypertrophy
Enzo R Porrello, Univ of Melbourne, Melbourne, Australia; Angelo D'Amore, Baker Heart Rsch Inst, Melbourne, Australia; Claire L Curl, Catherine E Huggins, Stephen B Harrap, Univ of Melbourne, Melbourne, Australia; Walter G Thomas, Baker Heart Rsch Inst, Melbourne, Australia; Lea M Delbridge; Univ of Melbourne, Melbourne, Australia
The Hypertrophic Heart Rat (HHR) displays spontaneous cardiomyocyte hypertrophy in association with an apparent reduction in myocyte number in adulthood. This suggests the possibility of reduced hyperplasia or increased apoptosis during early cardiac development. The angiotensin AT 1 and AT 2 receptor subtypes have been implicated in both cellular growth and apoptosis, but the precise mechanisms are unclear. The aim of this study was to determine the relationship between cardiac AngII receptor expression levels and neonatal cardiomyocyte growth and apoptotic responses in the HHR compared with the Normal Heart Rat (NHR) control strain. Cardiac tissues were freshly harvested from male HHR and NHR at several developmental stages (p2 and 4, 6, 8, 12wks). HHR cardiac weight indices were considerably smaller than NHR at day 2 (4.33Ϯ0.19 vs 5.01Ϯ0.08 mg/g), but 'caught-up' to NHR by 4 weeks (5.10Ϯ0.15 vs 5.16Ϯ0.11 mg/g). By 12 weeks, HHR hearts were 27% larger than NHR. Tissue AT 1A and AT 2 mRNA expression levels were quantified by real-time RT-PCR. Relative to NHR, HHR neonatal hearts exhibited a 4.6-fold higher AT 2 /AT 1 mRNA expression ratio. Cultured neonatal cardiomyocytes were infected with AT 1A and/or AT 2 receptor-expressing adenoviruses to achieve a physiological level of receptor expression (150 fmol receptor protein/mg total cell protein). In addition, to emulate receptor expression in neonatal HHR hearts, cells were co-infected with AT 1A and AT 2 receptors at a 4:1 ratio. Apoptosis incidence was studied by morphological analysis after 72 hours exposure to 0.1 M AngII. When infected with the AT 1A receptor alone, a higher proportion of HHR myocytes appeared apoptotic than NHR (22.7 Ϯ 4.1% vs 1.1 Ϯ 0.6%, P Ͻ 0.001). This implies that intrinsic differences predispose HHR cells to accentuated AT1-mediated apoptosis. Interestingly, the bax-1/bcl-2 mRNA expression ratio was significantly higher (50%) in HHR neonatal hearts. When cells were co-infected with AT 1A and AT 2 receptors, evidence of apoptosis in HHR cells virtually disappeared (0.4 Ϯ 0.1%). These findings suggest a novel capacity of AT 2 receptors to counteract accentuated AT 1A receptor-induced apoptosis in the HHR in early cardiac growth.
P166 Cardiac Myosin Activator CK-1316719 Increases Myocyte Contractility and Myosin ATPase Activation in a Model of Heart Failure
Robert Anderson, Raja Kawas, Maria Pokrovskii, Guillermo Godinez, Kenneth Lee, John Mak, Bradley Morgan, David Morgans, Jr, Fady Malik, Roman Sakowicz, Kathleen Elias; Cytokinetics, South San Francisco, CA Improving cardiac contractility by directly activating cardiac myosin may be a preferred treatment for heart failure (HF) over the current inotropic therapies that increase intracellular calcium or act via second messenger activation. Previously we reported that small molecule myosin activators increase cardiac myocyte contractility without increasing intracellular calcium or inhibiting phosphodiesterase in non-failing cells. We now report cellular and biochemical responses to the myosin activator CK-1316719 in a rat model of HF. Heart failure was confirmed in vivo by significant decreases in fractional shortening (M-mode echocardiography) in 12-week post myocardial infarction (MI) Sprague Dawley rats compared to sham animals. Myocytes were isolated from the left ventricle and septum for cellular contractility, myofibril ATPase, and mRNA analysis. CK-1316719 (0.4 -5 uM) treatment increased cellular contractility equivalently and in a dose dependent manner in both sham and MI myocytes. In contrast, isoproterenol treatment (20 nM) resulted in a truncated response in only MI cells demonstrating ␤-adrenergic desensitization, a characteristic of HF. Increased ANF mRNA expression in MI cells corroborated HF at the cellular level. In fura-2 loaded myocytes, CK-1316719 increased cellular contractility in both MI and sham cells without increasing the calcium transient, consistent with the proposed mechanism of action. Sham and MI myofibrils displayed similar dose dependent increases in ATP turnover (pCa 6 and 7) with CK-1316719. In summary, treatment with CK-1316719 results in equivalent increases in cardiac myocyte contractility with no change in the calcium transient in both sham and MI cells, and similar ATPase activation increases in sham and MI myofibrils. These results indicate that myosin activators are equally effective in non-HF and HF states and may be useful therapeutics in the treatment of heart failure. the hypothesis that phosphodiesterase type 5A (PDE5A), an enzyme that degrades cGMP, contributes to altered ventricular performance with advanced age and is a factor that reduces AKT activation. PDE5A protein abundance, mRNA expression, and enzyme activity were elevated in old (26 month) compared with young adult (6 month) rat hearts (PϽ0.05). Old and young rats were treated for 2 weeks with chronic sildenafil (60 mg/d by subcutaneous injection). Plasma concentrations of free sildenafil were 10 nM. After chronic treatment with sildenafil, rats were subjected to pressure-volume loop analysis. Rats chronically treated with sildenafil showed that baseline tau was significantly lower than sham control old rats (nϭ8; PϽ0.05) but not significantly different from young control or young treated with sildenafil. As with acute administration of sildenafil, chronic treatment resulted in a marked inhibition of the inotropic response to isoproterenol in the old as well as in the young. We have previously observed that under conditions of pathologic cardiac hypertrophy, PDE5A inhibition results in a reduction in AKT signaling. In the present study, we observed an aging-associated reduction in total AKT and activated AKT expression that was partially reversed by chronic treatment with sildenafil. In sum, these data suggest that inhibition of the PDE5A pathway enhances ventricular relaxation in old hearts and restores AKT expression, suggesting that this pathway may be exploited to modulate diastolic function in aged myocardium.
P168 Adenosine Regulation of the Cardiomyocyte Microtubular Cytoskeleton During Hypertrophy
John T Fassett, Xin Xu, Yingjie Chen, Robert Bache; Univ of Minnesota, Minneapolis, MN Contractile dysfunction in the hypertrophied heart is in part due to cardiomyocyte cytoskeletal remodeling with accumulation of a dense microtubular network that increases the viscous load on the myofilaments. Adenosine or its stable analogue, 2-chloroadenosine can attenuate hypertrophy and detrimental remodeling in mice subjected to pressure overload in response to transverse aortic constriction (TAC). The mechanism however, by which adenosine attenuates hypertrophy and cardiac dysfunction is unclear. Here, the role of adenosine in cardiac cytoskeletal remodeling during hypertrophy was investigated. Consistent with the ability of adenosine to attenuate hypertrophy, diminished adenosine levels in cd73KO mice were associated with greater hypertrophy and heart failure in response to TAC. Notably, sham cd73 mice already showed increased levels of tubulin compared to WT, and tubulin levels in response to TAC were substantially increased over WT, suggesting that adenosine levels may diminish accumulation of microtubules in cardiomyocytes. In neonatal cardiomyocytes, phenylephrine(PE) caused hypertrophy with increased microtubule accumulation in the cytoskeletal fraction, while CADO treatment reduced hypertrophy and the accumulation of microtubules. To distinguish between anti-hypertrophic effects vs. microtubular effects of CADO, hypertrophied cardiomyocytes containing increased microtubules were treated with CADO. In hypertrophied cells, CADO still diminished microtubules but left sarcomeric actin intact, implying an effect on microtubules independent of an effect on hypertrophy. The CADO-induced loss of microtubules was blocked by DPCPX, implicating the Adenosine A1 receptor in adenosine mediated depletion of microtubules. Furthermore, treatment of cardiomyocytes with PE reduced activation of Lim Kinase (LimK; an enzyme which promotes microtubule destabilization), while CADO restored LimK activation, suggesting a potential mechanism by which adneosine may destabilize microtubules. Together these results imply a novel role for adenosine in preventing the accumulation of microtubules in cardiomyocytes and preserving cardiac function during cardiac hypertrophy.
P169 Calpain 1 Gene Expression and Calpain-Like Protease Activity Increase with Atrophic Remodeling of the Heart
Peter Razeghi, Kedryn K Baskin, Kaelin Volpini, Heinrich Taegtmeyer; Univ of Texas Health Science Ctr, Houston, TX Background: Cardiac hypertrophy is an independent risk factor for the development of heart failure. Regulators of cardiomyocyte atrophy are potential targets for reversing cardiac hypertrophy. Calpain 1 and calpain 2 are essential regulators of skeletal muscle atrophy. Their role in heart muscle is undefined. Hypothesis: Calpain 1 and 2 regulate cardiomyocyte atrophy. Methods: We used two models of unloading-induced cardiac atrophy and one model of starvation-induced cardiomyocyte atrophy. Failing human hearts of 10 patients (8 men, age: 40.4 Ϯ 5.7) were unloaded with a left ventricular assist device (mean duration was 200 Ϯ 38 days, range: 64 -437 days). Myocardial samples were obtained from failing human hearts before and after mechanical unloading. Normal rat hearts were unloaded for 7 days by heterotopic transplantation into the abdomen of a recipient rat. Neonatal rat ventricular cardiomyocytes (NRVM) were starved of amino acids for 18 hours. Using quantitative RT-PCR we measured transcript levels of calpain 1 and calpain 2 at baseline and after treatment. In the unloaded rat hearts we also measured calpain-like protease activity. Results: In patients with left ventricular systolic dysfunction, mechanical unloading increased cardiac transcript levels of calpain 1 but unloading did not significantly change calpain 2 gene expression. The change in calpain 1 transcript levels correlated negatively with the duration of unloading (r2ϭ-0.73, pϽ0.01). Unloading of the heterotopically transplanted rat heart significantly increased calpain 1 transcript levels and calpain-like protease activity. In nutrient deprived NRVM (no amino acids) calpain 1 transcript levels increased. Conclusions: Calpain 1 gene expression and activity increases during cardiomyocyte atrophy suggesting that calpain 1 may regulate reversal of hypertrophy. Future studies will examine the trophic effect of calpain 1 inhibitors in models of atrophy and calpain 1 activators in models of hypertrophy.
P170 Supramolecular Protein Structure for Extracellular Antithrombotic Protection of Vascular Wall
Alexander V Vavaev, Elena G Tischenko, Alexander V Maksimenko; Russian Cardiology Rsch-and-Production Complex, Moscow, Russian Federation Reactive oxygen species damage the blood vessel wall at initial and advanced stages of vascular pathology. Oxidative stress contributes to atherogenic modifications of low-density lipoproteins, development of lipid streaks on the luminal surface, alterations in the glycocalyx, ulceration and rupture of atherosclerotic plaques. Such a wide range of damaging activity implies the necessity of both intra-and extracellular protection of vascular wall, which can be realized by gene therapy and exogenous biological antioxidants. Recent our studies in vivo have shown that modified superoxide dismutase (SOD) and catalase (CAT) as well as extracellular superoxide dismutase, an enzyme that employs the specificity of glycosaminoglycan-protein interactions, can be effectively used as antioxidant protectors. Covalent binding of SOD to CAT via the vascular wall glycosaminoglycan chondroitin sulfate (CHS) leads to formation of a supramolecular bienzyme conjugate (SOD-CHS-CAT) which manifests in vivo the highest antithrombotic activity in comparison with several SOD and CAT derivatives. We have shown (on the rat model of arterial thrombosis induced by the treatment of vessel with ferrous chloride) that the antithrombotic effects of covalently modified biocatalysts exceed those of native enzymes, free CHS and their mixtures. A single-bolus injection of the mixture between SOD-CHS and CAT-CHS conjugates had a significantly lower antithrombotic effect compared with that of the SOD-CHS-CAT conjugate. This could be explained by different surface distribution of the conjugates in the circulation after their intravenous administration. The bienzyme conjugate was effective at doses two orders smaller then those for native SOD and CAT and an order of magnitude smaller than that for CHS-modified derivatives, administered either singly or as their mixture. Our results stress the importance of the attachment of a bioantioxidant to the vascular wall and the stable connection of SOD and CAT activities on its surface. Extracellular bioantioxidants are prospective for the development of highly efficient pharmacological protectors of the vascular wall against oxidative damage in conjunctive courses of thrombolytic, pulmonary, psychiatric or preventive cure.
P171 Oxidant Stress from Endothelial Nitric Oxide Synthase Uncoupling Plays a Major Role in Pulmonary Hypertension
Ryan J Tedford, Milena Gebska, Mobusher Mahmud, Hazim El-Haddad, Blake Stevenson, Hunter C Champion; The Johns Hopkins Hosp, Baltimore, MD Models of pulmonary hypertension are associated with pulmonary vascular remodeling. Reactive oxygen species (ROS) may importantly contribute to this process, but the sources of ROS remain poorly understood. Endothelial nitric oxide synthase (eNOS) has been shown to be a major producer of ROS in vascular endothelium when depleted of substrate L-arginine and/or its cofactor tetrahydrobiopterin (BH4). Uncoupled eNOS is a monomer while active eNOS forms a dimer. We tested the hypothesis that chronic hypoxia leads to eNOS uncoupling, thereby stimulating ROS generation and contributing to pulmonary vascular remodeling. In C57Bl/6 mice, 6 weeks of hypoxia induced pulmonary arterial hypertension that was associated with profound pulmonary vascular remodeling in medium (250 -400 m) and small (100 -250 m) arterioles. O 2 production assessed by luminol chemiluminescence and immunostaining with dihydroethidium increased in the lungs of mice exposed to hypoxia. Nitrotyrosine, a marker of end-product of tissue oxidative damage, increased and matrix metalloproteinase (MMP)-2 and -9 were activated under conditions of hypoxia. Hypoxia significantly reduced dimeric form of eNOS, accompanied by reduced Ca 2ϩ -depedent NOS activity, whereas normoxic controls harbored both dimeric and monomeric forms and higher activity. Supplementation of the eNOS cofactor BH4 (1mg/g food) prevented eNOS uncoupling, and was accompanied by reduced O 2 production, nitrotyrosine formation, and MMP-2 and -9 activation. Moreover, supplementation with BH4 resulted in a significant reduction in mean PA pressure and pulmonary vascular resistance in mice exposed to chronic hypoxia. Supplementation with BN4 (an analog of BH4 that is not a cofactor for NOS) did not reduce these biochemical markers of NOS uncoupling and did not alter the pulmonary hemodynamic response to chronic hypoxia. In PA explants from patients undergoing lung transplant, eNOS was also found to be uncoupled. Thus, uncoupled eNOS is associated with pulmonary hypertension in animal models and human pulmonary hypertension and these data support the future investigation of BH4 supplementation as a treatment for pulmonary vascular disorders.
P172 3'-Azido-3'-Deoxythymidine Inhibits Thymidine Phosphorylation in H9C2 Cells
Matthew D Lynx, Edward E McKee; Univ of Notre Dame, South Bend, IN AZT (3'-azido-3'-deoxythymidine, zidovudine) inhibits thymidine phosphorylation in isolated rat liver and heart mitochondria, as shown by previous work from this laboratory. This inhibition may lead to depletion of TTP within the mitochondria and could cause the mitochondrial DNA depletion that observed in tissues experiencing AZT toxicity. In order to further advance this mechanism of toxicity, the H9C2 cell line will be used. H9C2 cells are derived from rat cardiac myoblasts and provide a good model for the affects of AZT on cardiac tissue. We will demonstrate that AZT inhibits thymidine phosphorylation in short term trials conducted with H9C2 cells. The time course of thymidine salvage and phosphorylation was measured by incubating the cells in media supplemented with 1 M [3H]-thymidine. The H9C2 cells phosphorylated thymidine to TTP, which reached a plateau after 20 minutes of incubation. The time course of AZT phosphorylation was determined by incubating the H9C2 cells with media containing 1 M [3H]-AZT. AZT was phosphorylated to AZT-5'-monophosphate (AZTMP), reaching a plateau after 60 minutes of incubation. AZT-5'-triphosphate (AZTTP) was first detectable after 90 minutes of incubation. As seen from these two time courses, at 10 minutes of incubation thymidine is still being phosphorylated at a linear rate, and the AZT pool consists almost entirely of AZT, with little or no AZTMP or AZTTP present. In order to see the effect of AZT on thymidine phosphorylation, flasks of H9C2 cells were incubated for 10 minutes in media with 1 M [3H]-thymidine and varying concentrations of AZT, ranging from 0 to 200 M. From this data, the 50% inhibitory concentration (IC50) for AZT inhibition of thymidine phosphorylation was calculated to be 5.3 M AZT. This demonstrates that AZT readily inhibits thymidine phosphorylation in H9C2 cells. AZT may be inhibiting both thymidine kinase 1 and thymidine kinase 2 in these cells, similar to the AZT inhibition of thymidine kinase 2 observed in isolated rat heart and liver mitochondria. This work will provide the basis in H9C2 cells for our proposed mechanism of AZT toxicity. Future trials in H9C2 cells will look at the long term effect of AZT exposure on the TTP pool and correlate it to AZT-related mitochondrial DNA depletion.
P173
Identification of PI16 as a New Candidate Gene in Heart Failure by a Genetic Yeast Screen for Secreted Proteins
Robert J A Frost, Martin J Lohse, Stefan Engelhardt; Univ of Wuerzburg, Wuerzburg, Germany
Remodeling of the myocardium is of central importance for the development of congestive heart failure. Experiments with conditioned media demonstrated communication between cardiomyocytes and fibroblasts via secreted factors. The aim of our work is the identification and characterization of proteins secreted from the heart. We performed a systematic search for secreted proteins in a murine cardiac cDNA-library using a genetic yeast screen. Out of 1.7 x 10 7 screened yeast transformants we identified 54 non-redundant clones containing a signal sequence for secretion. Among them are well-known genes like the atrial natriuretic peptide, genes with so far unknown cardiac expression and genes with so far unknown function and expression. We then studied regulation of these genes during the development of heart failure. The mRNA-expression of protease inhibitor 16 (PI16) was strongly upregulated both in murine cardiac hypertrophy (aortic banding: ϩ242Ϯ82%, pϽ0.01) and heart failure (beta 1 -adrenergic receptor transgenic mice: ϩ203Ϯ56%, pϽ0.01). We also found significant upregulation of PI16 mRNA in human heart failure (ϩ250Ϯ137%). PI16 is a putative 489 amino acid protein with so far unknown function. We generated a specific polyclonal antibody and found also at the protein level a strong and early upregulation of PI16 expression in heart failure. Serum stimulation of neonatal rat cardiomyocytes strongly induced PI16 protein expression. We further identified a splice variant of the murine and human PI16 lacking exon 5. PI16 is secreted into the culture medium after transfection of neonatal rat cardiomyocytes with a PI16-expressing adenovirus. Moreover, PI16 accumulates after secretion extracellularly in the heart and binds to cardiac cells. Taken together, using a genetic yeast screen of a heart cDNA-library we identified 54 proteins putatively secreted from the heart. PI16, a newly identified secreted protein is strongly upregulated early in heart failure suggesting a possible involvement in cardiac remodeling.
P174
Resveratrol: A Fountain of Miracles in Cardiovascular Disease
Mahesh Thirunavukkarasu, Suresh V Penumathsa, Lijun Zhan, Nilanjana Maulik; Univ of Connecticut Med Ctr, Farmington, CT Diabetes is the most significant comorbidity of patients with heart failure (HF) which adversely affects outcomes in patients with HF and coronary arteriolar disease. Oxidative stress has been implicated in the pathology and complications of diabetes, which leads to myocardial ischemia reperfusion injury. Therefore to examine the efficacy of Resveratrol (2.5mg/kg b.wt), a constituent present in red wine, was administered orally for 15 days to assess its effect on streptozotocin (65mg/kg) induced diabetic rat myocardium after ischemia and reperfusion. The mechanism(s) responsible for the enhanced angiogenesis as well as cardioprotective effect of resveratrol is found to be through Trx-1, NO/HO-1 and VEGF. In our present study resveratrol demonstrated significant reduction in glucose level by continuous glucose monitoring (CGM) using implantable glucose sensors in normal and diabetic rats. Sprague Dawley rats were divided into five groups i) Control ii) Diabetic iii) Diabetic ϩ resveratrol iv) diabeticϩresveratrolϩL-NAME (nitric oxide inhibitor), v) diabetic ϩ L-Name. After the treatment the hearts were excised and subjected to 30 min of global ischemia followed by 2hrs of reperfusion. Resveratrol treated diabetic rats demonstrated significantly higher left ventricular function throughout reperfusion compared to the diabetic or L-NAME treated animals (dp/dtmax 1457Ϯ 51 vs 999 Ϯ44 mmHg/sec at 120 min reperfusion). However, resveratrol treated animals showed better aortic flow (1.3ml/min) compared to the diabetic animals. Resveratrol treatment reduced infarct size compared to the control diabetic animals (40Ϯ4 vs 54 Ϯ 2). Cardioprotection from ischemic injury in resveratrol treated diabetic rats were also showed decreased cardiomyocyte apoptosis by TUNEL assay. Western blot revealed induction of Trx-1, HO-1 compared to the diabetic animals. We observed increase in antioxidative enzyme, Mn-SOD activity in resveratrol treated myocardium. Our approach to pharmacological preconditioning by resveratrol through nitric oxide mediated upregulation of Trx-1, HO-1 and increased Mn-SOD activity along with the reduction in glucose level for cardioprotection is a novel and potentially exciting strategy for treating diabetic myocardium.
P175 Different Expression of Connexins 40 and 43 in Atrial Tissue from Patients with Coronary Artery Disease in Sinus Rhythm with and Without Type 2 Diabetes Mellitus
Pascal Daleau, Geneviè ve Comeau, Dominique Fournier, Paul Poirier; Quebec Heart Inst, Quebec, Canada
The incidence and prevalence of type 2 diabetes are expanding in North America and 70 -80% of patients with diabetes will die of heart disease. Also, diabetes is an independent risk predictor of atrial fibrillation (AF), hypertension and left ventricular diastolic dysfunction being thought to explain in part this association. Nevertheless, inherent structural mechanisms at the atrial level could also be involved. We assessed changes in the expression of two proteins specifically involved in atrial electrophysiology (i.e. the potassium channel Kv1.5 -underlying IKur -and the gap junction connexins, Cx40 and Cx43) in atrial tissues from patients with and without type 2 diabetes submitted to coronary artery bypass surgery (CABS). Recruited patients, i.e. 10 diabetics and 8 controls, were in sinus rhythm and both groups were matched for age, sex, diastolic and systolic functions, and co-morbidities. No difference was observed between the 2 groups for heart rate variability indexes and blood analysis apart as expected, fasting blood glucose (7.2Ϯ1.6 vs 5.2Ϯ0.6 mmol/L respectively for diabetic and non-diabetic patients; pϭ0.003). Metabolic control was adequate in patient with diabetes with a glycated hemoglobin of 7.1Ϯ1.0%. A sample of atrial appendage was harvested during CABS and prepared for protein isolation and western blotting. Densitometric analyses were normalised to ␣-tubuline. While hKv1.5 level was similar between the two groups, Cx43 was reduced to ϳ20% in the diabetic group compared to controls; Cx40 was barely detectable in controls but increased ϳ4 fold in the diabetic group. These ratios were similar for all the phosphorylated and non-phosphorylated forms of the Cxs (all p values Ͻ0.001). In conclusion, the reduction in Cx43 expression that we observed in the diabetic patients has also been reported in other cardiac pathologies and have been associated with an increased risk for cardiac arrhythmias. Conversely, Cx40 over expression could partially compensate for Cx43 down regulation. Thus, the respective up-and down-regulations of Cx40 and Cx43 could represent another mechanism linking diabetes to AF.
P176
Calcineurin-Dependent Regulation of Cardiac L-Type Calcium Channel
Samvit Tandan, Yanggan Wang, Kenneth E Richardson, Beverly A Rothermel, Joseph A Hill; UT Southwestern Med Ctr, Dallas, TX Introduction: Evidence from in vivo models of pressure overload suggests that calcineurin, a major mediator of pathological hypertrophy, is capable of regulating its proximal activator, the L-type Ca 2ϩ channel. Based on this, we hypothesized that calcineurin physically and functionally interacts with the L-type Ca 2ϩ channel. Methods and Results: Coimmunoprecipitations from extracts of rat heart and brain using antibodies against calcineurin and ␣ 1 1.2, the major, pore-forming subunit of the channel, revealed evidence of ␣ 1 1.2calcineurin association. GST pulldowns provided evidence for direct interaction between calcineurin and two major regions of ␣ 1 1.2: the N-terminus and a C-terminal domain spanning ser1928, a PKA phosphorylation site. In the presence of PKA, the C-terminal domain spanning ser1928 was phosphorylated in vitro, and recombinant calcineurin antagonized the action of PKA, indicating that ␣ 1 1.2 is a potential substrate for calcineurin in vitro. To test functional significance, voltage-clamp recordings revealed significant up-regulation of I Ca,L in cultured cardiomyocytes expressing constitutively active calcineurin. Conversely, inhibition of calcineurin with cyclosporine A (CsA) and tacrolimus -two structurally distinct calcineurin antagonists -decreased I Ca,L . This inhibition occurred over a time course of several minutes and was partially reversible upon drug washout. CsA had no non-specific effects on I Ca,L . To test for other mechanisms whereby calcineurin might up-regulate Ca 2ϩ channel function, we mapped 2kb of genomic sequence upstream of the ␣ 1 1.2 gene, identifying several putative NFAT, GATA4, and MEF2 binding sites. Studies performed in cells transiently transfected with an ␣ 1 1.2 promoter-luciferase reporter suggested that ␣ 1 1.2 transcription is regulated by calcineurin. Conclusions: These findings are consistent with a model wherein calcineurin regulates the L-type Ca 2ϩ channel at two distinct levels: post-translational modulation involving direct binding to the channel, and transcriptional regulation involving NFAT-mediated activation of channel expression.
P177
Coupling of Plasma Membrane Calcium Entry to Plasma Membrane Extrusion Revealed by Novel L-Type Calcium Channel Block
William C Lester, Elizabeth A Schroder, Douglas A Andres, Jonathan Satin; Univ of Kentucky, Lexington, KY The maintenance of Ca 2ϩ homeostasis is crucial for cardiac myocyte function. In heart failure, as in cardiac development, there is a decrease in the density of L-type calcium channel (Ca V 1.2) current (I Ca,L ). To maintain Ca 2ϩ homeostasis, plasma membrane (PM) Ca 2ϩ influx must be matched by PM efflux. In this study we tested the hypothesis that chronic regulation of PM Ca 2ϩ channels regulates PM efflux. We studied mRNA and Ca 2ϩ handling responses to long-term regulation of influx and efflux induced by over-expression of the small GTPase Rem and the Na ϩ -Ca 2ϩ exchanger (NCX1.1), respectively. Rem partially inhibited I Ca,L but not I Ca,T , and increased Ca V 1.2 mRNA. Rem lowered diastolic Ca 2ϩ , and reduced the transient amplitude. Chronic Rem also slowed Ca 2ϩ transient duration from 1.6 Ϯ 0.2 s (nϭ14) to 2.5 Ϯ 0.3 s (nϭ20). To measure SR load and NCX function we perfused the cells with Ca 2ϩ free bath solution for 25 s then rapidly applied 50 mM caffeine. The caffeine-induced transient relaxations had a bi-exponential time course in control cells. The fast phase was eliminated by 10 mM Ni 2ϩ , consistent with NCX-mediated efflux. Rem significantly slowed caffeine-induced relaxation (total time 13.2ϩ/-0.5s, nϭ20 vs 8.6ϩ/-0.5s, nϭ14, Rem vs control, p Ͻ 0.05), suggesting Rem inhibits NCX function. Surprisingly, NCX over-expression also eliminated fast relaxation kinetics (total time 14.7ϩ/-0.6s, nϭ8). To test whether this effect reflected insufficient basal Ca 2ϩ for allosteric NCX activation we increased the bath [Ca 2ϩ ] from 1.8 to 6mM and measured caffeine-induced relaxation kinetics. 6 mM Ca 2ϩ fully restored the fast kinetic phase in NCX over-expressed cells and partially restored the fast phase in Rem over expressed cells. 6 mm Ca 2ϩ did not affect the kinetics of control cells. Neither Rem nor Ca 2ϩ channel auxiliary subunits altered heterologously expressed NCX. This data suggests that chronic I Ca,L block by Rem lowers cytosolic Ca 2ϩ . In turn, lowered Ca 2ϩ reduces NCX activity via allosteric inactivation of NCX. Elevated bath Ca 2ϩ only partially overcomes this inactivation in Rem over-expressing cells because of tonic I Ca,L blockade. We conclude that Ca V 1 channelmediated PM entry coordinately controls store loading and Ca 2ϩ efflux. infarcted myocardium (1-100 M) the effect is significant. These results have potential implications for understanding the role of hMSCs and the therapeutic effects of beta-blockers in myocardial infarction.
P186 Mesenchymal Stem Cell Therapy in a Canine Myocardial Infarction Model: Assessment of Regional Persistence and Function Using MRI
Wesley D Gilson, Ana V Soto, Dorota Kedziorek, Danielle Crawford, Danielle Crawford, Parag Karmarkar, Jeff W Bulte, Dara L Kraitchman; Johns Hopkins Univ, Baltimore, MD Purpose: To determine the persistence of targeted magnetically-labeled mesenchymal stem cells (MSC) and their effect on regional contractile function in a canine model of myocardial infarction (MI) using MRI. Methods: A reperfused MI was created under X-ray fluoroscopy by closed-chest coronary artery occlusion in 13 dogs. MRI was performed at 72h post-MI to assess MI size and heart function. Using an MRI-compatible injection catheter, autologous MSCs labeled with ferumoxides were injected transendocardially in 7 dogs, targeting to normal (N), peri-infarction (P), and MI. MSC persistence, MI size, and regional cardiac function were studied serially (1, 2, 4 & 8 weeks post-MI) using fast gradient echo MRI, delayed contrast-enhanced (CE) MRI, and myocardial tagging, respectively. A 6-sector per slice model was used to track regional persistence of labeled MSCs, and each sector was classified according to infarct status based on CE-MRI. Systolic strain rate (SSR) was determined from tagged MRI in N, P, and MI regions and compared between treated and untreated dogs. Results: Infarct size was similar between treated and untreated dogs at 72h (19.3Ϯ9% vs. 20.0Ϯ5%) and 8 weeks post-MI (8.1Ϯ2% vs. 8.9Ϯ2%). At 72h post-MI, the distribution of MSC injections was 52% (14 of 27) in MI, 30% (8 of 27) in P, and 19% (5 of 27) in N regions. Labeled MSC clusters persisted in MI regions throughout the study (14 of 14), while a disappearance of clusters was seen in P and N regions with 50% (4 of 8) and 20% (1 of 5) of original injections remaining at 8 weeks. SSR improved in N, P, and MI regions in treated animals over time from 72h to 8 weeks (pϽ0.01 in all regions) and significantly improved in N regions (pϽ0.01) compared to untreated animals. No cardiomyocyte regeneration was indicated by histology in P and MI myocardium. Conclusions: Serial MRI of transendocardially implanted ferumoxide-labeled MSCs showed persistence of MSC injections particularly in infarcted myocardium with improvements in regional contractile function demonstrated in noninfarcted myocardium. This study suggests methods that may be useful for tailoring therapy to individual patients, as well as for targeting therapy for improved efficacy.
P187 Withdrawn
P188
Validation of the Wall Motion Score for Assessing Left Ventricular Dysfunction in Mice with Myocardial Infarction
Yan Zhang, Junya Takagawa, Richard E Sievers, Muhammad Khan, Matthew L Springer, Elyse Foster, Yerem Yeghiazarians; Univ of California, San Francisco, San Francisco, CA Background: Wall Motion Score Index (WMSI) is a potentially useful measure of improved cardiac function after cell or gene therapy studies in mouse models of myocardial infarction (MI). While WMSI based on a 16-segment model has been clinically validated in post-MI patients, it has not been used in mice because of their small heart size and difficulty interpreting the images. The aim of this study was to determine if WMSI is a practical and accurate method for measuring left ventricular (LV) function in a mouse model of MI using a novel high-resolution echocardiography system. Methods: 48 adult male mice underwent surgery to induce MI by a mid-LAD ligation. Echocardiography was performed under anesthesia one month post MI by using a Vevo 660 system (VisualSonics, Toronto) equipped with a 30 MHz mechanical transducer. WMSI was analyzed by a modified 16-segment model on short axis views (4-apical, 6-mid and 6-basal), grading wall motion as 1-normal, 2-hypokinetic, 3-akinetic, 4-dyskinetic and 5-aneurysmal. It was calculated as the ratio of the sum of wall motion score over total segments. We measured LV ejection fraction (LVEF) and volumes (ESV and EDV) by cylindrical-hemiellipsoid model and fractional shortening (FS%) by M-mode. All hearts were harvested after echocardiography. Tissue sections were collected and infarct size (IS) was measured in a blinded manner. Correlations were assessed between WMSI and above-mentioned echocardiographic parameters as well as IS. Results: All recorded images were of good quality and interpretable. The WMSI was 1.64 Ϯ 0.33 and the IS was 34.3 Ϯ 15.3%. Linear correlation analyses showed that WMSI correlated significantly with IS (r ϭ 0.86, pϽ0.0005), LVEF (32.76 Ϯ 8.95%) (r ϭ -0.84, pϽ0.0005), FS% (23.87 Ϯ 4.42%) (r ϭ -0.39, pϭ0.006), and ESV (51.53 Ϯ 8.11 l) (r ϭ 0.41, pϭ0.004). Stepwise linear regression analysis revealed that IS was an independent determinant of WMSI with R 2 ϭ 0.75, p Ͻ 0.0005. Conclusions: High-resolution echocardiographic assessment of WMSI in mice is feasible, and correlates strongly with both 2-dimensional measurements of LV systolic function and infarct size. WMSI may be an important tool in assessing regional and global function in mice with experimental MI treated with novel therapies.
